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Abstract 
 
Cryptococcus neoformans is an opportunistic fungal pathogen, which is widespread in 
the environment. Due to its global distribution and association with pigeon excreta, 
human exposure to this pathogen is frequent but initial infection is rapidly cleared or 
contained in immunocompetent hosts. In immunocompromised hosts, however, C. 
neoformans can cause severe disease often with dissemination to the central nervous 
system. Without rapid treatment disseminated infection is invariably lethal. With the 
rise of transplant and cancer therapy patients, the pool of vulnerable hosts is ever 
larger. Thus, studies of the interaction between Cryptococcus neoformans and the 
immune system are paramount for the development of novel treatment options. 
In this study, different aspects of the interaction between C. neoformans and phagocytic 
cells, such as macrophages and dendritic cells, were explored.  
One of the key features of Cryptococcal pathogenesis is its ability to persist and 
replicate within macrophages, as well as its ability to escape via a novel non-lytic 
mechanism known as vomocytosis. The impact of vomocytosis on disease progression 
is not yet fully appreciated, but it has been linked to dissemination of the fungal cell 
within the host. Vomocytosis is a highly regulated process, influenced by both fungal 
and host parameters. Macrophage polarisation is one such parameter, whereby 
alternatively activated macrophages show diminished occurrence of vomocytosis 
events. In this work, the interplay between two modulators of vomocytosis was 
explored. It was found that inhibition of the atypical MAP kinase ERK5, a known 
 II 
regulator of vomocytosis, limits alternative activation of macrophages, thus, 
providing a link between both phenomena.  
Cryptococcal meningitis occurs mainly in HIV+ patients. The effect of chronic viral 
exposure on vomocytosis has not been studied before. My work revealed that viral 
exposure significantly enhances vomocytosis, acting through low levels of type-I 
interferons. Preliminary work expanded this finding to include bacterial co-infection 
settings, which can also elicit a type-I interferon response.  
Lastly, the consequences of prolonged exposure to Cryptococcal cells or components 
on antigen presentation and antigen-induced T cell proliferation were explored. This 
setting emulates long-term latent infection within the lungs of immunocompetent 
hosts, which are frequently exposed to this fungus. The presence of Cryptococcal 
capsule components negatively impacts antigen-induced T cell proliferation by 
altering the antigen processing capabilities of antigen presenting cells.  
Overall, this work highlights the complex interaction between C. neoformans and the 
innate immune system and underscores the importance of incorporating biological 
context cues into our experimental systems. 
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1 Introduction 
 
1.1 Cryptococcus neoformans 
 
1.1.1 Discovery and classification 
Cryptococcus neoformans was first isolated in 1894 almost simultaneously from human 
bone infection [1] and from fermented peach juice [2]. At that time, it was described 
as a “Saccharomyces-like” organism, but was later renamed as Cryptococcus neoformans 
in 1901 by Jean-Paul Vuillemin [3]. Under the current classification, C. neoformans is 
one of the thirty-nine species of the genus Cryptococcus [4]. C. neoformans is further 
classified into two varieties according to genotypic differences; C. neoformans var. 
neoformans and C. neoformans var. grubii [5]. A third variety, C. neoformans var. gattii, is 
now considered a separate species: C. gattii [6].  
 
The work presented in this report was performed using two strains from C. neoformans 
var. grubii; the reference strain for this variety, H99, and a strain derived from H99 to 
generate congenic strains in the different mating types, Kn99 [7]. 
 
1.1.2 General characteristics 
C. neoformans is, in its most abundant form, a unicellular (yeast) organism which 
replicates by budding. It is typically 4 – 10 µm in diameter and presents a thick 
polysaccharide capsule linked to its cell wall [8]. When cultured it yields cream-
coloured colonies, except in the presence of laccase substrate such as 3,4-
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dihydroxyphenyalanine (DOPA), where the colonies are brown as a result of melanin 
production [3]. During its sexual cycle, C. neoformans undergoes a morphological 
change and grows as a hyphal fungus. As part of this cycle it produces spores of 1 – 2 
µm in diameter which are released into the environment. Nonetheless, yeast cells are 
the most predominant form both in the environment and during infection. Contrary 
to other human pathogens like Candida albicans whose dimorphic switch is considered 
a virulence trait, hyphal C. neoformans is unable to persist during mammalian infection 
[9, 10].  
 
Unlike its sister species C. gattii, which is predominantly present in sub-tropical 
regions, C. neoformans has a worldwide distribution [11]. It is associated with avian 
excreta, particularly that of pigeons, which makes it readily available in urban as well 
as rural settings [12]. In fact, the production of antibodies against Cryptococcus at an 
early age supports that exposure to C. neoformans is common in humans even in urban 
areas [13]. 
 
1.1.3 Pathogenicity and infection 
C. neoformans is an opportunistic fungal pathogen. As such, it infects animals, 
including humans, but only results in disease in previously weakened individuals 
(Figure 1.1). Cryptococcosis is particularly relevant in human immunodeficiency virus 
(HIV)+ patients, where it is considered an acquired immunodeficiency syndrome 
(AIDS)-defining illness. A study conducted in 2014 estimated over 200000 cases of 
Cryptococcal meningitis in HIV+ patients per year, 73% of which were reported in 
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sub-Saharan Africa. These amounted to 180000 deaths in 2014, which represents 15% 
of AIDS-related deaths [14]. 
 
 
 
 
The infection cycle begins with inhalation of the infectious propagule. This could be 
desiccated yeast cells (approx. 3 µm) or spores (1 – 2 µm), which are commonly found 
in the environment as mentioned before [12]. Once inside the host, the infection is 
rapidly cleared or contained in immunocompetent individuals. In 
immunocompromised hosts however, or upon immunosuppressive treatments 
combined with a latent infection, the infection can disseminate. C. neoformans has a 
tropism for the central nervous system and can bypass the brain-blood-barrier causing 
meningoencephalitis. In these cases, infection is invariably lethal without rapid 
treatment [12]. 
  
Figure 1.1 Schematic depiction of C. neoformans infectious cycle 
See text below for description. CNS = Central Nervous System 
SPORES 
IMMUNOCOMPETENT 
IMMUNOSUPPRESSED 
Dissemination	to	CNS 
Severe	disease 
Clearance/Containment 
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1.2 Immunology of C. neoformans infection 
 
1.2.1 General remarks 
As mentioned before, infection with C. neoformans is virtually unavoidable due to its 
availability in both rural and urban settings, and global distribution. Remarkably, 
infection is asymptomatic and rapidly cleared or contained in most cases. However, 
chronic or acute infections can be seen in immunocompromised hosts as is the case of 
cancer, transplanted or HIV+/AIDS patients. In these cases, pulmonary infection can 
involve pneumonia and acute respiratory distress syndrome, whereas dissemination 
to the central nervous system (CNS) presents as meningoencephalitis [15]. 
Cryptococcal encephalitis is one of the leading causes of death in HIV+/AIDS patients 
in sub-Saharan Africa [14]. Given the high prevalence of Cryptococcus infections in 
HIV+ patients, further details regarding this particular immunological context will be 
given in section 1.5.  
 
The impressive difference in terms of outcome of infection among immunocompetent 
and immunocompromised host reveals the importance of an intact immune response 
when dealing with this pathogen. A brief description of the adaptive and innate 
immune responses to C. neoformans infection is given below. 
 
1.2.2 Adaptive immune response to C. neoformans 
Immune responses can be broadly classified into T helper type 1 (Th1), Th2 and Th17. 
Each response is brought about by different cues or pathogen types, and is therefore 
tailored to deal with specific challenges. The immune system is constantly facing 
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diametrically different stimuli, and thus a balance is struck between the responses 
elicited by them. The position of such immunological balance, and the ability of 
skewing it towards one side or the other, will greatly influence the outcome of 
infection.  
 
Protective responses to C. neoformans are predominantly orchestrated by Th1 CD4+ T 
cell-mediated immune responses [16]. This kind of response is characterized by the 
release of Th1 cytokines, such as IFNg and TNFa, which enhance uptake and killing 
of C. neoformans by neutrophils, macrophages and dendritic cells. Th1 cytokines also 
polarise macrophages to a “classical activation” phenotype, also termed M1, which 
possess enhanced phagocytic and antimicrobial activity. 
 
Th2 cytokines, such as IL-4, IL-5, IL-9 and IL-13, induce eosinophil recruitment to the 
site of infection as well as polarisation of macrophages to an “alternative activation” 
phenotype, also termed M2. M2 macrophages have an important role in anti-parasitic 
responses and in tissue repair and remodelling [17]. Th2 responses are considered to 
be detrimental during C. neoformans infection, reducing the host’s ability to eliminate 
the pathogen [15]. C. neoformans actively skews the Th1-Th2 balance towards a Th2 
profile by expressing eicosanoids [18] and inducing production of IL-10 [19].  
 
Th17 are also thought to be important for protection against C. neoformans [16]. There 
is some debate, however, as to the extent of the role of Th17 on cryptococcosis; 
Wozniak et al [20] propose that it is a secondary role, since inhibition of production 
and/or signalling of IL-17A showed no effect in the outcome of infection in an 
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experimental mouse model, whereas Murdock et al [21] suggest it is a primary role, 
since late fungal clearance was impaired in IL-17A-deficient mice.  
 
B cells and antibody production also play a role in the immune response to C. 
neoformans, as highlighted by the presence of antibodies reactive to Cryptococcal 
antigens in the sera of immunocompetent children [13, 22]. This suggests that 
exposure to C. neoformans and subsequent mounting of an antibody response occurs 
early in life [13]. Moreover, low antibody titres and B cell deficiencies have been linked 
to higher risk of developing cryptococcal infections [23, 24]. This finding is also 
reflected in murine cryptococcosis models, where B cell deficiency and low IgM 
production correlates with increased susceptibility to C. neoformans infection and 
higher fungal burden in the lung [25-27]. 
 
Antibodies binding to C. neoformans can also act as opsonins and enhance uptake by 
host phagocytes [28-30].  
 
1.2.3 Innate immune response to C. neoformans 
The innate immune system constitutes the first line of defence against C. neoformans 
infection and serves a pivotal role for the mounting of long-lasting adaptive responses. 
Given that C. neoformans is responsible for severe disease almost exclusively in hosts 
with impaired adaptive immunity, such as AIDS, the importance of studying the 
innate immune response against this pathogen is heightened.  
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1.2.3.1 Complement System 
The complement system is a cascade of serum proteins that complements the activity 
of antibodies and phagocytic cells in the clearance of pathogens and damaged cells. 
This system can be triggered by three different pathways, namely classical, alternative 
and lectin pathway, which differ in their recognition of non-self particles. The three 
pathways ultimately converge in the formation of the C3-convertase and the assembly 
of the membrane-attack complex [31]. 
 
It has long been known that the complement system is important for the clearance of 
C. neoformans [32]. Experiments restricting the activation by the classical and lectin 
pathways, either by using C4-deficient guinea pigs [32] or by studying the binding 
kinetics of C3 in the presence of Mg-EGTA [33], have showed that the alternative 
activation pathway has a predominant role in the clearance of C. neoformans.  
Deposition of complement molecules on C. neoformans act as opsonins and enhance 
phagocytosis mainly through engagement of the complement receptor 3 (CR3) [34].  
 
1.2.3.2 Phagocytes – Neutrophils, Dendritic Cells and Macrophages 
Cryptococcal cells are readily phagocytosed by a variety of leukocytes. This 
phenomenon is mediated by direct recognition of the yeast cells (Toll-like receptor 
(TLR)4 binds components of the capsule [35]) or by receptor-mediated recognition of 
complement [34] or antibody [36] opsonisation. In the lung environment, where the 
abundance of serum components is low, non-opsonic uptake predominates [37]. 
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Neutrophils are the first to be recruited to the site of inflammation, and have the ability 
to kill C. neoformans cells by oxidative burst in vitro. Interestingly, neutropenia in mice 
has been shown to be beneficial for survival [38, 39]. In these reports, the beneficial 
effect was ascribed to altered cytokine release which enhanced protective responses, 
and was limited to pulmonary infection models [38, 39].  
 
Dendritic cells (DC) act as a bridge between innate and adaptive immunity, having a 
predominant role in antigen presentation. In a murine model, cryptococcal cells were 
internalised by DC within 2 hours post inoculation. Activated DC were then retrieved 
7 days post infection, and were capable of inducing T cell proliferation ex vivo [40].  
 
Macrophages are at the heart of the interaction with C. neoformans cells. This pathogen 
is able to survive within the phagosome of macrophages. Unlike other intracellular 
pathogens, it does not escape to the cytosol and does not inhibit phagosome-lysosome 
fusion [41]. It does, however, interfere with the maturation/acidification process [42]. 
As mentioned before, macrophages can be polarised towards different activation 
phenotypes, M1 and M2 being the best studied ones. During Cryptococcus infection, 
M1 macrophages are considered to be beneficial for survival, whereas M2 
macrophages to have the opposite effect [15, 16]. Regardless of their activation state, 
there is still debate as to whether macrophages play a role in the dissemination of C. 
neoformans to the CNS (see 1.3.3). Other than replicating within the phagosome, 
Cryptococcus can escape the macrophage via a lytic or non-lytic mechanism. The 
different outcomes of the interaction between macrophages and Cryptococcus will be 
described in section 1.3.2.  
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1.3 Immune evasion strategies of C. neoformans 
 
1.3.1 Virulence factors 
C. neoformans possesses a variety of virulence factors that aid in its pathogenicity. The 
three most important and well-studied virulence traits consist of its ability to grow at 
37°C, the presence of a thick capsule and the ability to produce melanin [12].  
 
C. neoformans is not only able to grow at 37°C, the mammalian host body temperature, 
but it thrives in it. Its optimal and maximum growing temperatures are 32°C and 40°C, 
respectively. It is considerably more thermotolerant than its non-pathogenic genus 
siblings, and is in fact the one of the two Tremallelles which can grow optimally at over 
30°C (the second species being C. gattii) [43].   
 
The presence of a thick polysaccharide capsule is arguably the most striking virulence 
factor in this organism, and the best studied one. The main components of the capsule 
are the polysaccharides glucuronoxylonmannan (GXM) and galactoxylomannan 
(GalXM) [44]. The size of the capsule is highly influenced by the environment 
encountered by the yeast, generally enlarging upon infection. In vitro, factors such as 
osmolarity, carbon source, pH, nutrient concentration and temperature influence 
capsule size [45]. While cell-bound, the polysaccharide capsule inhibits phagocytosis; 
the sugars can also be shed during infection to avert attachment [46]. Capsule 
components have been shown to dampen antigen presentation processes and produce 
a subdued lymphoproliferative response when compared to acapsular strains [19]. 
Shed components of the capsule have also been shown to have immunomodulatory 
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properties [8]. Remarkably, acapsular mutants are non-virulent [8], highlighting the 
importance of this structure for pathogenicity.  
 
Finally, deposition of melanin in the cell wall is considered a virulence factor. This 
pigmented molecule confers protection from UV light and freeze-thaw cycles in the 
environment, and it also protects the yeast against reactive oxygen species (ROS) 
generated in the phagolysosome [4]. As stated before, melanin is produced by the 
enzyme laccase from the dopamine precursor.  
 
In addition to the virulence factors mentioned above, the production of giant cells is 
yet another mechanism by which C. neoformans avoids clearance. Once inside the host 
and subjected to the lung environment, a proportion of the infecting yeast cells evades 
phagocytosis by expanding their cell size to form titan cells of up to 100 µm in 
diameter [47]. These cells are thought to arise from DNA replication without 
concomitant fission, since they are polyploid and uninucleate. The role of these giant 
cells during infection is poorly understood, but a hypothesis is that they act as seeding 
points for infection; their increased resistance to phagocytosis and oxidative stress 
enables them to persist in the lung while allowing their smaller counterparts to 
disseminate within the host [48].  
 
1.3.2 Life in the phagosome 
One of C. neoformans most remarkable properties is that it is able to not only survive 
but prosper within phagocytes. This characteristic is not exclusive to this pathogen, 
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being displayed by a myriad of pathogenic organisms, such as Listeria monocytogenes, 
Legionella pneumophila, Mycobacterium tuberculosis and Salmonella enterica [49].  
 
Cryptococcus cells have developed numerous mechanisms to endure the harsh 
conditions present within the phagosomes of macrophages, and even to escape them. 
Phagosome maturation involves fusion with lysosomal vesicles, which results in the 
acidification of the phagosomal lumen, presence of multiple acidic proteases and the 
assembly of NADPH oxidase. This complex mediates the production of ROS aimed to 
damage the phagocytosed contents [31]. As previously mentioned, engulfed 
Cryptococci possess a melanin coat that absorbs ROS. They also present enzymes 
designed to fight the oxidative stress imposed by the phagolysosome environment 
(including superoxide dismutase, glutathione reductase and glutathione peroxidase, 
among others [8]). Yeast cells also secrete urease, which catalyses the hydrolysis of 
urea into ammonia thus neutralising the phagosome pH. Taken together these 
properties allow Cryptococci to establish a latent infection within macrophages [8, 50]. 
 
Cryptococci can also escape the macrophage via lytic or non-lytic pathways. No pore-
forming proteins have been found in Cryptococcus cells, therefore lytic expulsion is 
thought to be driven by excessive yeast replication causing physical stress on the host 
cell. Non-lytic exocytosis, also known as vomocytosis, is a highly regulated process 
seen so far in C. neoformans [51, 52], C. albicans [53] and C. krusei [54] infection. As a 
result of vomocytosis, both the expelled Cryptococci and the macrophage are 
undamaged, with no obvious signs of diminished replication capacity for the former 
or dysfunction for the latter. Hence, this escape mechanism ensures minimal 
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proinflammatory signalling, and is therefore thought to pose an advantage over lytic 
escape [50, 55]. A comprehensive review of vomocytosis can be found in section 1.4. 
 
1.3.3 Traversing to the brain 
One of the key features behind the mortality of C. neoformans infection is its ability to 
trespass the blood-brain barrier. The mechanism by which this pathogen conquers this 
immunologically-privileged site is not yet understood. However, there are three 
proposed mechanisms that could allow Cryptococcus to accomplish this feat. The first 
is by paracytosis, which involves moving between tight junctions of endothelial cells. 
The presence of the metalloprotease Mpr1 is thought to be implicated in this process. 
Supporting this hypothesis, the introduction of the MPR1 gene in S. cerevisiae resulted 
in the ability of this fungus to cross endothelial layers in vitro [56]. The second 
mechanism consists of transcytosis through endothelial cells. This process relies on 
the interaction between Cryptococcal hyaluronic acid and CD44, present on the 
luminal surface of endothelial cells. This binding leads to actin remodelling and 
engulfment of the fungus [57]. Finally, the third mechanism is termed “Trojan Horse”, 
as it involves the fungus travelling within phagocytes to the CNS, analogous to the 
Greek myth. Supporting evidence for this mechanism includes reports of reduced 
fungal burden in the brain after depletion of alveolar macrophages [58] and enhanced 
dissemination to the CNS in infection via transfer of Cryptococcus-loaded monocytes 
compared to Cryptococcus alone [59]. 
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1.4 Vomocytosis; what we know so far 
 
The following section has been submitted for publication as an independent Review 
to the scientific journal Cellular Microbiology.  
 
Vomocytosis, or non-lytic exocytosis, is the expulsion of live organisms that have 
previously been engulfed by a phagocyte, leaving both cells undamaged after the 
event (Figure 1.2). This process was first described in 2006 by two groups 
independently, while imaging macrophages infected with the yeast Cryptococcus 
neoformans [51, 52]. Various pathogens have evolved to survive within phagocytes or 
escape this harsh environment by destroying the phagocyte, but these were the first 
reports of a novel escape mechanism whereby a pathogen is released from a 
phagocyte without lysing of either cell. 
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Figure 1.2 Vomocytosis event 
Human monocyte-derived macrophages infected with GFP-tagged C. neoformans. Images 
from time-lapse microscopy showing a Cryptococcal cell (arrowed) undergoing 
vomocytosis. Number at the bottom of each frame indicates time post-infection 
(hours:minutes). Scale bar at the top corresponds to 5 µm.  
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1.4.1 Who is able to vomocytose? 
Vomocytosis was first seen to occur with the fungal pathogen Cryptococcus neoformans, 
and its sister species C. gattii and C. grubii [51, 52]. Following its initial discovery, 
vomocytosis was soon reported with Candida krusei [54] and Candida albicans [53]. 
These represent a jump from the Cryptococcus genus and include fungal pathogens 
that form pseudohyphae or hyphae.  
 
A related phenomenon termed “Lateral transfer” was soon described, whereby an 
internalised Cryptococcal cell is “transferred” from one infected macrophage to 
another [60, 61]. As with vomocytosis, both the transferred cell and macrophage 
remain undamaged after this event. Recently, Dragotakes et al. showed that lateral 
transfer is the combination of a non-lytic exocytosis event followed by phagocytosis 
by a nearby macrophage [62]. Events of lateral transfer have been observed for 
Scedosporium apiospermum and Lomentospora prolificans [63], although due to spore 
germination the accepting macrophage is lysed shortly after the event. Lateral transfer 
of Aspergillus fumigatus spores between macrophages has been reported. In this case, 
however, transfer is associated with necrosis of the donor macrophage [64]. 
 
Although first described in murine macrophage cell lines such as J774 and RAW246.7, 
vomocytosis has now been recorded in mouse, human, avian and fish primary 
macrophages [51, 52, 65, 66]. The interaction between C. neoformans and macrophages 
has been compared to that between the fungus and predatory amoebae in the 
environment. This has led to the proposal that the capacity C. neoformans has for 
mammalian infection evolved in response to selective pressure exerted during 
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interactions with such phagocytic predators. Amoebae are also able to vomocytose C. 
neoformans [67], although it should be noted that amoebae, unlike macrophages, also 
have a constitutive exocytosis pathway to release indigestible material [68].  
 
Studying vomocytosis in vivo presents considerable technical challenges.  However, 
in 2011 Nicola et al. reported that vomocytosis occurs in vivo, using a murine 
Cryptococcal infection model and quantifying the occurrence of non-lytic expulsion 
indirectly, through a novel flow cytometry approach [69]. This method involves 
sorting a highly pure pre-stained population of infected macrophages, and comparing 
numbers of infected macrophages after a 24-hour period either in vitro or recuperated 
from a live recipient. This approach allows for the analysis of large numbers of cells 
in a short time, although it suffers from a high “false positive background” as a result 
of Cryptococcal death and host cell proliferation. In 2016, Bojarczuk et al. were the first 
to directly show vomocytosis during whole organism infection using the transparent 
zebrafish larvae model [66]. To date, vomocytosis has not been directly evidenced in 
a mammalian host. Although intravital imaging could theoretically achieve this, in 
practice the rarity of the event and the extended periods of imaging required represent 
formidable technical challenges. 
 
1.4.2 What is the mechanism of vomocytosis? 
A key question for the field is the underlying mechanism that drives vomocytosis. 
How does this work? Why would phagocytes expel undamaged cargo? Is it triggered 
by the pathogen or the host cell?  To date, most of these questions remain unanswered. 
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However, recent data has begun to open the door to a mechanistic description of this 
process (Figure 1.3, page 20).  
 
One of the first observations was that vomocytosis does not occur with heat-killed 
Cryptococcus or with inert latex beads [51, 52]. This suggests that the phenomenon 
might be triggered by the fungus rather than the host cell, or alternatively that the host 
cell has a mechanism by which it can determine whether a phagosomal cargo is alive. 
 
Another fungal characteristic that affects vomocytosis is the presence of capsule; 
acapsular strains of C. neoformans showed diminished vomocytosis rates [51]. Other 
virulence factors which have been linked to vomocytosis are secretion of 
phospholipase B 1 (plb1) and presence of urease. Both defective strains (plb1D and 
ure1D) have been shown to be hypovirulent in animal models [70, 71], and both show 
a decrease in occurrence of vomocytosis [72, 73]. It should be noted, though, that these 
mutants all show attenuation leading to higher intracellular killing rates, which could 
confound observations of vomocytosis rate.  
 
Several host factors influence vomocytosis occurrence. Perhaps not surprisingly, 
given the involvement of Cryptococcal-urease, phagosomal pH has been linked to 
vomocytosis since its first description in 2006, with the addition of weak bases such as 
chloroquine or ammonium chloride resulting in enhanced vomocytosis of C. 
neoformans [51, 52, 69]. In line with this, it has been noted that vomocytosis occurs 
exclusively on non-acidified phagosomes [42]. Interestingly, it has recently been 
demonstrated that glucuronic acid residues in capsular polysaccharide are able to 
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buffer phagolysosomal pH [74], which could explain why acapsular strains of C. 
neoformans exhibit lower rates of vomocytosis. 
 
Host membrane integrity and composition have also been seen to affect vomocytosis. 
Infection with C. neoformans results in the disruption of the phagolysosomal 
membrane [75], and such permeabilisation was later shown to precede vomocytosis 
events [76]. Extensive phagolysosomal membrane permeabilisation, however, leads 
to a decrease in the occurrence of non-lytic exocytosis [77]. The lipid composition of 
the membrane is also thought to affect vomocytosis. Addition of exogenous oleic acid 
(OA) to macrophages infected with C. neoformans, which is a building block for 
phospholipids found in membranes, resulted in enhanced occurrence of vomocytosis 
events [78].  
 
Another host process that has been shown to affect vomocytosis is autophagy. This 
process allows eukaryotic cells to recycle cytoplasmic material and organelles and also 
has a role in the host’s defence against intracellular pathogens [79]. Host molecules 
known to be associated with autophagy were seen to be recruited to Cryptococcus-
containing phagosomes.  Of these, autophagy-related 5 (ATG5) in particular was then 
shown to have an effect on vomocytosis, since ATG5 knockdown reduces vomocytosis 
of C. neoformans [80]. 
 
The process of vomocytosis requires that internal vesicles release their cargo onto the 
extracellular milieu. For this to happen, the vesicle itself needs to be positioned near 
the edge of the cell and the vesicle and plasma membranes fuse together to allow the 
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cargo to be released. In 2016, Stukes et al. showed that annexin A2, a membrane 
binding protein involved in bringing membranes together and promoting fusion 
during several cellular processes including exocytosis of secretory vesicles, affects the 
occurrence of vomocytosis [81]. Using annexin A2 deficient cells (anxa2-/-), they 
noticed a decrease in phagocytosis and in vomocytosis of C. neoformans. Interestingly, 
the group showed that the absence of annexin A2, both in vitro and in vivo, results in 
an enlarged Cryptococcal capsule; suggesting that there might be a “sweet spot” in 
capsule size whereby too small (acapsular strains) or too large a capsule both abrogate 
vomocytosis. 
 
The host cytoskeleton is an obvious target to affect vomocytosis, given its clear role 
both in maintaining normal cellular structure and in driving the expulsion of several 
pathogenic bacteria [82]. Addition of cytochalasin D, which inhibits actin 
polymerisation within host macrophages, enhances vomocytosis of C. neoformans [51]. 
Johnston et al. showed that Cryptococci-containing phagosomes experience rapid, 
transient increases in actin polymerisation surrounding them, which they termed 
actin flashes. These flashes are assembled through the Arp2/3 complex, a nucleator of 
actin filaments, and are sensitive to pharmacological manipulation with actin 
stabilising/depolymerising agents. Utilising these tools, they found that stabilising or 
destabilising these actin flashes (with jasplakinolide or cytochalasin D, respectively) 
correspondingly reduced or increased vomocytosis rates. Thus, they revealed a new 
mechanism by which the host cell tries to retain internalised cargo, and inhibits 
vomocytosis, through assembly of transient actin cages surrounding the 
phagolysosome [76]. 
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Macrophages are very plastic cells, sensitive to myriad cellular signals, which underlie 
a wide spectrum of activation states. Not surprisingly, differently activated 
macrophages deal with Cryptococcal infection in different ways, including through 
modification of vomocytosis rates. At one end of this spectrum are so-called 
‘alternatively activated’ macrophages, also termed M2, which have been exposed to 
interleukins four or thirteen (IL-4 or IL-13, respectively). These cells have a normal 
phagocytic capacity but show an increased intracellular proliferation rate of fungal 
cells and reduced vomocytosis occurrence [83]. 
 
Lastly, to unravel the signalling pathways involved in vomocytosis, Gilbert et al. 
screened a panel of inhibitors directed at kinases known to be expressed in 
macrophages [84]. By doing so, they revealed that the host mitogen-activated (MAP) 
kinase ERK5 is a suppressor of vomocytosis, and as such, inhibition of ERK5 with the 
compound XMD17-109 leads to a significant enhancement of vomocytosis. Treatment 
of zebrafish larvae with this inhibitor recapitulated the increase of vomocytosis events 
seen in vitro, and moreover, showed that this resulted in decreased dissemination of 
the fungus [84], providing a molecular ‘handle’ for the future dissection of 
vomocytosis signalling. A more detailed comment on ERK5 signalling can be found 
in section 1.5. 
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1.4.3 What is the biological significance of vomocytosis? 
Vomocytosis poses an attractive “stealth” escape mechanism from phagocytes, 
without damage to the host cell and thus no release of immune-flagging molecules. 
Therefore, it has long been thought to play a role in dissemination. The mechanism 
for crossing of the blood-brain barrier, needed for dissemination to the central nervous 
system (CNS), is still not fully understood. One hypothesis involves the hijacking of 
phagocytes to transport it to distal sites of infection followed by vomocytosis, much 
like a Trojan Horse. Supporting evidence for this mechanism includes reports of 
reduced fungal burden in the brain after depletion of alveolar macrophages [58] and 
enhanced dissemination to the CNS in infection via transfer of Cryptococcus-loaded 
phagosomal acidification
capsule
membrane integrity
phospholipase B
ureaseERK5 activation
autophagy actin cytoskeleton
IL-4/IL-13
HOST FUNGAL
Figure 1.3 Molecular components affecting vomocytosis occurrence 
Several host (left) and fungal (right) factors have been shown to affect vomocytosis. 
Phagosomal acidification, formation of actin cages, polarisation towards an 
alternative activation phenotype and ERK5 activation have all been shown to 
inhibit vomocytosis of C. neoformans (red downward arrows). On the other hand, 
autophagy has been reported to enhance it (green upward arrow). There have been 
reports arguing both a promoting and an inhibiting effect of host membrane 
integrity and composition on vomocytosis.  
From the fungal side, absence of phospholipase B or urease leads to decreased 
vomocytosis occurrence. Capsule size also plays a role; acapsular and large capsule 
both inhibit vomocytosis.  
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monocytes compared to free Cryptococcus [59]. Gilbert et al. provided the first direct 
evidence that vomocytosis plays a role in dissemination of C. neoformans, since 
pharmacological enhancement of vomocytosis lead to reduced fungal dissemination 
in the zebrafish model [84]. It should be noted though, that the net effect on 
dissemination is highly dependent on the timing of the vomocytosis event and could 
increase dissemination at later points after initial infection. 
 
 
1.4.4 Bacterial “vomocytosis-like” events 
Even though the term vomocytosis has been used exclusively to describe expulsion of 
fungal pathogens, several reports describe similar processes occurring with bacterial 
entities. In 2009, Hagedorn et al. described a new non-lytic exit mechanism for 
Mycobacterium marinum from the amoeba Dictyostelium discoideum, which they propose 
could aid in the spreading of this bacterial pathogen [85]. Other reports in 2009 and 
2016 describe the non-lytic expulsion of uropathogenic E. coli (UPEC) from bladder 
epithelial cells [86, 87]. In this case, the expulsion serves to reduce intracellular 
bacterial burden and eliminate live bacteria from the host with the flow of bodily 
fluids. Also very reminiscent of vomocytosis, an article describes the non-lytic release 
of the opportunistic bacterial pathogen Serratia maracescens from an epithelial cell line, 
with both cells remaining viable and undamaged after the event [88]. Taken together, 
these suggest that vomocytosis might be a conserved mechanism employed by 
different pathogens with varying consequences for infection. 
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1.4.5 Concluding Remarks 
Since its discovery in 2006, vomocytosis has piqued the interest of the scientific 
community, revealing a novel process in the plethora of host and pathogen 
interactions. Slowly but steadily, the repertoire of pathogens and hosts seen to make 
use of this unusual escape mechanism has been expanding. This suggests that this 
process is not merely anecdotal for the infection of macrophages with C. neoformans, 
but rather a much more widely used escape/emptying mechanism (Figure 1.4).   
 
How does this process come about? What are the consequences for the outcome of 
infection? These questions have puzzled scientists for over a decade. The exact 
mechanism that drives this event remains elusive to date. However, recent advances 
in understanding some of the regulatory steps that underpin expulsion may open the 
Mostly studied in Cryptococcus, but also reported
in Candida, Scedosporium* and Lomentospora*
Vomocytosis-like events observed with bacteria
Influenced by host and fungal factors
Affects dissemination within the host
Seen in vitro and in vivo, using amoeba,
zebrafish, murine and human cell modelsVOMOCYTOSIS
Figure 1.4 Key features of vomocytosis 
* In these species lateral transfer, a form of vomocytosis, was reported. 
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door to a detailed mechanistic understanding in the near future. In addition, the use 
of whole animal transparent models, such as zebrafish larvae, and the automation of 
time-lapse scoring with machine learning algorithms will undoubtedly accelerate our 
gain of new insights into this fascinating process.  
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1.5 Extracellular-signal regulated kinase (ERK) 5 
 
1.5.1 Mitogen-activated protein kinases 
Mitogen-activated protein kinases (MAPKs) are highly conserved enzymes, expressed 
in all eukaryotic cells, which mediate multiple intracellular processes. Their signalling 
cascade (Figure 1.5) consists of the sequential activation of 3 modules; MAPK kinase 
kinase (MAPKKK), MAPK kinase (MAPKK) and MAPK, and is triggered after sensing 
of extracellular signals such as presence of growth factors, cytokines or environmental 
stresses [89]. Four members of the MAPK family have been identified: extracellular-
signal-regulated kinase 1/2 (ERK1/2), c-Jun-amino-terminal kinase (JNK), p38 and 
ERK5 [90].  
 
1.5.2 ERK5 discovery and structure 
ERK5 was simultaneously reported by two independent groups in 1995 [91, 92], one 
of them naming it big MAPK (BMK)-1 due to its large size compared to ERK1/2 (ERK5 
weighs 102 kDa while ERK1/2 are 44 kDa and 42 kDa, respectively).  
Structurally, the kinase domain present in the N-terminus is similar to that of ERK1/2 
[91], whereas the extended 410 amino acid long C-terminal tail is unique to ERK5 [91].  
Within this C-terminal tail there is a nuclear localisation signal (NLS) domain [93], 
important for subcellular localisation of ERK5, two proline-rich (PR) domains and a 
myocyte enhancer factor 2 (MEF2)-interacting region [94]. Truncation of the C-
terminal tail results in enhanced ERK5 activity [93], thus suggesting that it may have 
an autoinhibitory function.  
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1.5.3 ERK5 signalling cascade 
MEK5 is the upstream MAPKK capable of phosphorylating and activating ERK5 [89]. 
Once phosphorylated by MEK5, ERK5 undergoes autophosphorylation in several 
A-/B-/C-Raf MEKK2/3 MEKK 1/2/3/4 MEKK 1/2/3/4
MEK4/7MEK3/6MEK1/2 MEK5
JNK1/2/3p38 MAPKERK1/2 ERK5
Extracellular
Stimuli
MAPKKK
MAPKK
MAPK
Substrates
Physiological
Response
Growth Factors Cytokines EnvironmentalStresses
e.g. EGF, VEGF,
FGF-2, HGF, NGF
e.g. IL-6, IL-8 e.g. oxidative stress,
osmotic stress, U.V.
e.g. p90RSK,
Elk-1, Sap1a
e.g. MEF2D, SGK,
Sap1a, p90RSK
e.g. ATF-2, MEF2C,
MAPKAPK2/3
e.g. c-Jun, Elk-1
e.g. Survival/Proliferation/Differentiation/Apoptosis
Figure 1.5 Mitogen-activated protein kinase (MAPK) signalling cascade 
MAPK signalling cascade transduces extracellular signals, such as presence of 
growth factors, cytokines or environmental stresses, into cellular responses. There 
are four MAPK cascades; ERK1/2, ERK5, p38 MAPK and JNK 1/2/3. The response 
is brought about by the sequential phosphorylation and activation of three 
modules; MAPK kinase kinase (MAPKKK), MAPK kinase (MAPKK) and MAPK. 
Activated MAPK then phosphorylate their substrates, usually transcription factors 
but could also include structural proteins, cytoplasmic enzymes and 
phospholipids, to exert their cellular response. Image modified from 
Nithianandarah-Jones et al, Cellular Signalling, 2012 [89]. 
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sites of its C-terminal tail [95]. Downstream targets of ERK5 include members of the 
myocyte enhancer factor (MEF) family; MEF2A, C and D [96], as well as c-Myc, CREB 
and Sap1-a [97, 98]. Activation of these effector molecules results in changes in cellular 
proliferation, survival and differentiation [89]. 
 
Activation of ERK5 has been observed in the response to stress (H2O2 [99]), growth 
factors (G-CSF [100] and EGF [101]) and cytokines (LIF [102]). Most recently, it has 
been described as a negative regulator of vomocytosis of C. neoformans [84]. The exact 
mechanism by which ERK5 is able to influence vomocytosis remains to be elucidated, 
but its relationship with other known modulators of vomocytosis has been explored 
in this work (see Chapter 4). 
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1.6 Cryptococcus and HIV co-infection 
 
For the first 100 years after the initial discovery of C. neoformans, this was a relatively 
“low profile” rare fungus, only known to mycologists and few clinicians. It was not 
until the onset of the HIV pandemic in 1980 that the deadly potential of this fungus 
was really discovered. Ever since, the HIV+ population, together with an increase in 
immunosuppressed population due to organ transplant and cancer, has kept 
Cryptococcus in the limelight [103, 104].  
 
A lot of work has focused on the HIV-Cryptococcus relationship, revealing the 
undoubted requirement for T cells to effectively clear or contain the infection. Aside 
from a diminished CD4+ T cell count at the later stages of infection, HIV+ patients 
experience a long-lasting viral infection with the concomitant mounting of an anti-
viral immune response [105]. Therefore, the immunological context encountered by 
Cryptococcus in this population differs from that of an uninfected host and will be 
described in more detail below. 
 
1.6.1 The anti-viral immune response 
As it happens with the other pathogens, the response mounted towards viral infection 
can be classified into innate and adaptive. The first one being the fastest, charged with 
recognising the threat and instructing the adaptive response to produce and activate 
CD8+ T cells [31]. This report will focus on the innate anti-viral response, where 
recognition and induction of type-I interferons are key. 
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Type-I interferons were originally termed viral interferons due to their role in anti-
viral response [106]. This group is comprised of IFNa, IFNb, IFNe, IFNk and IFNw in 
humans. The two most studied type-I interferons are IFNa and IFNb, of which there 
are 13 and 1 subtypes, respectively. The genes for type-I interferons share 
chromosomal location (clustered in chromosome 9 in humans) and the resulting 
cytokines have similarities in structure, regulation and function, a key feature being 
that they all signal through the IFNa/b receptor (IFNAR) [107]. More recently, a third 
family of interferons was described. Type-III interferons, IFNl1, IFNl2 and IFNl3, 
are more closely related in structure and sequence to IL-10 than to IFNa/b. They do 
not signal through the shared IFNAR receptor but through their own IFNLR, which 
is expressed primarily on epithelial cells. Nonetheless, they are induced by viral 
infections and are capable of eliciting an anti-viral response, thereby justifying their 
classification as interferons [108].  
 
Virtually every cell in our body has the ability to produce type-I interferons, although 
plasmacytoid dendritic cells produce the highest titres and are considered natural 
producers of these cytokines [109, 110]. Type-I interferons can be induced by a viral 
infection per se through the activation of intracellular sensors (such as the helicases 
RIG-I or MDA-5) or through signalling by the endosomal toll-like receptors TLR3, 
TLR7, TLR8 or TLR9. Alternatively, type-I interferons can be induced in a paracrine 
positive feed-back loop by type-I interferons produced by a neighbouring cell (see 
figure 1.6) [111].  
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Irrespective of how they came about, all type-I interferons signal through their shared 
receptor to induce the expression of “interferon-stimulated genes”, ISG. Some of the 
ISG code for proteins which have known anti-viral properties, the best studied in this 
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Figure 1.6 Induction of type-I interferons 
Cytosolic sensors (RIG-I or MDA-5) or endosomal toll-like receptors (TLR3, TLR7-9 in 
plasmacytoid dendritic cells, not shown) recognize viral components and initiate a signalling 
cascade which ends with the production of IFNb. IFNb, and later IFNa, signal through the 
IFNa/b receptor (IFNAR) to induce the expression of interferon-stimulated genes. These 
include antiviral proteins and type-I interferons. See text for more detail. Image adapted 
from Haller et al, Virology, 2006 [111].  
dsRNA = double-stranded Ribonucleic acid, IFN = interferon, IFNAR = IFNa/b receptor, 
IKK = inhibitor of nuclear factor kB kinase, IPS-1 = IFNb promoter stimulator 1, IRF = IFN-
regulatory factor, ISG = interferon-stimulated gene, ISGF = IFN-stimulated gene factor, JAK1 
= Janus kinase 1, MAVS = mitochondrial antiviral signalling protein, MDA-5 = Melanoma 
Differentiation-Associated protein 5, Mx = Myxovirus resistance protein , OAS = 2’-5’ 
oligoadenylate synthase, PKR = protein kinase R, RIG-I = retinoic acid-inducible gene I, 
STAT = signal transducer and activator of transcription, TBK-1 = TANK binding kinase 1, , 
TLR3 = Toll-like receptor 3, TRIF = TIR-domain-containing adapter-inducing IFNb, TYK2 = 
Tyrosine kinase 2. 
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respect are protein kinase R (PKR), 2’-5’ oligoadenylate synthase (OAS) and 
myxovirus resistance proteins (Mx). PKR is a dsRNA-dependent protein kinase which 
phosphorylates the alpha subunit of the protein synthesis initiation factor 2, eIF-2a. 
This phosphorylation inhibits translation of proteins dampening viral replication, as 
this depends on host machinery to produce its progeny. The second is an 
oligoadenylate synthase, which catalyses the synthesis of 2’-5’ oligoadenylates from 
ATP. These, in turn, activate RNAse L which degrades viral and cellular RNA. Finally, 
Mx proteins are GTPases which can interact with themselves and with viral 
ribonucleoproteins. Depending on whether this interaction takes place in the 
cytoplasm or in the nucleus, it inhibits viral assembly or transcription, respectively 
[31, 107]. 
 
The expression of ISG helps create an anti-viral state in infected and uninfected 
proximal cells, limiting viral spread and aiding NK cells, and CD8+ T cells at a later 
stage, to clear or contain the infection. 
 
1.6.2 Human immunodeficiency virus 
Human immunodeficiency virus (HIV) is a single stranded positive lentivirus. It 
infects CD4+ cells, mainly CD4+ T cells, and causes their depletion leading to acquired 
immunodeficiency syndrome (AIDS). Upon infection, an anti-viral response is 
mounted which includes production of type-I interferons and activation of CD8+ T 
cells. Over the first months of HIV infection, a race occurs between the CD8+ cytolytic 
T cell response and the ability of the virus to mutate the epitopes targeted by this 
response. Reaching a balance defines the initial viral set point. Over time, the 
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depletion of CD4+ T cells, coupled with exhaustion of both CD4+ and CD8+ T cells, 
causes the onset of AIDS. Type-I interferons are produced throughout the course of 
infection [105, 112, 113], with positive as well as negative effects in terms of prognosis. 
Apart from the anti-viral effects of type-I interferons mentioned in the previous 
section, prolonged production of these cytokines can lead to a state of “immune 
activation” which increases the risk of serious non-AIDS events such as atherosclerotic 
vascular disease. 
 
The interplay between type-I interferons and cryptococcosis has been addressed 
before, with opposing findings in the literature [114, 115]. This disparity might be 
attributed to minute differences in the infection models or specific Cryptococcus strain 
used. Nonetheless, they clearly show a need for further study of this complex 
interaction. The next section describes the current knowledge on the impact of type-I 
interferons on fungal infections. 
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1.7 Type-I interferons and fungal infections 
 
Type-I interferons are best known for their anti-viral effects on both virus-infected and 
uninfected bystander cells, where they induce the transcription of various interferon-
stimulated genes, which interfere with multiple stages of viral replication and spread 
(see Figure 1.6). The best studied type-I interferons are IFNa and IFNb, but this family 
also includes IFNe, IFNk and IFNw. As mentioned before, all type-I interferons signal 
through a common receptor; interferon-a/b receptor (IFNAR), which is present in the 
surface membrane of virtually all human cells [116, 117]. These so-called “antiviral 
cytokines” also play a role in non-viral infectious settings, although these effects are 
still poorly understood and often need to be examined in a species-specific manner 
[118].  
 
Among non-viral infectious settings, the vast majority of the work has focused on 
bacterial infections. Both protective as well as detrimental roles have been reported 
during infection with numerous bacteria [118].  
 
The mechanisms of action responsible for their beneficial role, when elucidated, have 
been very diverse; regulating tryptophan availability through activation of 2,3-
dioxygenase (Chlamydia trachomatis [119]), aiding in macrophage polarisation towards 
a classically activated phenotype with heightened bactericidal activity (Legionella 
pneumophila [120]), contributing to macrophage activation and production of pro-
inflammatory cytokines (Escherichia coli, Streptococcus pneumoniae [121]). 
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Detrimental roles have also been attributed to type-I interferons during bacterial 
infections, with the most notable examples being Listeria monocytogenes and 
Mycobacerium tuberculosis. In the former, it has been shown that type-I interferons are 
responsible for sensitising lymphocytes to the pore-forming virulence factor 
listeriolysin O, leading to apoptosis [122-125], and blocking macrophage 
responsiveness to IFNg through downregulation of its receptor IFNgR [126, 127]. For 
the latter, suppression of host-protective cytokines [128-131], blocking of macrophage 
responsiveness to IFNg [130, 132, 133] and enhanced trafficking of M. tuberculosis-
permissive cells [134, 135] have been reported to contribute to the negative role of 
IFNa/b in M. tuberculosis infection. Other bacterial infections where IFNa/b enhance 
susceptibility or contribute to the exacerbation of disease include Brucella abortus [136], 
Yersinia pestis [137] and Staphylococcus aureus [138].  
 
The interplay between type-I interferons and fungal infections has not been 
extensively studied, although the reports available show that the effects also range 
from protective to detrimental for the host, depending on the fungal species (and 
sometimes on the protocol followed!). I will summarise the main findings pertaining 
to the most studied fungal species; Histoplasma, Pneumocystis, Aspergillus, Candida and 
Cryptococcus (Figure 1.7, page 40). 
 
1.7.1 Histoplasma 
Histoplasma capsulatum is a dimorphic primary fungal pathogen. Infection starts with 
inhalation of airborne conidia, where the higher body temperature of the host triggers 
differentiation into pathogenic yeasts. Within the host, yeasts are taken up primarily 
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by macrophages, and to a lesser extent by neutrophils and dendritic cells [139]. Early 
reports showed that macrophages co-infected with lymphocytic choriomeningitis 
virus (LCMV) and H. capsulatum exhibited decreased anti-histoplasma activity, which 
was reversed in the presence of an IFNAR neutralising antibody [140]. Thus 
suggesting a permissive role of type-I interferons in H. capsulatum infection. In line 
with these results, Inglis et al. showed that mice lacking IFNAR1, a subunit of IFNAR, 
better controlled infection with H. capsulatum in lungs and spleen than wildtype mice 
[141]. It was later described, however, that type-I interferons produced by dendritic 
cells are key to controlling the growth of H. capsulatum within the host. Their 
production is mediated by TLR7/9 recognition of yeast cells, and is required for the 
onset of a protective Th1 response [142], having an overall beneficial role for the host. 
 
It is currently unclear what causes the difference between these studies and which 
factors determine whether type-I Interferons are protective or detrimental in H. 
capsulatum infection. 
 
1.7.2 Pneumocystis 
Pneumocystis jirovecii is an opportunistic human fungal pathogen. It causes severe 
pneumonia in immunocompromised patients, most often those suffering from AIDS 
[143]. Studies on the effect of type-I interferon during Pneumocystis infection have tried 
to mimic immunocompromised conditions such as low CD4+ T cell count and bone 
marrow failure resulting in pancytopenia. Initial work in mice, using the murine strain 
P. carinii, showed that type-I interferon signalling has differential effects in CD4-
depleted versus CD4-sufficient hosts. In CD4-depleted hosts, IFNAR signalling aids 
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the recruitment and activation of CD8+ cells which ultimately leads to immune-
mediated lung damage. In CD4-sufficient animals, however, IFNAR signalling helps 
down-regulate inflammation after pathogen clearance [144]. 
 
The same group then looked at Pneumocystis infection in mice lacking lymphocytes 
and IFNAR (IFrag-/-). Using this model, they showed that type-I interferon signalling 
and B cells are important for the maintenance of haematopoiesis during Pneumocystis 
infection, which otherwise causes bone-marrow failure [145, 146]. 
 
1.7.3 Aspergillus 
Aspergillus are saprotrophic fungi, often found on decaying matter in the 
environment. Upon starvation, they release airborne conidia which are routinely 
inhaled by humans [147]. These can reach the alveoli in the lung and, if unchallenged 
due to a weakened immune system, can germinate and cause disease known as 
invasive aspergillosis. A. fumigatus is the main species responsible for invasive 
aspergillosis and as such has been the principal focus of scientific research [148]. In 
fact, the first report of type-I interferons having an effect on fungal infection 
corresponds to Tandon et al., where they show that treatment with IFNa or polyIC (a 
type-I interferon inducer) increases survival of mice infected with A. fumigatus [149].  
Since then, several studies have confirmed the beneficial effect of type-I interferons on 
A. fumigatus infection. Gafa et al. showed that addition of exogenous IFNb enhances 
activation of A. fumigatus-infected dendritic cells, which improves their ability to 
prime a Th1 response [150]. It was later reported that human bronchial epithelial cells 
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are able to internalise conidia, and this event induces the expression of IFNb by these 
cells [151].  
 
It is well known that plasmacytoid DC (pDC) are the main producers of type-I 
interferons [152]. Ramirez-Ortiz et al. demonstrated that depletion of these cells 
renders mice hypersusceptible to challenge with A. fumigatus [153], confirming their 
protective role. Later on, the same group showed that pDC detect A. fumigatus hyphae 
through the surface lectin Dectin-2, and respond with production of IFNa, TNFa and 
formation of extracellular traps [154]. 
 
Recently, monocytes have been described as an early source of type-I interferons in A. 
fumigatus infection [155]. They are reported to prime for production of type-III 
interferons in other pulmonary cells, and together activate neutrophils for clearance 
of A. fumigatus [155]. In line with these findings, treatment with polyICLC, a more 
stable version of polyIC, dramatically protected mice from invasive aspergillosis [156], 
through transient production of type-I interferons and early recruitment and 
activation of neutrophils. 
 
1.7.4 Candida 
Candida species are present on human mucosal surfaces as a commensal organism, 
mainly in the gastrointestinal tract. Upon immunosuppression or disturbance of the 
microbiome, Candida can cause disease ranging from superficial infection (oral and 
vaginal candidiasis) to life-threatening systemic infection (disseminated candidiasis) 
[157]. C. albicans is the leading cause of hospital-acquired infections [158], potentially 
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due to its ability to form biofilms on medically implanted devices [159], and has 
therefore been the focus of scientific studies.  
 
Research on the effect of type-I interferons on infection with C. albicans have generated 
conflicting results, indicating that the effect of these pleiotropic cytokines is more 
complex than previously thought.  
 
Initial reports showed that treatment with polyIC enhanced susceptibility to systemic 
candidiasis in mice with severe combined immunodeficiency (SCID) [160], suggesting 
that type-I interferons play a detrimental role on innate immunity to Candida infection. 
In line with these initial findings, Guarda et al. showed that type-I interferons inhibit 
IL-1 production and inflammasome activation, which then translates to a higher 
susceptibility to C. albicans challenge in wildtype mice [161].  
 
Treatment with IFNb specifically was shown to increase fungal burden and enhance 
mortality of mice infected with C. albicans through IFIT2-mediated inhibition of 
NADPH oxidase activity [162]. In vitro, it was shown to decrease expression of C-type 
lectins Dectin-1 and mannose receptor, and decrease uptake of unopsonised C. albicans 
in monocyte-derived macrophages [163].  
 
Majer et al. also showed that type-I interferon signalling has a detrimental effect for 
the host in a mouse model of experimental candidiasis. Paradoxically, the mechanism 
observed in this case is enhanced activation and recruitment of neutrophils to the site 
of infection and exacerbated immunopathology [164]. Following a very similar 
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protocol, however, del Fresno et al. arrived at the opposite conclusion; IFNAR 
deficiency, through a decrease in neutrophil recruitment to the site of infection, results 
in a higher mortality rate [165]. This suggests a protective role of type-I interferon 
signalling during Candida infection. Supporting this notion, two further studies found 
protective type-I interferon responses, mediated by TLR7/9 in conventional DC [166, 
167]. 
 
Earlier work had found that type-I interferons enhance the antifungal activity of 
neutrophils in oral candidiasis [168]. This effect was later seen in a systemic 
candidiasis model, acting through production of IL-15 [169]. 
 
Furthermore, a genome-wide transcription approach revealed a very strong type-I 
interferon signature profile during C. albicans infection in human peripheral blood 
mononuclear cells. Association analysis then confirmed that defects in this pathway 
enhance susceptibility to candidiasis [170]. 
 
A few studies investigated the therapeutic capability of IFNa in vulvovaginal 
candidiasis (VVC), having promising results using vaginal epithelium cell lines [171] 
and in a rat model [172]. In vivo data from VVC patients showed decreased levels of 
IFNb and IL-23 compared to healthy controls, suggesting a protective role for these 
cytokines in VVC [173]. 
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1.7.5 Cryptococcus 
Research on the effects of type-I interferons on cryptococcal infection have yielded 
conflicting results. On the one hand, Sato et al. showed that IFNAR KO mice had 
increased mucus production in their lungs which allowed for an enhanced fungal 
clearance rate, suggesting a detrimental role for type-I interferons in C. neoformans 
infection [114]. 
 
On the other hand, using the same model, Biondo et al. found that IFNAR KO mice 
were incapable of controlling infection with C. neoformans, showing higher fungal 
burden and a Th2-skewed immune response [174]. Thus, this study implies that type-
I interferon signalling is necessary to establish a protective Th1 response. Consistent 
with these findings, Sionov et al. showed that treatment with polyICLC greatly 
enhanced survival of mice infected with C. neoformans, and that this protective effect 
was mediated by type-I interferon production and polarisation to a Th1/Th17 
response [115]. 
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Key for induction of a protective 
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fungal burden in lungs and spleen.
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depleted mice.
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IFN-I help maintain extra-medullar 
haematopoiesis in Ifrag-/- mice.
Increases survival of infected mice.
Enhances activation of infected DC 
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protective Th1/Th17 response. 
Histoplasma
Pneumocystis
Aspergillus
Candida
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Beneficial effects of type-I IFN Detrimental effects of type-I IFN
Figure 1.7 Reported effects of type-I interferons on fungal infections 
Main findings regarding the effects of type-I interferons on the host undergoing a fungal 
infection, as discussed in text. Credits for figures: Centers for Disease Control and Prevention 
website -Histoplasma, Pneumocystis and Aspergillus- and Microbiology Society -Candida-. 
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1.7.6 Genetic deficiencies in Type-I interferon signalling 
Genetic deficiencies in the IFN-I signalling pathway have not yet been directly linked 
to increased incidence of fungal infections. There is, however, an association between 
gain-of-function mutations in the signal transducer and activator of transcription 1 
(STAT1) and chronic mucocutaneous candidiasis (CMC) disease [175]. STAT1 is 
involved in the signalling of type-I and type-II interferons [116]. This mutation causes 
enhanced type-II interferon (IFNg) signalling, which inhibits transcription of IL-17 and 
impairs protective Th17 responses [175]. 
 
Signalling of type-I interferons requires the formation of a heterodimer between 
STAT1 and STAT2 [116]. Deficiencies in STAT2 are not common, with thus far only a 
single family being described [176]. In this case, one sibling developed disseminated 
measles after routine immunisation with the vaccine strain and an infant sibling died 
of severe disseminated viral infection. Other surviving family members, however, 
have remained generally healthy despite documented history of viral infections [176]. 
 
A couple of cases of IFNAR deficiencies have been reported [177, 178]. One patient 
presented with a severe case of cytomegalovirus infection, and was later found to have 
a deficiency in IFNAR1 subunit. This patient received attenuated measles, mumps and 
rubella (MMR) vaccine without adverse reaction [178]. A second patient with an 
IFNAR2 subunit deficiency developed a severe encephalitis as a complication of MMR 
vaccination [177]. Cells from either patient were unresponsive to type-I interferons 
[177, 178]. Given the increasing body of work describing the impact of type-I 
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interferons on fungal infections, interesting questions remain about how such patients 
might respond to fungal challenge. 
 
 
1.7.7 Concluding remarks 
Type-I interferons were first discovered for their role in controlling viral infections. 
Over the years, several research groups looked into the interplay of type-I interferons 
and other, non-viral pathogens, focusing mainly on bacteria. Evidence summarised 
here shows that their effect extends beyond viral and bacterial settings to include 
fungal pathogens.  
 
The net effect of these pleiotropic cytokines on the outcome of fungal infections is not 
straightforward, ranging from beneficial to detrimental to the host in different fungal 
infection settings. However, an increasing body of research is looking to harness the 
immunomodulatory ability of type-I interferons as therapeutic tools to fight fungal 
infections and reduce inflammation and pathology.  
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2 Aims and Objectives 
 
The findings presented in this Thesis aim to broaden the understanding of 
Cryptococcal infection. The work was carried out with a particular emphasis on the 
understudied phenomenon of vomocytosis, and on the incorporation of biological 
context cues into the experimental design. 
With this in mind, the following objectives were proposed; the first objective was to 
delve deeper into the regulation of vomocytosis and explore how different modulators 
interact between them (Chapter 4). A second objective was to evaluate the potential 
impact of the biologically relevant viral infection context on vomocytosis (Chapter 5). 
Finally, the third objective was to explore the effects of prolonged exposure to C. 
neoformans or its components, on antigen presentation and antigen-induced T cell 
proliferation (Chapter 6).  
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3 Materials and Methods 
 
Parts of this chapter have been published in research articles of which I am a co-
author [84, 179]. The complete articles can be found in the Appendix. 
 
A brief description of the experimental protocols and techniques used is detailed 
below. All reagents were purchased from SIGMA unless otherwise stated.  
 
 
3.1 Generation of stocks and Cell culture  
 
3.1.1 Cryptococcal strains  
The main body of work was done using C. neoformans strain Kn99a, either wildtype 
or fluorescently-labelled. Wildtype strain was a kind gift of Dr. Kirsten Nielsen and 
was GFP-tagged [180] by Dr. Ewa Bielska in house. mCherry-expressing Kn99a [181] 
was a kind gift from Dr. JK Lodge. 
 
Mutant strain of C. neoformans Dras1 [182, 183] was supplied by Dr. Elizabeth Ballou 
and the acapsular strain Dcap59Duge1 [184], designated DCap, was provided by 
Guilhem Janbon. 
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3.1.2 Cryptococcal culture  
Cryptococcal glycerol stocks were kept at -80°C. Every 2 – 4 weeks, working stocks 
were made by streaking glycerol stocks onto 5% Yeast Peptone Dextrose (YPD) 2% 
Agar plates. These were incubated at 25°C for 24 – 72 hours and stored at 4°C 
thereafter. When streaking GFP- or mCherry-modified strains, 250 µg/mL 
Hygromycin was added to the plate to select for the mutant.  
 
“Overnight” liquid cultures were made by inoculating 3 mL YPD broth with a loopful 
of the working stock of the desired strain and incubating for 18 – 24 hours at 25°C on 
an orbital rotator set at 20 rpm.  
 
3.1.3 Bacterial culture 
Wildtype strain of Pseudomonas aeruginosa, strain PA14, was maintained on Lysogeny 
broth (LB) 2% Agar plates. “Overnight” liquid cultures were made by inoculating 10 
mL LB broth with a loopfull of PA14 and incubating for 18 – 24 hours at 37°C on a 
shaking incubator set at 200 rpm.  
 
3.1.4 Virus stocks and titration 
HIV-1 and SIVvpx virus stocks were generated by Dr. Leanne Taylor-Smith while at 
Dr. Mahdad Noursadeghi’s laboratory. A brief description of the strains and titration 
methods used is below. 
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HIV-1 virus stocks were generated by transfection of human embryonic kidney 293T 
cells (European Collection of Authenticated Cell Cultures) as previously described 
[185, 186]. TheR9HIVΔenv virus was derived from clade B HIV-1 strain (NL43) with 
500bp deletion in env,pseudotyped with vesiculostomatitis virus G envelope. 
SIV3mac single round virus-like particles (VLPs) containing vpx (SIV3vpx) were 
generated by transfection into 293T cells with pSIV3+ and pMDG plasmids [187, 188]. 
At 48, 72h and 96h viral containing supernatant was harvested, centrifuged at 800 x g 
for 10 min and filtered through 0.45 µm filter then centrifugedon a 20% sucrose 
cushion at 20,000 x g for 2h at 4°C. Purified virus was then re-suspended in RPMI 
media and frozen at -80°C. 
 
To quantify single round HIV infection, a vial was thawed for each harvest and serial 
dilutions used to infect CCR5/CD4 and CXCR4/CD4 transfected NP-2 cells. At 72h 
post infection, wells were fixed in ice cold acetone-methanol and viral infection was 
assessed by p24 staining using a 1:1 mixture of the anti-p24 monoclonal antibodies 
EVA365 and EVA366 (NIBSC, Center for AIDS Reagents, UK). Infected cells were 
detected by light microscopy to provide a virus titre (focus-forming U/mL). The 
SIV3vpx particles were quantified after thawing using a reverse transcriptase (RT) 
assay colorimetric kit (Roche) following the manufacturer’s instructions to provide a 
RT ng/mL titre. 
 
Recombinant measles virus (MeV) strain IC323 expressing GFP (MeV-GFP) was a 
generous gift from Dr. Dalan Bailey. It was generated as previously reported in 
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Hashimoto et al. [189] and represents a virulent field isolate from Japan (Ichinose-B 
(IC-B) strain) isolated from a patient with acute measles in 1984 [190].  
 
Virus stocks were generated using Vero cells (ATCC CCL-81) over-expressing human 
SLAM receptor (Vero-hSLAM cells), grown in DMEM supplemented with 0.4 
mg/mLG418. Once at 80% confluency, Vero-hSLAM cells were infected with MeV-
GFP at MOI of 0.01:1 in 5 mL media for 1 hour at 37°C. After 1h, a further 10 mL of 
DMEM supplemented with 10% foetal bovine serum (FBS) was added and infection 
allowed to continue for 48 h, when flasks were frozen at -80°C. After thawing, the 
collected supernatants were centrifuged at 2500 rpm for 10 min at 4°C to pellet cell 
debris, and virus-containing supernatant was aliquoted and kept at -80°C. 
 
For titration of MeV-GFP virus, the TCID-50 method was followed. Vero-hSLAM cells 
were seeded into flat-bottomed 96 well plates and infected with serial dilutions of 
thawed MeV-GFP in triplicate. After 72 h, wells were scored for positive or negative 
infection under UV illumination on a Nikon TE- 2000 microscope. 
 
3.1.5 Macrophage cell line J774A.1  
The murine monocyte/macrophage cell line J774A.1 was cultured at 37°C with 5% 
CO2 as described below. Dulbecco’s Modified Eagle Media (DMEM) supplemented 
with 2 mM L- Glutamine, 100 units/mL Streptomycin, 0.1 mg/mL Penicillin and 10% 
FBS was used during culturing. This media will henceforth be referred to as Complete 
DMEM (cDMEM).  
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Stocks of J774A.1 were stored in a liquid nitrogen tank. When needed, cryovials were 
carefully retrieved from the stocks and quickly thawed in a 37°C water bath. Once 
completely thawed, the contents were added to 10 mL warmed cDMEM and spun at 
1000 x g for 5 minutes at room temperature. The resulting pellet was re-suspended in 
15 mL warmed cDMEM and transferred to a T75 tissue culture flask. Flasks were kept 
in a 37°C, 5% CO2, humidified incubator.  
 
Once confluent, as checked by observation under an inverted light microscope, cells 
were passaged. Old media was poured off and replaced with 10 mL fresh warmed 
cDMEM, and cells brought to suspension using a cell scraper. An appropriate dilution 
of the cell suspension was transferred to a new T75 flask and returned to the 
humidified incubator. Cells from passages 5 – 12 only were used for experiments.  
 
3.1.6 Generation of stocks of J774A.1  
Cells no older than passage 2 were used for generating stocks. Freezing media 
consisted of 50% FBS, 40% serum-free cDMEM and 10% dimethyl-sulfoxide (DMSO). 
Eight flasks of J774A.1 at confluent growth were brought to suspension in a total of 10 
mL warmed cDMEM using a cell scraper. Cells were then spun at 1000 x g for 5 
minutes at room temperature. The resulting pellet was re-suspended in 10 mL 
freezing media, yielding 4 – 6 million cells per mL. The suspension was aliquoted into 
1 mL cryovials and frozen to -80°C at a 1°C/minute cooling rate using an isopropanol-
containing chamber. Cryovials were kept at -80°C for 24 hours before being 
transferred to a liquid nitrogen tank.  
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3.1.7 Human macrophage isolation and culture  
All work with human tissue was approved by the University of Birmingham Ethics 
Committee under reference ERN_10-0660. All donors provided written consent prior 
to donation. 20-40 mL of blood were drawn from healthy donors by venepuncture. 6 
mL of whole blood were carefully layered on top of a double layer of Percoll (densities 
of 1.079 and 1.098 g/mL). Samples were centrifuged in a swing bucket rotor at 150 x 
g for 8 minutes, followed by 10 minutes at 1200 x g, with acceleration and brake set to 
zero. The resulting white disc of peripheral blood mononuclear cells (PBMC) was 
transferred to a clean vial and incubated with red blood cell lysis buffer at a ratio of 
1:3 for 3 minutes, with gentle mixing throughout to prevent clot formation. Cells were 
then washed with ice cold phosphate-buffered saline (PBS) twice, with centrifugation 
at 400 x g for 6 minutes in between each wash, and counted with a haemocytometer. 
1 x 106 PBMC were seeded onto 48-well plates in RPMI media containing 1% 
penicillin/streptomycin, 5% heat-inactivated AB human serum (which I will refer to 
as cRPMI) supplemented with 20 ng/mL M-CSF and kept at 37°C and 5% CO2 in a 
humidified incubator. Cells were washed with PBS and re-suspended in fresh media 
on days 3 and 6 of differentiation. Macrophages were ready to use on day 7. A yield 
of 1 x 105 macrophages per well was estimated.  
 
3.1.8 Generation of bone marrow-derived dendritic cells 
Murine bone marrow-derived dendritic cells (BMDC) were produced following the 
method described in Lutz et al [191]. Briefly, bones from hind legs of wildtype BoyJ 
mice were exposed and cleaned with 70% ethanol. Within a cell culture hood, the 
epiphyses were excised with sterilized scissors, exposing the bone marrow. The bones 
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were then perfused with RPMI containing 2% heat-inactivated FBS using a syringe 
fitted with a 24G needle, washing down the bone marrow onto a petri dish. Clumps 
of cells were disaggregated by repeated passages through the needle. The cells were 
counted and made up to a concentration of 3 x 106 cells per 200 µL in PBS, spinning at 
350 x g for 5 minutes if necessary. 200 µL of cell suspension were carefully dispensed 
onto a petri dish containing 10 mL DC-media supplemented with 20 ng/mL GM-CSF 
(hereto referred as differentiation media). DC-media consists of RPMI containing 1% 
penicillin/streptomycin and 10% heat-inactivated FBS. Cells were kept at 37°C and 
5% CO2 in a humidified incubator. On day 3, 10 mL differentiation media were added 
to the dish. On days 6 and 8, 9 mL of media were carefully aspirated from the dish 
and replaced with 10 mL fresh differentiation media. On day 10, 8 mL of media were 
discarded before collecting the cells in the remaining media. The resulting dendritic 
cells were counted and seeded onto culture plates for future assays. 
 
3.1.9 CD4+ T cell isolation 
OT-II mice were generously provided by Dr. David Withers (University of 
Birmingham) and Prof Gordon Brown (University of Aberdeen). Splenocytes were 
isolated by Dr. Guillaume Desanti and the population was enriched in CD4+ T cells 
following the manufacturer’s instructions in a mouse CD4+ T Cell isolation kit 
(Miltenyi Biotec, #130-104-454). The kit works by labelling the splenocytes with a 
negative selection cocktail coupled to biotin. Then adding anti-biotin microbeads, 
followed by magnetic cell separation using a MACS column separator. Unlabelled 
CD4+ T cells were collected in the flow through of the column. 
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3.2 Experimental procedures 
 
3.2.1 Cryptococcal growth curve protocol 
To assess the effect of different compounds on the viability and growth rate of 
Cryptococcus, a growth curve assay was performed. This assay was carried out on a 
48-well plate as follows: 495 µL of YPD broth containing the different compounds to 
be tested were dispensed into individual wells. Each well was subsequently 
inoculated with 5 µL of a ten-fold diluted cryptococcal overnight culture (final 
dilution in well: 1000-fold). Immediately after, the plate was sealed with a breathable 
membrane and taken to a fully automated plate reader (BMG Omega Fluostar). The 
plate was incubated at 37°C without CO2 for 24 hours, with orbital shaking during the 
non-reading part of the cycle. Optical density measures at 600 nm were taken every 
30 minutes during the incubation period.  
 
3.2.2 Cryptococcal infection assay 
Cryptococcal infection assays using human monocyte-derived macrophages were 
carried out in the same plate as the differentiation process described in section 3.1.7, 
to avoid unnecessary detaching and re-seeding steps. For the majority of the infection 
assays performed, macrophages were not previously activated. In initial experiments 
(Figures 5.5 and 5.7 – IFNa data only), human monocyte-derived macrophages were 
activated with 1 µg/mL LPS and 1000 IU/mL IFNg in cRPMI overnight.  
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Immediately before infection, cryptococcal cells from an overnight liquid culture were 
opsonised by incubation with PBS containing 10% human serum (AB serum) for 1 
hour at room temperature on an orbital rotator set at 20 rpm. Alternatively, 
opsonisation was done by incubation with 10 µg/mL anti-capsule antibody (18B7, a 
kind gift from Dr. Arturo Casadeval) in PBS for 1 hour (same conditions as with serum 
opsonisation). 
 
Macrophage media was replaced with serum-free cRPMI, and opsonised-Cryptococcus 
were added to each well respecting an MOI = 10. If the effect of any compound was 
being tested, these would be added to the well at the desired concentration at this 
time.  
 
Two hours later, the media was removed and each well washed 3 times with PBS. 
Fresh serum-free media, containing the appropriate drug concentration if applicable, 
was added to every well. This time point was noted as T0.  
This standard infection assay was followed by different techniques (see below) to 
allow for different read-outs.  
 
3.2.3 Cryptococcus:virus co-infection assay 
Human monocyte-derived macrophages were infected with either attenuated HIV or 
MeV-GFP, and subsequently infected with C. neoformans as follows: 
 
For attenuated HIV co-infections, 24 h before Cryptococcal infection, human 
monocyte-derived macrophages were infected either with R9HIVΔenv at a MOI of 
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10:1, SIV3vpx at 3 ng/mL or both, in serum free-RPMI. At 24 h post infection, duplicate 
wells were fixed in ice cold acetone-methanol and infected cells were identified by 
staining for p24 protein as described above (see section 3.1.4). Experimental wells 
were infected with antibody opsonised-Cryptococcus Kn99a-GFP for 2 hours, washed 
to remove extracellular fungal cells, and replenished with fresh serum free-media. 
 
Alternatively, macrophages were infected with MeV-GFP at an MOI of 5:1 in serum 
free-media and kept at 37°C with 5% CO2. After 24 hours, cells were washed with PBS 
and fresh cRPMI was added. After 3 days, cells were co-infected with serum 
opsonised-Cryptococcus Kn99a-mCherry for 2 hours, washed to remove extracellular 
fungal cells, and replenished with fresh serum free-media. 
 
3.2.4 Cryptococcus:bacteria co-infection assay 
J774A.1 cells were seeded in a 48 well plate, at 0.5 x 105 cells per well, in cDMEM and 
kept at 37°C with 5% CO2 overnight. As of this point, the culture media used was not 
supplemented with antibiotics.  
 
Cells were activated using 150 ng/mL phorbol myrstate acetate (PMA) in serum free-
DMEM for 1 hour, and subsequently infected with AB serum opsonised-Cryptococcus 
Kn99a-GFP at an MOI = 10.  
 
P. aeruginosa PA14 from an overnight liquid culture was washed three times with PBS 
before bacterial concentration was inferred by optical density at 600 nm reading. 
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After 2 hours, Cryptococcus-infected wells were washed three times with PBS to 
remove extracellular fungal cells, and replenished with fresh serum free-media 
containing PA14 at an MOI = 0.25. 
 
3.2.5 Macrophage polarisation assay 
To study the impact of different compounds on the activation state of macrophages, a 
polarization assay was performed. This assay was performed on J774A.1 murine 
macrophages using cDMEM containing heat-inactivated FBS, which will be referred 
to as cDMEM-HI. Macrophages were seeded on a 96-well plate the day prior to the 
experiment at 0.2 x 106 cells/mL in cDMEM-HI and kept in the humidified incubator 
overnight. The following day macrophages were activated with PMA (as indicated in 
section 3.2.4) or incubated with fresh cDMEM-HI for 1 hour. After activation, cells 
were incubated with cDMEM-HI containing the polarising stimuli, in the presence or 
absence of the compound of interest, for 24 hours. Once the incubation was over, the 
plate was put on ice. Supernatants were transferred to a new plate and stored for 
further cytokine measurements and cells were stained for flow cytometry (see sections 
3.3.1 and 3.3.3). 
 
The polarising stimuli used were as follows: 20 ng/mL IL-4 (Immunotools), 20 ng/mL 
lipopolysaccharide (LPS) and 1000 IU/mL IFNg (Immunotools). Compounds tested 
include ERK5 inhibitor XMD17-109 1 µM and DMSO control. 
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3.2.6 Dendritic cell activation assay 
Cells were generated as described in section 3.1.8 and seeded onto a 48-well plate at 1 
x 106 cells per well. One hour after seeding, the activating stimuli was added to the 
cells in RPMI containing 1% penicillin/streptomycin and 10% heat-inactivated FBS. 
Cells were incubated for 24 hours at 37°C with 5% CO2. Once the incubation was done, 
the plate was placed over ice and the supernatant carefully removed. Cells were then 
stained for flow cytometry and the supernatant used in ELISA assays (see sections 
3.3.3 and 3.3.1). 
 
The activating stimuli used were 1 mg/mL chicken ovalbumin (OVA, Invitrogen 
#vac-pova-100) or 100 ng/mL ovalbumin peptide 323-339 (OVAp, #O1641), added in 
combination with AB serum-opsonised Dras1 (see section 3.2.2) at an MOI = 1 or PBS 
10% AB as control. 
 
3.2.7 Dendritic cell:T cell co-culture assay 
To explore the effect of Cryptococcal exposure on antigen presentation and T cell 
proliferation, an in vitro dendritic cell:T cell co-culture was set up. A schematic 
representation of this experimental system can be found in Chapter 6, Figure 6.1.  
 
BMDC were generated as described in section 3.1.8 and seeded in a round-bottomed 
96 well plate at 40 x 103 cells per well. Cells were kept in 50 µL of RPMI containing 
penicillin/streptomycin, supplemented with 10% heat-inactivated FBS, and activating 
stimuli was added in 50 µL increments to make up 200 µL final total volume. 
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BMDC were stimulated with OVA or OVAp (final concentration in well: 1 mg/mL 
and 100 ng/mL, respectively), and AB serum-opsonised C. neoformans (see section 
3.2.2) at an MOI = 1 or PBS 10%AB serum as control. The majority of the work was 
done using the mutant strain Dras1, but wildtype Kn99a and Dcap59Duge1 were also 
tested. 
 
If the effect of drugs or the presence of inert beads were being investigated in the 
system, they were also added at this point. Drugs tested include IFNa (R&D, #12100-
1) at a final concentration of 10 pg/mL, ERK5 inhibitor XMD17-109 at a final 
concentration of 1 µM or DMSO control. 7 µm inert beads (Micro particles based on 
polystyrene, #78462) were treated in the same way as C. neoformans before being 
added to BMDC; they were washed with PBS three times and opsonised in PBS 10% 
AB serum for 1 hour (see section 3.2.2). Stimulated BMDC were incubated at 37°C with 
5% CO2 overnight. 
 
CD4+ T cells from spleen of OT-II mice were isolated as described in section 3.1.9. The 
population enriched in CD4+ T cells was then labelled with carboxyfluorescein 
succinimidyl ester (CFSE) using CellTraceTM CFSE Cell Proliferation kit (Invitrogen, 
#C34554) and following manufacturer’s instructions. CFSE-labelled CD4+ T cells were 
added to stimulated BMDC at 5:1 ratio (200 x 103 cells per well). 
 
After 4 days-incubation, supernatants were carefully removed and stored at -80°C for 
further cytokine profiling, and cells were stained for flow cytometry (see sections 3.3.2 
and 3.3.3).   
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3.3 Molecular Techniques 
 
3.3.1 Enzyme-linked Immunosorbent assay (ELISA) 
Supernatants from infection or polarisation assays were stored at -80°C until analysis. 
IL-10, IL-12p40, TNFa and Ym1 levels were measured by sandwich ELISA using 
various kits and antibody pairs, see table below. In all cases the ELISA protocol 
provided by R&D was followed, using an 8-point standard curve with recombinant 
protein. 
 
Cytokine Species Brand 
Capture Antibody Detection Antibody 
[Highest Std] 
# Catalogue # Catalogue 
IL-10 
mouse 
R&D 
DY417 DY417 
2000 pg/mL 
human DY217B DY217B 
IL-12p40 
mouse 
R&D 
DY499 DY499 2000 pg/mL 
human DY1240 DY1240 4000 pg/mL 
TNFa 
mouse R&D DY410 DY410 
2000 pg/mL 
human BD 551220 554511 
Ym1 mouse R&D MAB2446 BAF2446 5000 pg/mL 
 
 
3.3.2 Multianalyte profiling (Luminex)  
Supernatants from DC:T cell co-cultures were stored at -80°C until analysis. IL-2, IFNg, 
TNFa, IL-4, IL-13 and IL-17A levels were measured using a custom multiplex panel 
(ProcartaPlex Immunoassay, Invitrogen), following manufacturer’s instructions and 
Table 3.1 Antibody pairs used for ELISA measurements 
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acquired in a Luminex 200 system. Multianalyte profiling follows a similar protocol 
to conventional sandwich ELISA, but allows for the concentration of multiple proteins 
within one sample to be read simultaneously.  
 
 
3.3.3 Flow Cytometry 
The staining protocol was carried out on the same plate as the experiment was done 
previously, to avoid damaging potentially important epitopes during detachment of 
the cells. Throughout the staining protocol the cells were kept on ice, exposed to EDTA 
for a prolonged period of time and finally fixed with the fixative included in Foxp3 / 
Transcription Factor Staining Buffer Set (eBioscience #00-5523-00), ensuring the lifting 
of the majority of the cells within the samples. 
 
Cells were placed on ice and washed twice with PBS, spinning at 350 x g for 5 minutes 
each time. Afterwards, the samples were incubated with 10 µL of a fixable live-dead 
dye (Thermo Fisher) at room temperature, protected from the light. After 10 minutes, 
10 µL of a blocking solution was added on top, to inhibit non-specific binding of the 
labelling antibodies to the samples on the following step. The samples were kept on 
ice and protected from the light form here onwards. After at least 15 minutes, 30 µL 
of the antibody mix was added to the samples and incubated for 30 minutes. The cells 
were then washed twice with PBS containing 2 mM EDTA and 0.1% BSA, spinning at 
350 x g for 5 minutes each time. The samples were then fixed by incubation with 100 
µL of the fixative present in Foxp3 / Transcription Factor Staining Buffer Set 
(eBioscience #00-5523-00) overnight at 4°C or 20 minutes at room temperature. 
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Finally, the samples were washed twice with PBS containing 2 mM EDTA and 0.1% 
BSA, spinning at 350 x g for 5 minutes each time. 
 
Fixed samples were acquired on an Attune flow cytometer and data was analysed 
using FlowJo v10. 
 
A table containing the specific antibodies and dilutions used is below. Isotype controls 
were included for every activation marker used. 
 
Antigen Conjugate Company # Catalogue Clone Isotype Dilution 
CD4 eFluor450 eBioscience 48-0041-82 GK1.5 Rat IgG2b, k 200 
CD11c PECy7 eBioscience 25-0114-82 N418 
Arm. 
Hamster 
IgG 
1000 
CD11b BV605 BD 563015 M1/70 Rat IgG2b, k 300 
CD40 PEDazzle594 BioLegend 124629 3/23 Rat IgG2a, k 50 
CD45 PerCPCy5.5 eBioscience 45-0451-80 30 F11 Rat IgG2b, k 200 
CD86 FITC BD 561962 GL1 Rat IgG2a, k 200 
CD115 PEeFluor610 eBioscience 61-1152-82 AFS98 Rat IgG2a, k 1000 
CD135 PECy5 eBioscience 15-1351-81 A2F10 Rat IgG2a, k 50 
CCR7 
(CD197) PerCPCy5.5 eBioscience 45-1971-80 4B12 
Rat 
IgG2a, k 50 
MR 
(CD206) PECy7 BioLegend 141720 C068C2 
Rat 
IgG2a, k 200 
 60 
OX40L 
(CD252) FITC Invitrogen MA5-17912 OX89 Rat IgG1 50 
PDL2 
(CD273) BV711 BD 740818 TY25 
Rat 
IgG2a, k 100 
MGL 
(CD301) PE BioLegend 145704 
LOM-
14 
Rat 
IgG2b, k 100 
MHC-II PB BioLegend 107619 M5/114.15.2 
Rat 
IgG2b, k 1000 
Live-
Dead Aqua Thermo L34957 - - 500 
 
 
3.3.4 Live imaging 
Time-lapse imaging was performed following a standard infection assay, typically to 
study vomocytosis rates. Time-lapse movies were created by compiling images taken 
every 5 minutes over 18 hours. Throughout the imaging period, samples were 
incubated at 37°C in a 5% CO2 atmosphere within the imaging chamber of a Ti-E 
Nikon Epifluorescence Microscope. The resulting files were analysed using NIS 
viewer software. 
 
For analysis, time-lapse movie files were blinded and scored manually. Information 
regarding number of infected macrophages, proliferation of phagocytosed 
cryptococci, macrophage lysis and vomocytosis events was recorded.  
Table 3.2 Antibodies and reagents used in flow cytometry 
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3.4 Statistical analysis 
 
The statistical analysis was performed using GraphPad Prism software version 6. The 
particular test used in each case is specified in the figure legend. Generally, differences 
in categorical data (vomocytosis occurrence and infection efficiency) were analysed 
by Chi2 test followed by Fisher’s Exact test; differences in percentage data (such as 
proliferation of T cells) were analysed by TwoWay ANOVA followed by Tukey’s post-
test on Arcsine-transformed data; all other data (IPR, expression of activation markers 
and cytokine levels) were analysed using Mann-Whitney test, or TwoWay ANOVA 
followed by Tukey’s post-test.  
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4 Studying the effect of ERK5 inhibition on 
macrophage polarisation 
 
Some of the results shown in this chapter have been published in a research article of 
which I am a co-author [84]. The complete paper can be found in the Appendix. 
 
Macrophages are very plastic cells which can adopt different activation states 
according to the external cues they sense. In turn, their activation state will influence 
the way they respond to their environment [192]. One aspect that has been shown to 
be affected by macrophage polarisation is vomocytosis of Cryptococcus neoformans; IL-
4-polarised cells exhibit lower occurrence of vomocytosis than their LPS-polarised 
counterparts [83]. More recently, inhibition of the MAP kinase ERK5 has been linked 
to vomocytosis [84]. This prompted us to explore whether ERK5 could affect 
macrophage polarisation. 
 
The first insight into the ability of macrophages to display different activation 
phenotypes came in the 1990s, when Stein et al. reported that IL-4 stimulation 
produced an “alternative activation” to that elicited by IFNg [193]. Since then, different 
activating stimuli responsible for specific activation states have been reported and 
compiled into what is now known to be a fluid activation spectrum [194]. Adoption 
of a systematic nomenclature to designate each activation phenotype, with its defining 
markers and effector molecules, has been challenging [195]. In this work, I have used 
the widely-accepted IL-4 and LPS + IFNg polarising agents. These are known to 
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induce opposite ends of the activation continuum, traditionally termed alternative 
and classical activation phenotypes, or more accurately M(IL-4) and M(LPS + IFNg), 
respectively [195].  
 
 
4.1. Setting up a macrophage polarisation assay 
To assess the impact of ERK5 inhibition on macrophage activation, a polarisation 
assay was devised. This consists of stimulating J774 cells with the prototypical 
polarising agents; IL-4 or LPS + IFNg, and assessing their activation state 24 hours 
post-stimulation through expression of surface markers by flow cytometry and 
evaluation of secreted molecules in the culture supernatant by ELISA. The panel of 
surface markers and secreted proteins studied can be seen in the following table. 
 
Marker Function Polarisation 
CD11b Integrin (myeloid marker)  
CD86 Co-stimulatory molecule (binds to CD28) 
Classical 
IL-12p40 Pro-inflammatory cytokine 
CD206 Mannose receptor 
Alternative MGL Lectin 
Ym1 Chitinase-like protein 
Live-Dead Viability dye  
 
 
Table 4.1. Surface markers and cytokines examined in polarisation assays. 
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M(IL-4) macrophages were characterised by expression of CD206, CD301 and 
secretion of Ym1. CD206 (C-type Mannose Receptor 1, also known as MR) and CD301 
(Macrophage galactose-type C-type lectin, also known as MGL) are transmembrane 
receptors for glycoproteins whose expression is enhanced by IL-4-stimulation. Ym1, 
also termed Chitinase-3-like protein 3 (Chi3l3), is a lectin with affinity for 
glycosaminoglycans. As its name suggests, it binds chitin, but has no chitinase 
activity. Its expression is also enhanced by IL-4-stimulation.  
 
M(LPS + IFNg) were characterised by expression of CD86 and secretion of IL-12p40. 
CD86 is a co-stimulatory molecule, necessary for priming of T cells, where it binds to 
CD28 and CTLA-4 [196, 197]. IL-12 is a cytokine produced by activated antigen-
presenting cells, such as macrophages and dendritic cells, which polarises the T cell 
response to Th1 [198, 199]. It should be noted that IL-12 is a heterodimer composed of 
p35 and p40 subunits [200]. The reagents used in this work only bind to the p40 
subunit, which is shared with the cytokine IL-23. This cytokine can also be produced 
by macrophages, and has been implicated in polarisation to a Th17 response [201, 202]. 
 
Activating J774 cells with PMA before infection assays is standard practice, since it 
has been shown to increase the phagocytic ability of these cells [203]. However, it is 
also thought to drive production of IFNg and hence polarise the cells towards a 
classical activation phenotype [204, 205], hindering any potential effect of IL-4. Initial 
experiments while optimising the assay were performed both with PMA-activated 
and non-activated J774 macrophages (Figure 4.1).  
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Figure 4.1 Optimisation of J774 polarisation assay 
J774 macrophages were incubated with the indicated dose of IL-4, 1000 IU/mL 
IFNg, 20 ng/mL LPS or LPS combined with IFNg for 24 hours. After incubation, 
the cells were stained for different activation markers and analysed by flow 
cytometry, and the culture supernatant was probed for cytokine production by 
ELISA.  
Bars correspond to Geometric Mean + SD of expression of CD86 (A), MGL (C) or 
CD206 (D). Flow cytometry data was analysed by Two-way ANOVA with 
Tukey’s post-test. Asterisks over bars indicate a significant difference with the 
basal condition (indicated as “–“); * = p<0.05, ** = p<0.01, *** = p<0.001, **** = 
p<0.0001. Data shown is representative of two independent experiments.  
Cell culture supernatants were analysed for different cytokines. Bars correspond 
to Mean + SD of levels of IL-12p40 (B) or Ym1 (E). Data corresponds to one pilot 
experiment. 
In both cytometry and ELISA data, coloured bars correspond to non-activated 
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Figure 4.1 shows that J774 cells were successfully polarised with LPS + IFNg to express 
the surface marker CD86 (A) and secrete IL-12p40 (B). Conversely, stimulation with 
IL-4 leads to increased expression of the surface markers MGL (C) and CD206 (D), and 
secretion of Ym1 (E). Technically, it shows that the doses of IL-4 used during 
optimisation of the assay are already at saturating levels of the markers assayed, and 
that a combination of LPS + IFNg achieves the more robust polarisation, compared to 
each stimulus on its own. Rather surprisingly, PMA-activation did not have an effect 
on the markers or secreted molecules studied. Nonetheless, the following experiments 
were carried out on non-activated J774 cells to dissect the effect of ERK5 inhibition 
exclusively and limit potential artefacts due to PMA-activation in conjunction with 
the treatment.  
 
 
4.2 Inhibition of ERK5 during macrophage polarisation 
Treatment with the ERK5 inhibitor XMD17-109 (XMD) at 1 µM, either on its own or 
in conjunction with LPS + IFNg stimulation, did not affect the expression of the surface 
marker CD86, traditionally regarded as a “classical activation marker” (Figure 4.2A). 
On the other hand, treatment with this inhibitor significantly reduced the expression 
of MGL induced by IL-4, rendering it similar to basal level expression (Figure 4.2C). 
In terms of the secreted molecules evaluated, inhibition of ERK5 enhanced the 
secretion of IL-12p40 induced by LPS + IFNg (Figure 4.2B) and reduced that of Ym1 in 
response to IL-4 (Figure 4.2D). 
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Figure 4.2 Inhibition of ERK5 enhances pro-inflammatory response in J774 cells 
J774 macrophages were stimulated with 20 ng/mL IL-4 or 20 ng/mL LPS + 1000 
IU/mL IFNg for 24 hours, in the presence or absence of 1 µM ERK5 inhibitor XMD17-
109 (XMD) or DMSO control. After incubation, cells were stained for activation 
markers by flow cytometry and supernatant was analysed for cytokine production 
by ELISA. 
Bars correspond to Geometric Mean + SD of expression of CD86 (A) or MGL (C) with 
respect to the unpolarised condition. Data from three independent experiments, 
analysed by Two-way ANOVA with Tukey’s post-test: * p £ 0.05; ** p £ 0.01; *** p £ 
0.001; **** p £ 0.0001. Asterisks not associated with connecting brackets represent 
differences with respect to the basal expression on each group. 
Cell culture supernatants were analysed for cytokine production. Bars correspond to 
levels of IL-12p40 (B) or Ym1 (D) with respect to the DMSO control. Data from three 
independent experiments, analysed by paired ratio t-test: ** p £ 0.01. 
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Collectively this shows that inhibition of ERK5 in J774 cells leads to a shift in the 
population to a pro-inflammatory phenotype, with increased IL-12p40 secretion when 
stimulated with LPS + IFNg and reduced response to IL-4 polarisation. 
 
 
The effects of ERK5 inhibition on macrophage polarisation were also tested on human 
monocyte-derived macrophages. In this context, inhibition of ERK5 also lead to a pro-
inflammatory phenotype, with enhanced TNFa secretion when stimulated with LPS 
+ IFNg and reduced secretion of IL-10 in response to IL-4 (Figure 4.3).  
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Figure 4.3 Inhibition of ERK5 enhances pro-inflammatory response in human 
macrophages 
Human monocyte-derived macrophages were stimulated with LPS + IFNg or IL-4, 
in the presence of the ERK5 inhibitor XMD17-109 (XMD) or DMSO control. After 
24 hours, cell culture supernatants were analysed for pro-inflammatory cytokine 
TNFa (A) and regulatory cytokine IL-10 (B). Bars correspond to Mean + SD levels 
of cytokine with respect to that present in DMSO control condition. Data from at 
least three independent experiments, analysed by paired ratio t-test: * p £ 0.05.  
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4.3 Closing remarks 
Overall, the results shown in this chapter point to a clear link between macrophage 
polarisation and the atypical MAP kinase ERK5. Since earlier work has shown that 
both inhibition of ERK5 [84] and polarisation of macrophages [83] lead to changes in 
the occurrence of vomocytosis, it is plausible that the molecular mechanism for 
vomocytosis shares intermediary signalling molecules with either phenomenon.  
Previous work from this lab showed that inhibition of ERK5 was able to enhance 
vomocytosis beyond the effect of saturating doses of IFNg [206]. This suggests that 
even though they may share signalling molecules, their mechanisms of action are not 
redundant. Further work is necessary to pinpoint the molecular mechanism by which 
ERK5 influences macrophage polarisation, and how it is able to modulate 
vomocytosis.  
 
It has been discussed before that macrophage polarisation responds to the cells 
sensing different stimuli in their environment. In vitro, this has been recapitulated by 
stimulating with recombinant cytokines or sterile preparations. In vivo, however, 
macrophage polarisation is often seen during infection, with intracellular bacteria 
producing a “classical activation” phenotype [207, 208] and parasitic infections 
resulting in “alternatively activated” cells [17]. 
 
Cryptococcus neoformans is able to infect macrophages and persist within the host as a 
latent infection [12]. Thus, it is likely that Cryptococcus-infected macrophages will 
encounter different infectious scenarios, with different polarising abilities. The results 
presented here would relate to bacterial or parasite:cryptococcal co-infection. In 
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resource-poor settings like rural Africa, most cryptococcosis patients will also be 
endemically infected with parasites [209, 210]. The results here presented suggest that 
these co-infection settings could impact the fungus’s vomocytosis rates. Nevertheless, 
cryptococcosis is most associated with HIV+ patients [14], who suffer from a chronic 
viral infection. The effects of viral infection on vomocytosis will be addressed in the 
next chapter.  
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5 Exploring the impact of viral infection on 
vomocytosis 
 
Some of the results presented in this chapter have been published in a research article 
of which I am a co-author [179]. The complete article can be found in the Appendix. 
 
The relevance of cryptococcosis to HIV+ patients is undeniable, and yet most studies 
on Cryptococcal infection have been performed on otherwise healthy cells. Co-
infection settings can drastically alter the cellular response to any one pathogen, with 
important consequences for overall disease progression. In this chapter I describe our 
work looking at Cryptococcal infection on macrophages undergoing a viral infection, 
with a particular focus on vomocytosis.  
 
As mentioned in the introduction to this work, viral infection triggers an anti-viral 
immune response. Sensing of viral PAMPS (Figure 5.1) and the ensuing of an 
appropriate immune response is a very complex process. It involves the recognition 
of viral PAMPS either from the extracellular media through Toll-like receptor (TLR)-
binding or intracellularly via RNA or DNA sensors. Signalling cascades from these 
sensing steps converge in the activation of nuclear factor (NF)-kB for production of 
pro-inflammatory cytokines, and activation of the interferon regulatory factor (IRF) 3 
or IRF7, which lead to the production of type-I interferons (IFN) [211, 212].  
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Figure 5.1 Viral sensing signalling cascade 
Host cells have several innate receptors capable of sensing invading viruses. Toll-like 
receptors (TLR) present on the cell surface (TLR2 and TLR4) and endosomal membrane 
(TLR3, TLR7/8 and TLR9) recognise viral glycoproteins and nucleic acids, respectively. 
Within the cytoplasm, viral RNA is sensed by RIG-I and MDA-5, and viral DNA is sensed 
through cGAS-STING. Any virus may be sensed by multiple different receptors during its 
infection cycle. Once these pattern recognition receptors are engaged, they lead to the 
activation of NF-kB and expression of pro-inflammatory cytokines, and activation of IRF3 
(via TBK1:IKKe) or IRF7, which lead to the production of type-I interferons. Figure adapted 
from Melchjorsen, J., Viruses, 2013 [211] and Takeuchi et al., Cell, 2010 [212]. 
cGAS = cyclic GMP-AMP synthase, ER = Endoplasmic reticulum, IFN = interferon, IKK = 
inhibitor of nuclear factor kB kinase, IRF = interferon regulatory factor, MDA-5 = melanoma 
differentiation associated gene-5, NF-kB = nuclear factor kB, RIG-I = retinoic acid inducible 
gene-I, STING = stimulator of interferon genes, TBK1 = TANK binding kinase 1, TLR = toll-
like receptor. 
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5.1 HIV infection enhances vomocytosis of Cryptococcus neoformans 
As explained on the introduction, HIV targets CD4+ cells such as T cells, macrophages 
and CD4-expressing dendritic cells. Over the course of infection, HIV will cause the 
decline of CD4+ T cell numbers ultimately leading to the condition known as AIDS 
[31]. 
To gain entry into cells, two receptors, CD4 and a co-receptor, act sequentially to 
trigger fusion of viral and cellular membranes. Both receptors interact with the viral 
envelope glycoprotein [213]. Interaction with CD4 causes a conformational change 
within the viral protein subunit gp120, which exposes a binding site for a co-receptor 
[214]. Engagement of both CD4 and co-receptor with the viral envelope glycoprotein 
induces a further conformational change which exposes the membrane fusion peptide 
in the gp41 subunit, essential for membrane pore formation and cell entry of the viral 
particle [215].  
The two co-receptors widely used in vivo are the chemokine receptors CCR5 and 
CXCR4 [216]. HIV strains can be broadly classified according to their co-receptor 
usage into R5, X4 or R5X4 strains, which use respectively CCR5, CXCR4 or either, as 
co-receptor [217]. An older system classified HIV strains as macrophage (M)-tropic or 
T cell (T)-tropic according to their ability to replicate in these cells in vitro [217].  
Despite macrophages expressing both CD4 and CCR5 on their surface, HIV-1 does not 
replicate well in these cells [218-220]. This is due to the restriction factor SAMHD1, a 
dNTP hydrolase which limits reverse transcription and acts as a post-entry restriction 
step for HIV [221, 222]. The lentiviral accessory gene vpx, not present in HIV-1, 
encodes for a protein which targets SAMHD1 for proteasomal degradation [223].  
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In order to study the interaction of HIV and Cryptococcus within macrophages, we 
modified a system developed by the Noursadeghi lab which uses two virus-like 
particles (VLP) to achieve a fully infectious preparation. One of the VLP consists of 
the gene for vpx within the simian immunodeficiency virus envelope (SIVvpx), while 
the other is an envelope-deficient attenuated strain of HIV (R9HIVDenv). When both 
VLPs are added to the culture well, this system ensures single-round replication of the 
attenuated virus within macrophages, yielding an infection rate similar to 
macrophage-tropic HIV strains [224].  
 
The results shown below (Figures 5.2 and 5.3) were obtained by Dr. Leanne Taylor-
Smith and are included in this thesis, with her consent, as they are integral to the 
development of my PhD research. 
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Figure 5.2 HIV infection enhances vomocytosis of C. neoformans 
Human monocyte-derived macrophages were infected with attenuated HIV and 
subsequently infected with GFP-tagged C. neoformans. Infected cells were imaged every 
5 minutes over a period of 18 hours (A). Time-lapse microscopy videos were manually 
scored for vomocytosis (B), uptake (C) and intracellular proliferation rate (IPR, D) of 
C. neoformans. 
A. Schematic representation of the experimental plan. 
B. Graph shows percentage of Cryptococcus-infected macrophages which have 
experienced at least one vomocytosis event during the 18 hour-experiment. Categorical 
vomocytosis data was analysed using Chi2 followed by Fisher’s exact test. * p < 0.05 
C. Graph shows percentage of Cryptococcus-infected macrophages. Categorical 
phagocytosis data was analysed using Chi2 followed by Fisher’s exact test. 
D. Graph shows intracellular proliferation rate (IPR) of C. neoformans over 18 hours. 
IPR data was analysed using Mann-Whitney test. 
All data corresponds to 7 independent experiments. Approximately 580 macrophages 
were scored. Data obtained by Dr. Leanne Taylor-Smith. 
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Figure 5.3 Viral exposure enhances vomocytosis of C. neoformans 
A. Human monocyte-derived macrophages were infected with virus like particles (VLP) 
as indicated. After 24 hours, HIV viral infection was assessed by p24 staining (blue). 
B. Human monocyte-derived macrophages were infected with VLPs as indicated, and 
subsequently infected with GFP-tagged C. neoformans. Time-lapse microscopy videos were 
manually scored for vomocytosis. Graph shows percentage of Cryptococcus-infected 
macrophages which have experienced at least one vomocytosis event during the 
experiment. Raw vomocytosis data was analysed by Chi2 followed by Fisher’s exact test. * 
p < 0.05; **** p < 0.0001. Data from 5 independent experiments. Approximately 810 
macrophages were scored. Data from HIV + vpx condition also shown in Figure 5.2. 
Data obtained by Dr. Leanne Taylor-Smith. 
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Human monocyte-derived macrophages were infected with attenuated HIV (in 
conjunction with SIVvpx to ensure macrophage infection) for 24 hours, and 
subsequently infected with GFP-labelled C. neoformans. The infected cells were then 
imaged over 18 hours and the resulting time-lapse movies were manually scored for 
vomocytosis, uptake and intracellular proliferation rate (IPR) of the fungus (Figure 
5.2). The figure shows that infection with HIV induced an enhancement of 
vomocytosis of C. neoformans, without significantly altering phagocytosis or IPR. 
 
Immunostaining of the capsid protein p24 was performed on infected wells to confirm 
HIV infection (Figure 5.3A). The images show that attenuated HIV alone was capable 
of replicating only in a minority of the cells present, whereas the fully infectious HIV 
+ SIVvpx condition reached 100% infection. It is important to note that the Vpx 
complement was delivered to the cells within a viral envelope, but it does not contain 
p24. Interestingly, however, despite the varying infection rates in these different 
conditions, all three combinations enhanced vomocytosis (Figure 5.3B), albeit to 
different extents. Consequently, the effect on vomocytosis is not specific to HIV 
infection, but rather may be a broader effect of viral exposure. 
 
 
5.2 Other viral infections affect vomocytosis 
To test whether the effect seen is specific to HIV, we turned to a different virus; 
measles virus (MeV). MeV belongs to the family Paramyxoviridae within the genus 
Morbillivirus and, as the name suggests is the causative agent of measles. MeV infects 
cells primarily through interaction with the signalling lymphocyte activation 
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molecule (SLAM) [225], which is present on immature thymocytes, activated T 
lymphocytes, macrophages and dendritic cells. Thus, MeV is an excellent candidate 
to test whether the effects observed are exclusive to HIV infection, or can also be 
achieved with a distinct virus capable of infecting macrophages, whose prevalence 
has no correlation with that of cryptococcosis.  
 
Human monocyte-derived macrophages were infected with GFP-tagged MeV, and 
subsequently infected with mCherry-labelled C. neoformans. Time-lapse microscopy 
movies were scored for vomocytosis, uptake and IPR of the fungus (Figure 5.4). The 
figure shows that infection with MeV also enhanced vomocytosis of C. neoformans, 
without altering phagocytosis rates or IPR.  
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Figure 5.4 MeV infection enhances vomocytosis of C. neoformans 
Human monocyte-derived macrophages were infected with GFP-tagged measles virus 
(MeV) and subsequently infected with mCherry-tagged C. neoformans. Infected cells were 
imaged every 5 minutes over a period of 18 hours (A). Time-lapse microscopy videos were 
manually scored for vomocytosis (B), uptake (C) and intracellular proliferation rate (IPR, 
D) of C. neoformans. 
A. Schematic representation of the experimental plan. 
B. Graph shows percentage of Cryptococcus-infected macrophages which have experienced 
at least one vomocytosis event during the 18 hour-experiment. Categorical vomocytosis 
data was analysed using Chi2 followed by Fisher’s exact test. * p < 0.05 
C. Graph shows percentage of Cryptococcus-infected macrophages. Categorical 
phagocytosis data was analysed using Chi2 followed by Fisher’s exact test. 
D. Graph shows intracellular proliferation rate (IPR) of C. neoformans over 18 hours. IPR 
data was analysed using Mann-Whitney test. 
All data corresponds to 3 independent experiments. Approximately 300 macrophages were 
scored. 
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5.3 Active viral infection is not required to enhance vomocytosis 
To further extend this finding and test whether an active viral infection is required, 
macrophages were stimulated with polyinosinic-polycytidilic acid (polyIC) before 
being infected with C. neoformans (Figure 5.5). polyIC is a double stranded RNA 
synthetic analogue, which binds to TLR3 and mimics a viral infection. Stimulation 
with this generic viral PAMP also induced an increase in vomocytosis (A), and did 
not affect uptake nor intracellular proliferation of the fungus (B and C). 
 
 
 
 
Taken together, the data above show that infection with two unrelated viruses leads 
to an enhancement in vomocytosis of C. neoformans. HIV and MeV belong to different 
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Figure 5.5 Active viral infection is not required for enhancement of vomocytosis 
Human monocyte-derived macrophages were stimulated with different doses of a 
double-stranded RNA synthetic analogue, polyIC, and infected with C. neoformans. 
Time-lapse microscopy videos were manually scored for vomocytosis (A), uptake (B) 
and intracellular proliferation rate (IPR, C) of the fungus. 
A. Graph shows percentage of infected macrophages which have experienced at least 
one vomocytosis event during the experiment. Chi2 followed by Fisher’s exact test 
were performed on vomocytosis raw counts. *** p < 0.001 
B. Percentage of infected macrophages. Categorical phagocytosis data was analysed 
by Chi2 followed by Fisher’s exact test. 
C. Intracellular proliferation rate (IPR) of C. neoformans over 18 hours. IPR data was 
analysed using Friedman followed by Dunn’s post-test. 
Data corresponds to 3 independent experiments. Approximately 830 macrophages 
were scored.  
 81 
genera (Lentivirus and Morbillivirus, respectively) and achieve infection of 
macrophages through different receptors (CD4 and SLAM, respectively), but 
nevertheless cause an enhancement of vomocytosis of C. neoformans without affecting 
other parameters of fungal infection. Moreover, the same effect was seen when 
stimulating with the sterile viral PAMP polyIC, showing that an active viral infection 
is not required, something that is further supported by our observation that addition 
of Vpx complement in the form of a viral particle also causes an enhancement of 
vomocytosis. 
 
 
5.4 Enhancement of vomocytosis is not dependent on TBK1:IKKe 
signalling nor TLR3 sensing  
The different infection or stimulation settings studied in this chapter have all involved 
the sensing of viral antigens and concomitant triggering of an anti-viral response. 
Hence, we turned to the signalling cascade involved in these events in the search for 
a possible mechanism by which the enhancement of vomocytosis is accomplished (see 
Figure 5.1). 
 
We initially tested pharmacological inhibition of the TBK1:IKKe complex, which is 
central to viral sensing. This complex is engaged in different viral sensing pathways, 
and leads to activation of IRF3 and type-I IFN production. The compound used, 
BX795, inhibits the catalytic activity of TBK1:IKKe by blocking its phosphorylation 
[226]. 
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Similarly, we also tested the effect of inhibiting viral sensing through TLR3-binding. 
A dsRNA:TLR3 complex inhibitor was tested, which selectively inhibits TLR3-binding 
by direct and high affinity competition [227] (Figure 5.6A). 
 
The figure shows that the compounds did not affect vomocytosis when used in a viral 
infection setting, despite them being able to abrogate the effect seen with polyIC 
stimulation. PolyIC is a defined PAMP, which triggers an anti-viral response through 
its engagement with TLR3 and signalling through TBK1:IKKe [228]. Both inhibitors 
revoked the effect of polyIC on vomocytosis, therefore serving as an indirect control 
for the compounds effectiveness (Figure 5.6B). Conversely, infection with HIV is a 
much more complex stimulus which is sensed through various mechanisms [229], and 
the effect of this infection on vomocytosis could not be abolished by inhibition of these 
two molecules alone. This suggests that the effect on vomocytosis is not due to a 
particular signalling molecule, but rather to the overall ensuing of an anti-viral state. 
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Figure 5.6 Vomocytosis effect is not dependent on TBK1:IKKe engagement nor TLR3 
sensing  
Human monocyte-derived macrophages were infected with attenuated HIV (A) or 
stimulated with polyIC (B) and subsequently infected with C. neoformans, in the 
presence or absence of a TBK1:IKKe or TLR3:dsRNA inhibitor. 
Graphs show percentage of infected macrophages which have experienced at least one 
vomocytosis event during the experiment. Error bars correspond to SD. Raw 
vomocytosis data was analysed by Chi2 followed by Fisher’s exact test. **** p< 0.0001 
Data corresponds to 2 (A) or a single (B) donors. Approximately 2000 and 350 
macrophages were scored, respectively. 
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5.5 Type-I interferons enhance vomocytosis 
The hallmark of an anti-viral response is the production of type-I interferons. This 
group is comprised of IFNa, IFNb, IFNe, IFNk and IFNw in humans [211]. The two 
most studied type-I interferons are IFNa  and IFNb, which are also the most abundant 
in plasma of HIV+ patients [105]. We therefore tested whether stimulation with 
recombinant IFNa or IFNb would be enough to enhance vomocytosis of C. neoformans 
(Figure 5.7). 
 
 
 
 
 
Figure 5.7 Type-I interferons enhance vomocytosis of C. neoformans 
Human monocyte-derived macrophages were stimulated with different doses of IFNa 
(left, yellow data) or IFNb (right, green data), and infected with C. neoformans. Time-lapse 
microscopy videos were manually scored for vomocytosis (top row), phagocytosis (second 
row) and intracellular proliferation of the fungus (third row). Vomocytosis raw data was 
analysed by Chi2 followed by Fisher’s exact test. *** p < 0.001. Data corresponds to at least 
3 independent experiments. Approximately 2300 macrophages were scored. 
Extracellular growth of C. neoformans in the presence of type-I interferons was monitored 
(last row). Optical density readings at 600nm were taken every 30 minutes, in the presence 
of 10 pg/mL of IFNa (left, yellow), 50 pg/mL IFNb (right, green), or un-supplemented 
YPD controls. Data representative of at least 2 independent experiments. 
 85 
 
 
- 5 10
0
20
40
60
80
100
%
 P
ha
go
cy
to
si
s
IFNα (pg/mL)
- 5 10
0.0
0.5
1.0
1.5
IP
R
IFNα (pg/mL)
5 10 15 20 25
0.0
0.5
1.0
1.5
Time (h)
O
D
 (6
00
 n
m
)
Kn99α Kn99α + IFNα
- 10 50
0
20
40
60
80
100
%
 P
ha
go
cy
to
si
s
IFNβ (pg/mL)
- 10 50
0.0
0.5
1.0
1.5
IP
R
IFNβ (pg/mL)
- 5 10
20
40
60
80
%
 V
om
oc
yt
os
is
***
IFNα (pg/mL)
- 10 50
0
5
10
15
20
%
 V
om
oc
yt
os
is
IFNβ (pg/mL)
***
0 5 10 15 20 25
0.0
0.5
1.0
1.5
Time (h)
A
bs
 6
00
 n
m
Kn99α Kn99α + IFNβ
IFNα IFNβ
Vo
m
oc
yt
os
is
Ph
ag
oc
yt
os
is
In
tra
ce
llu
la
r
Pr
ol
ife
ra
tio
n
G
ro
w
th
 86 
Stimulation with low doses of IFNa or IFNb enhanced vomocytosis (first row), 
without affecting uptake or IPR (middle rows). The doses used are in line with those 
found in the plasma of HIV+ patients [105], and translate to 7.3 and 14 IU/mL IFNa 
and IFNb, respectively. At these doses, interferons did not affect cryptococcal growth 
(last row). 
 
The genes for type-I interferons share chromosomal location (clustered in 
chromosome 9 in humans) and the resulting cytokines have similarities in structure, 
regulation and function, a key feature being that they all signal through the IFNa/b 
receptor (IFNAR) [107] to generate an anti-viral state. 
 
 
To further confirm the role of type-I interferons in the enhancement of vomocytosis, 
Cryptococcus-viral co-infection experiments were repeated in the presence of an 
IFNAR blocking antibody (clone MMHAR-2, Figure 5.8). The reagent used is a 
monoclonal blocking antibody, which prevents interaction of the receptor with its 
ligand, without triggering intracellular signalling, and has been used extensively in 
the literature [230]. 
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Figure 5.8 Type-I interferon signalling is necessary for effect on vomocytosis 
Human monocyte-derived macrophages were infected with attenuated HIV (A) or GFP-
tagged MeV (B) and subsequently infected with C. neoformans, in the presence or absence 
of a IFNa/b receptor (IFNAR) blocking antibody. 
GFP-negative cells, which do not have a strongly active MeV infection, were termed 
“Non-MeV”. 
Graphs show percentage of Cryptococcus-infected macrophages which have experienced 
at least one vomocytosis event during the experiment. Raw vomocytosis data was 
analysed using Chi2 followed by Fisher’s exact test. ** p < 0.01: *** p < 0.001: **** p < 
0.0001. Approximately 1500 macrophages were scored. 
Data corresponds to 2 and 3 biological repeats, respectively. 
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Figure 5.8 shows that the enhancement of vomocytosis was completely abrogated 
when type-I interferon signalling is blocked, regardless of which virus is co-infecting. 
In the case of MeV, the GFP-tag allows for visual discrimination of cells with active 
viral infection from neighbouring GFP- cells within the well, referred to as Non-MeV 
in Figure 5.8B. It is remarkable that the effect on vomocytosis is restricted to those cells 
where the infection with MeV is clearly distinguished as GFP+. It should be noted that 
neighbouring “Non-MeV” cells might be infected with MeV but at a dose which falls 
below the detection limit of our instrument. Since type-I interferons have an autocrine 
and paracrine function, this data could be explained by two scenarios: the effect on 
vomocytosis requires both type-I interferon signalling and an active infection, or the 
levels elicited by MeV are too low to be active at greater distances. Figures 5.3 and 5.5 
confirm that an active viral infection is not needed for enhancement of vomocytosis, 
therefore favouring the second option. Unfortunately, the levels of type-I interferons 
elicited by MeV in our in vitro settings could not be measured by conventional ELISA 
to confirm this hypothesis. However, it is well documented that MeV, and viruses in 
general, have developed multiple strategies to subvert detection and dampen anti-
viral responses [231]. Thus, the possibility that the amount of type-I interferons 
elicited by the viral infections tested is too low to exert effects on distant cells is very 
likely. 
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5.6 Co-infection with Pseudomonas aeruginosa enhances vomocytosis 
of C. neoformans 
Type-I interferons are traditionally regarded as “anti-viral” cytokines, which help 
create an antiviral state and thus help fight off the infection [31, 118]. More recently, 
their role in non-viral infections has been investigated [118]. Several bacterial 
infections have been found to elicit the production of type-I interferons (see signalling 
diagram in Figure 5.1), and in turn these “anti-viral” cytokines play a role in the 
outcome of bacterial infections [232]. Given the broad nature of the effect seen, 
preliminary work has been carried out to determine whether the effect on vomocytosis 
could be recapitulated in the context of bacterial co-infection. 
 
Human monocyte-derived macrophages were co-infected with C. neoformans and 
Pseudomonas aeruginosa. P. aeruginosa is a Gram-negative bacterium commonly found 
in the environment. It is an opportunistic bacterial pathogen, mainly infecting hospital 
patients, and is able to colonise medical devices such as catheters [233]. P. aeruginosa 
can infect macrophages and rapidly leads to lysis of these phagocytes [234]. Different 
multiplicities of infection (MOI) were tested to accommodate for the rapid lysis of 
macrophages and an MOI = 0.25 was chosen (1 bacterium every 4 macrophages), 
which allows for 10 hours of imaging before most macrophages are lysed by the 
bacterial infection. Macrophages were also stimulated with LPS, to simulate a “sterile” 
bacterial infection. Time-lapse microscopy videos were manually scored for 
vomocytosis, IPR and macrophage lysis (Figure 5.9).  
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The following figure corresponds to data from a single donor, and should be repeated 
to attain the desired statistical stringency.  
 
 
 
 
The figure shows that co-infection with P. aeruginosa enhanced vomocytosis of C. 
neoformans (Figure 5.9A). As mentioned before, even at this low MOI P. aeruginosa 
causes lysis of macrophages. Time-lapse videos were scored manually for 
vomocytosis, taking special care that the events recorded were not due to lysis but 
bona fide vomocytosis. Paired data of vomocytosis and lysis time (as frame number the 
events were recorded) is shown in Figure 5.9B. Vomocytosis events spread across the 
full time scored (120 frames in total), and when paired with macrophage lysis times it 
was clear that both events were separate in time. 
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Figure 5.9 Co-infection with P. aeruginosa enhances vomocytosis of C. neoformans 
Human monocyte-derived macrophages were stimulated with 20 ng/mL LPS or infected with 
P. aeruginosa, and subsequently infected with C. neoformans. Time-lapse microscopy videos 
were manually scored for vomocytosis (A). Vomocytosis raw counts were analysed by Chi2 
followed by Fisher’s exact test. * p < 0.05 
B. Paired times of vomocytosis and macrophage lysis events. 
Data corresponds to a single pilot experiment. Approximately 500 macrophages were scored. 
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Stimulation with LPS alone did not affect vomocytosis. This could mean that, unlike 
with viruses, an active bacterial infection is needed to enhance vomocytosis. 
Alternatively, it could mean that activation of the LPS sensing pathway alone is not 
sufficient to elicit the effect, or simply be due to the dose used. Further work is needed 
to dissect these options, and to solidify the findings pertaining bacterial infection and 
enhanced vomocytosis of C. neoformans. 
 
 
5.7 Closing remarks 
Throughout this chapter, I have explored the possibility that viral infection could have 
an effect on vomocytosis of C. neoformans. This stemmed from the prevalence of 
cryptococcosis on HIV+ patients, but the research soon expanded beyond this 
particular co-infection pairing. Both viral co-infection settings explored, HIV and 
MeV, as well as sterile polyIC stimulation, lead to a significant enhancement of 
vomocytosis without altering fungal uptake nor IPR. This effect is not due to a 
particular sensing or signalling molecule, but rather a novel effect of type-I 
interferons. 
 
Preliminary work suggests that co-infection with the bacterial opportunistic pathogen 
P. aeruginosa also results in an enhancement of vomocytosis. This would broaden the 
scope of effect reported beyond viral co-infection to include bacterial co-infection 
settings. Whether the effect observed with P. aeruginosa is also triggered by type-I 
interferons remains to be explored. Nonetheless, the role of type-I interferons in non-
viral infections has been addressed in the past few years, and bacterial infections have 
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been found to elicit the production of these so-called “anti-viral” cytokines [232]. In 
fact, P. aeruginosa has been shown to elicit production of IFNb [235], which would fit 
with the proposed novel effect of type-I interferons. Further work using different 
bacterial pathogens and blocking IFNAR would help assess whether type-I 
interferons are also playing a role in the enhancement of vomocytosis in bacterial co-
infections.  
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6 Cryptococcus effect on antigen presentation 
 
Research presented in the previous chapter stemmed from the prevalence of 
cryptococcosis in immunocompromised AIDS patients, although it soon grew beyond 
those settings. This chapter focuses on a different aspect of Cryptococcal infection; 
namely, how a latent infection in an immunocompetent host can affect T cell priming.  
 
As mentioned in the introduction to this Thesis, infection with C. neoformans starts 
with the inhalation of desiccated yeast or spores from the environment (see Figure 
1.1). Once within the host, Cryptococcal cells encounter alveolar macrophages and 
other phagocytes which, in immunocompetent hosts, are able to clear or contain the 
infection [12, 104, 236]. Dendritic cells (DC) in the lungs and surrounding tissues, 
sample their environment and present antigens to T cells in draining lymph nodes. In 
the lymph nodes, these antigen-presenting cells prime naïve T cells to induce a specific 
adaptive immune response [31, 237].  
 
Studies show the presence of Cryptococcus-specific antibodies in children as young as 
5-years old [13], confirming that exposure and development of an adaptive response 
occur at an early age. Disease is then caused by de novo infection under an 
immunocompromised state, or re-activation of a latent inoculum [238, 239]. 
Cryptococcal meningitis is particularly relevant in HIV+ patients [14], thus 
underscoring the importance of a fully functional T cell response when dealing with 
this pathogen. 
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The work presented in this chapter set out to study the impact of the continued 
presence of Cryptococcus in the ability of DC to prime naïve T cells and mount an 
adaptive T cell response. 
 
 
6.1 Bone marrow-derived DC:T cell co-culture system 
 
To address this question, we developed the in vitro system described in Figure 6.1. The 
complete technical details can be found in Materials and Methods chapter. 
 
This system uses T cells from transgenic mice, known as OT-II, which are specific for 
the chicken ovalbumin peptide 323-339 (OVAp) [240]. Using these T cells ensures a 
robust proliferation response when presented with the appropriate peptide:MHC-II 
complex, either exogenously processed ovabulmin peptide (hereafter referred to as 
OVAp) or the complete OVA protein (hereafter referred to as OVA), and thus 
provides a good system for testing modulating abilities of foreign entities on antigen 
presentation and processing.  
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Figure 6.1 Experimental design for in vitro DC:T cell co-culture 
1 – 2. Bone marrow-derived dendritic cells (BMDC) were generated from bone marrow 
precursors obtained from BoyJ mice (1), stimulated with GM-CSF for 10 days (2). 
3 – 4. BMDC were seeded in a round-bottomed 96-well plate, and stimulated with opsonised 
C. neoformans or control (3), and with chicken ovalbumin (OVA) or ovalbumin peptide 323-
339 (OVAp, 4), overnight. 
5. Splenocytes from an OT-II transgenic mouse were isolated (5) and enriched in CD4+ 
lymphocytes using Miltenyi magnetic sorter (6). 
7. Population enriched in CD4+ lymphocytes was labelled with carboxyfluorescein 
succinimidyl ester (CFSE) following manufacturers guidelines, and added to the culture 
containing stimulated BMDC (7). 
8. Culture plate was incubated for 4 days at 37°C and 5% CO2 (8). Supernatant (SN) was then 
removed and stored for cytokine profiling, and cells were stained for T cell proliferation 
assessment. 
For full details of each step please refer to Materials and Methods. 
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In brief, bone marrow-derived dendritic cells (BMDC) were stimulated with OVA or 
OVAp, in the presence of opsonised-Cryptococcus or control. After 18 hours, CFSE-
labelled CD4+ T cells obtained from OT-II spleen were introduced to the culture. After 
4 days-incubation, cells were stained for proliferation analysis and the supernatant 
stored for further cytokine profiling.  
 
Carboxyfluorescein succinimidyl ester (CFSE) is a permeable, non-toxic fluorescent 
dye. When incubated with T cells, it permeates through the plasma membrane and 
covalently binds to all free amines [241]. Once the labelled T cells are added to the co-
culture and start to proliferate, the CFSE-signal dilutes evenly across the progeny. As 
a result, multiple generations of T cells can be classified according to the brightness of 
their CFSE signal; the brightest signal corresponding to cells that have not divided.  
 
The assay was optimised for use with the mutant strain of C. neoformans Dras1. Ras1 is 
a small-GTPase involved in filamentation, mating and thermotolerance of C. 
neoformans. Deletion of this factor results in cells with polarisation and growth defects, 
which arrest as large cells (7 – 8 µm compared to 5 µm for wildtype strain) when 
exposed to temperatures over 30°C [182, 183]. This means that in this system, which 
is incubated at 37°C over 4 days, the mutant will remain viable but not actively 
proliferating; thus mimicking a latent infection and preventing overgrowth of the 
DC:T cell co-culture by cryptococci. 
 
Figure 6.2B shows that stimulation by OVAp (purple bars) or OVA (blue bars) 
triggered up to 7 rounds of T cell proliferation over the 4-day incubation period. The 
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latter means that the BMDC are able to process and present the complete protein 
antigen to present the constituent peptide in the correct MHC-II context. All 
proliferation seen was antigen-dependent, as shown by lack of substantial 
proliferation beyond 1 cycle when no OVAp or OVA was added (yellow and white 
bars). 
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Figure 6.2 In vitro proliferation of T cells 
A. Gating strategy applied to cells recovered from co-culture described in Figure 6.1 for T cell 
proliferation analysis. 
B. The number of divisions experienced by a T cell during the experiment was determined by 
the intensity of its CFSE signal (see gating strategy in A). Graph shows percentage of T cells 
which experienced the designated number of divisions over the course of the co-culture 
experiment. Data corresponds to 9 independent repeats and error bars depict SD. Two-way 
ANOVA with Tukey’s post-test was performed on Arcsine-transformed data. * p < 0.05; *** p 
< 0.001; **** p < 0.0001. 
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6.2 Effect of latent infection with C. neoformans on antigen presentation 
and T cell proliferation 
 
The effect of the mutant strain of C. neoformans Dras1 on T cell proliferation was tested 
with both OVAp and OVA-induced T cell proliferation (Figure 6.3). Even though both 
antigens result in similar proliferation patterns, addition of Dras1 exclusively inhibited 
OVA-induced proliferation, typically by a mean ‘delay’ of 1-2 cell divisions (Figure 
6.3A). Addition of exogenously processed OVAp does not require antigen processing 
and presentation by the BMDC, hence Dras1 could be interfering with these processes.  
 
An alternative possibility is that the physical size of the Cryptococci inhibits cell-cell 
interactions between DC and T cells.  To test this, we applied beads of a similar size 
to Dras1 cells (7 µm diameter) in the presence of OVA (Figure 6.4).  However, T cells 
were not inhibited at all in these conditions, ruling out physical inhibition of MHC/T 
cell receptor (TCR) contact as a potential explanation.  Interestingly, however, even 
though addition of beads did not affect OVA-induced proliferation on their own 
(blue-coloured bars), when tested in conjunction with Dras1 cells, the presence of 
beads enhanced the inhibition of proliferation reported before (red-coloured bars). 
Thus, the presence of beads could have an additive effect on the inhibition of 
proliferation caused by Dras1. 
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Figure 6.3 Dras1 inhibits OVA-induced T cell proliferation 
BMDC:T cells were cultured in the presence of Dras1 or control, together with chicken 
ovalbumin (OVA, A) or ovalbumin peptide (OVAp, B). Graphs show percentage of T cells 
which experienced the designated number of cell divisions over the course of the co-culture 
experiment. OVA- and OVAp-induced proliferation (blue and purple bars, respectively) 
were shown in Figure 6.2. Data corresponds to 9 independent repeats and error bars depict 
SD. Two-way ANOVA and Tukey’s post-test performed on Arcsine-transformed data. * p < 
0.05; ** p < 0.01; *** p < 0.001. 
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To test whether Dras1 could be inhibiting T cell responses directly, rather than via 
antigen-presentation from DC, the OVA-induced proliferation experiment was 
repeated with addition of Dras1 24 hours after that of OVA, allowing the DC to process 
and present antigen prior to addition of the fungus (Figure 6.5). In this case, (“Delayed 
Dras1”) T cell proliferation was not inhibited by the presence of Cryptococci, although 
it should be noted that this data corresponds to only 2 independent experiments, and 
should be repeated further.  
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Figure 6.4 Beads do not inhibit OVA-induced T cell proliferation 
OVA-stimulated BMDC:T cell co-culture was incubated in the presence of 7 µm inert beads 
(light blue bars), Dras1 (red bars) or both (dark red bars). Graph shows percentage of T cell 
which experienced the designated number of cell divisions over the course of the 
experiment. Data corresponds to 3 independent repeats and error bars depict SD. Two-
way ANOVA and Tukey’s post-test was performed on Arcsine-transformed data. * p < 
0.05: ** p < 0.01; **** p < 0.0001. 
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Taken together, these data indicate that the presence of Dras1 inhibits T cell 
proliferation induced by OVA, but not by OVAp. The effect is not due to steric 
hindrance, since inert beads of the same size as Dras1 do not result in the same effect 
and does not occur if Dras1 is added at least 24 hours after addition of OVA. Thus, the 
most parsimonious explanation is that Dras1 directly inhibits antigen processing and 
presentation abilities of BMDC. 
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Figure 6.5 Delayed addition of Dras1 lifts inhibition of proliferation 
OVA-stimulated BMDC:T cell co-culture was incubated in the presence of Dras1 or 
control. Dras1 was added immediately after addition of OVA (normal conditions, red 
bars) or 24 hours after addition of OVA (“Delayed”, light blue bars). Data corresponds 
to 2 independent repeats and error bars depict SD. Two-way ANOVA and Tukey’s post-
test was performed on Arcsine-transformed data. * p < 0.05: ** p < 0.01.  
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6.3 Effect of C. neoformans on BMDC maturation 
 
Priming of naïve T cells requires three signals; presentation of the specific antigen in 
the correct peptide:MHC context (signal 1), expression of co-stimulatory molecules to 
interact with their counterparts on T cells (signal 2) and production of cytokines to aid 
in the functional differentiation of T cells (signal 3) [31]. To confirm that a lack in signal 
2 was not responsible for the decreased proliferation observed, the expression of a 
sample of co-stimulatory molecules [196, 242-245] on BMDC was studied (Table 6.1 
and Figure 6.6). 
 
 
 
 
Marker Function 
CCR7 
(CD197) 
Chemokine receptor expressed on activated APC. Provides a homing 
signal to secondary lymph nodes [242]. 
OX40L 
(CD252) 
Co-stimulatory molecule expressed on activated APC. Binds to OX40 in 
T cells and promotes T cell expansion and survival [243]. 
CD86 Co-stimulatory molecule expressed on activated APC. Binds to CD28 or CTLA-4 on T cells, and regulates T cell activation and survival [196]. 
CD40 Co-stimulatory molecule expressed on activated APC. Binds to CD154 on T cells and induces expression of other co-stimulatory molecules [244]. 
PDL2 
(CD273) 
Negative regulator of T cell activation. It binds Programmed death-1 
(PD-1) on T cells [245]. 
Table 6.1 Panel of co-stimulatory molecules measured on BMDC 
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It is generally accepted that culture of bone marrow-precursors with the growth factor 
GM-CSF results in a mixed population of CD11c+ MHC-II+ dendritic cells and 
macrophages [246]. Following the gating strategy devised in Helft et al. [246] to study 
bona fide dendritic cells, the expression of co-stimulatory molecules in this particular 
population was assessed (Figure 6.6). 
 
The figure shows that addition of Dras1 does not significantly impact on the expression 
of any of the molecules tested. Infection with C. neoformans is known to have a 
dampening immunomodulatory effect [247, 248], which agrees with the slight 
decrease seen, but it is not having a significant impact in these experimental 
conditions. This is not unexpected, since a change in DC activation would be reflected 
as a decrease in T cell proliferation for both OVA and OVAp.   
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Figure 6.6 Dras1 does not affect expression of co-stimulatory markers 
A. Gating strategy applied to BMDC recovered from stimulation with OVA, in the presence 
of Dras1 or control. 
B. Geometric mean + SD of expression of different co-stimulatory molecules on gated 
BMDC. All cells were stimulated with OVA, in the presence of Dras1 (red bars) or control 
(blue bars). Data corresponds to 2 independent experiments. 
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6.4 Effect of capsule on antigen presentation 
 
The production of a thick polysaccharide capsule is one of the most evident virulence 
factors of C. neoformans. The main components of the capsule are the polysaccharides 
glucuronoxylonmannan (GXM) and galactoxylomannan (GalXM), which make up 
90% and 7% of the capsule, respectively [249]. Capsule components can be shed 
during infection, serving anti-phagocytic and immune-modulating purposes. Shed 
GXM can be found in the lung of infected mice at a concentration of up to 250 µg/mL 
[250]. Therefore, the effect of purified capsule on the BMDC:T cell co-culture was 
tested (Figure 6.7). 
 
The figure shows that addition of purified capsule at a concentration of 4.7 µg/mL 
(dark green bars) induces the same inhibition of T cell proliferation as addition of 
Dras1 (A). Interestingly, addition of capsule does not inhibit proliferation of T cells 
induced by OVAp (B). This strongly suggests that the effect seen with Dras1 is largely 
due to capsule components. 
 
When added together with capsule, the effect of Dras1 is dramatically enhanced, with 
most T cells not going beyond one cell division (Figure 6.8). 
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Figure 6.7 Addition of capsule inhibits OVA-induced T cell proliferation 
BMDC:T cell co-cultures were stimulated with OVA (A, blue bars) or OVAp (B, purple bars), 
in the presence of different doses of capsule (green bars) or of Dras1 (red bars).  
Graphs show percentage of T cells which experienced the designated number of divisions 
over the course of the experiment. Data corresponds to 3 independent repeats and error bars 
depict SD. Two-way ANOVA followed by Tukey’s post-test was performed on Arcsine-
transformed data. * p< 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
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To further explore this, the effect of wildtype and acapsular strains on OVA-induced 
T cell proliferation was tested (Figure 6.9). As with Dras1, the wildtype strain Kn99a 
inhibits OVA-induced T cell proliferation. Remarkably, the acapsular strain 
(Dcap59Duge1 mutant lacking both GXM and GalXM [184], designated DCap) does not 
inhibit but rather enhances OVA-induced T cell proliferation. This could be the result 
of heightened BMDC activation when infected with DCap compared to stimulation 
with OVA alone, leading to enhanced antigen presentation and T cell proliferation. It 
should be noted though, that this figure corresponds to a single repeat and the 
variation depicts SEM between technical replicates.  
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Figure 6.8 Capsule enhances Dras1 inhibitory effect 
OVA-stimulated BMDC:T cell was performed in the presence of different doses of capsule and 
Dras1 (green shaded bars) or Dras1 alone (red bars). Graph shows percentage of T cells which 
experienced the designated number of cell divisions during the course of the experiment.  
OVA-induced proliferation (blue bars) and OVA + Dras1 (red bars) were also shown in Figure 
6.7. Data corresponds to 3 independent repeats and error bars depict SD. Two-way ANOVA 
followed by Tukey’s post-test performed on Arcsine-transformed data. * p< 0.05; ** p < 0.01; *** 
p < 0.001; **** p < 0.0001. 
 109 
 
 
 
Taken together, these results clearly show that addition of capsule from C. neoformans 
recapitulates the effect seen with Dras1. Addition of capsule specifically inhibits OVA-
induced T cell proliferation, in a dose-dependent manner. When added in conjunction 
with Dras1, the inhibitory effect is dramatically enhanced. Furthermore, an acapsular 
strain of C. neoformans had no inhibitory effect on this system. This argues for an effect 
of Dras1, through its shed capsule, on antigen processing and presentation by BMDC, 
which then leads to the reduction in T cell proliferation observed.  
 
As mentioned before, antigen presentation is but one of the signals needed to induce 
a T cell response. Secretion of cytokines by the antigen presenting cell (Signal 3) aids 
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Figure 6.9 Acapsular strain of C. neoformans does not inhibit OVA-induced proliferation 
OVA-stimulated BMDC:T cell co-culture was performed in the presence of Dras1 (red bars), 
wildtype C. neoformans (Kn99a, orange bars) or the acapsular strain Dcap59Duge1 (DCap, yellow 
bars).  
Graph shows percentage of T cells which experienced the designated number of divisions over 
the course of the experiment. Data corresponds to a single experiment and variation is SEM from 
technical replicates. Two-way ANOVA followed by Tukey’s post-test performed on Arcsine-
transformed data. * p< 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 110 
in the functional differentiation of the T cell response elicited [31]. Hence, 
supernatants from the co-cultures were analysed for their cytokine profile. The 
cytokines measured are listed in Table 6.2. 
 
Cytokine  Response 
IL-2 Necessary for T cell survival and replication  
IFNg Important macrophage activator 
Th1 
TNFa Pro-inflammatory cytokine 
IL-4 
Th2-inducing cytokines. Involved in 
allergic inflammation and IgE-switch Th2 
IL-13 
IL-17A Pro-inflammatory cytokine Th17 
 
 
 
Figure 6.10 shows the concentration of cytokines recovered from OVA-stimulated 
DC:T cell co-cultures, in the presence of increasing doses of capsule. Addition of the 
highest dose of capsule reduces the secretion of IL-2, IFNg and TNFa (blue lines). The 
presence of Dras1 (red lines) has an overall dampening effect on cytokine secretion, 
although this is not statistically significant.  
 
Given the inhibitory effect of capsule and Dras1 on T cell proliferation reported earlier, 
it is not surprising that these conditions also lead to a decrease in IL-2 secretion, which 
is necessary for T cell survival/replication [251]. The presence of capsule also 
decreases IFNg and TNFa production; collectively skewing the co-culture away from 
Table 6.2 Panel of cytokines measured in co-culture supernatant 
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a Th1 response. The presence of Dras1 results in a trend favouring a Th17 response. It 
should be noted that the panel used is very limited and any conclusions in terms of T 
helper response elicited are merely preliminary estimations. Further work, ultimately 
using a live animal model, should be carried out to allow for more comprehensive 
answers as to the quality of the T cell response elicited. 
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Figure 6.10 Capsule inhibits secretion of IL-2, IFNg and TNFa 
Cytokine profiling of supernatants from OVA-stimulated BMDC:T cell co-cultures in the 
presence of different doses of capsule, with or without Dras1 (red and blue lines, respectively). 
Data corresponds to 3 independent experiments, whose proliferation data is shown in Figures 
6.7 and 6.8. Error bars correspond to SD. Two-way ANOVA followed by Tukey’s post-test. * 
p< 0.05; ** p < 0.01. 
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6.5 Effect of inhibition of ERK5 on antigen presentation 
 
Given previous findings on the effects of ERK5 inhibition on macrophage polarisation 
and vomocytosis occurrence (discussed in chapter 4), the impact of ERK5 inhibition 
on this system was explored. 
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The figure shows that neither the ERK5 inhibitor, XMD17-109, nor the DMSO control 
induce T cell proliferation in the absence of antigen, nor do they inhibit OVA-induced 
proliferation (Figure 6.11A). Moreover, in the presence of XMD17-109 Dras1 has a 
slightly enhanced anti-proliferative effect (Figure 6.11B).  
 
In the current system, addition of inhibitors and T cells was performed without prior 
washing. To eliminate possible effects of the inhibitors directly on T cells, a washing 
step immediately before addition of the T cells was carried out (Figure 6.12). In this 
case, the delay seen previously with the ERK5 inhibitor in the presence of Dras1 is 
completely lifted. A direct effect of Dras1 on T cells is tempting to suggest, however 
Dras1 was not able to inhibit OVAp-induced proliferation even in “non-washed” 
settings (B), thus making this possibility less probable. The most likely explanation is 
that during the washing steps some of the Dras1 inoculum was lost. This would argue 
that a threshold “dose” of Dras1, or a prolonged interaction of Dras1 with BMDC 
beyond the first 18 hours, are necessary to impact T cell proliferation.  
 
 
Figure 6.11 XMD17-109 does not affect OVA-induced T cell proliferation 
OVA-stimulated BMDC:T cell co-cultures were performed in the presence of XMD17-109 (teal 
bars) or DMSO control (light teal bars), alone (A) or in conjunction with Dras1 (red coloured 
bars, B). Data for proliferation in the absence of Dras1 is the same in both graphs. 
Graphs show T cell proliferation resulting over the course of the experiment. Data corresponds 
to 3 independent repeats and error bars depict SD. Two-way ANOVA followed by Tukey’s 
post-test performed on Arcsine-transformed data. * p< 0.05; ** p < 0.01; *** p < 0.001; **** p < 
0.0001. 
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Figure 6.12 Washing step lifts inhibition on T cell proliferation 
A. OVA-stimulated BMDC:T cell co-culture where ERK5 inhibitors were washed before 
addition of T cells. Data corresponding to controls without XMD17-109 or DMSO were not 
washed, and is the same as shown in Figure 6.11B. 
B. OVAp-stimulated BMDC:T cell co-culture performed without washing step before 
addition of T cells.  
Graphs show T cell proliferation resulting over the course of the experiment. Data 
corresponds to 3 independent repeats. Two-way ANOVA followed by Tukey’s post-test 
performed on Arcsine-transformed data. * p< 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
 116 
6.6 Effect of IFNa on T cell proliferation 
 
The previous chapter discussed the impact of viral exposure, and of type-I interferons, 
on vomocytosis. Type-I interferons are antiviral cytokines, and as such can play a role 
in the induction of T cell effector responses. The impact of IFNa on this T cell 
proliferation system was tested (Figure 6.13).  
 
 
 
 
 
The figure shows that stimulation with IFNa alone did not affect OVA-induced T cell 
proliferation. In the presence of this cytokine, the impact of Dras1 was greatly 
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Figure 6.13 Stimulation with IFNa does not affect OVA-induced T cell proliferation 
OVA-stimulated BMDC:T cell co-cultures were performed in the presence of 10 pg/mL IFNa 
(yellow bars), Dras1 (red bars) or both (dark red bars).  
Graph shows percentage of T cells which experienced the designated number of divisions over 
the course of the experiment. Data corresponds to 2 independent repeats and error bars to SD. 
Two-way ANOVA followed by Tukey’s post-test performed on Arcsine-transformed data. * p< 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. 
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enhanced, with over 60% of T cell not experiencing a single cell division over the 
course of the experiment and none going beyond 3 cycles.  
 
The effect of IFNa on T cell proliferation has been subject of debate in the literature. 
Many early reports describe the anti-proliferative properties of IFNa on different 
systems. Holán et al. showed that stimulation with purified human IFNa inhibits 
proliferation of ConA-stimulated peripheral blood lymphocytes [252]. Furthermore, 
Erickson et al. proposed that this anti-proliferative effect could be achieved through 
changes in the cell cycle regulatory proteins, which then lead to a block of S-phase 
entry [253]. Mechanistically, Zella et al. showed that long-term stimulation with IFNa 
causes a decrease in CD3 and CD28 expression on T cells, which subsequently leads 
to lower levels of IL-2 and the anti-proliferative effect previously mentioned [254]. 
More recently, however, the reported effects of type-I IFN on T cells have expanded 
beyond anti-proliferative. It was described that IFNa-stimulation is important for the 
induction of Th1 responses to allergens [255] and to viral infections [256]. Moreover, 
Tough et al. showed that low doses of IFNb induce T cell proliferation in vivo [257], 
and Le Bon et al. reported type-I IFN acting directly on T cells to increase CD8+ 
expansion and cross-presentation [258]. In our system, addition of IFNa alone did not 
impact T cell proliferation, although it drastically enhanced the inhibitory effect of 
Dras1. Further work is needed to unravel the mechanism(s) at play.  
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7 Discussion 
 
Cryptococcus neoformans is a ubiquitous environmental fungus [12]. Due to its global 
distribution and association with pigeon excreta, it is able to reach rural and urban 
populations, as it is evident from the presence of antibodies to Cryptococcal antigens 
in children [13]. It is an opportunistic fungal pathogen, meaning that the vast majority 
of cases are in patients suffering from other debilitating illness such as AIDS. Even 
though the AIDS pandemic is much more manageable than it was in the 1980s, when 
Cryptococcal meningitis started to make its way to headlines, the rise in 
immunosuppressed patients from transplant therapy and cancer keep cryptococcosis 
as a significant healthcare issue. It is therefore paramount that we, the scientific 
community, continue to study this opportunistic fungus so as to gain better 
understanding of the infection process and develop novel treatment options. 
 
Throughout my PhD I have studied Cryptococcal infection using in vitro models. For 
the first part, I focused on the interaction of Cryptococcus with macrophages, and on 
the process of vomocytosis. For the last part, I looked at the effect of a latent 
Cryptococcal infection on antigen presentation.  
 
 
7.1 Inhibition of ERK5 affects macrophage polarisation and enhances 
vomocytosis of C. neoformans 
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Vomocytosis is a non-lytic exocytosis event, which was first described for Cryptococcus 
neoformans in 2006 using J774A.1 cells [51, 52]. Since then, it has been described in 
many different models, including live infection of zebrafish [65-67]. What is more, 
vomocytosis-like events have been reported for bacterial species [85-88]. Despite these 
advances, the process of vomocytosis remains poorly understood. Recently, our lab 
uncovered the first molecular handle capable of modulating vomocytosis; inhibition 
of the atypical MAP kinase ERK5 enhances vomocytosis [84]. 
 
ERK5 has been implied in the response to stress (H2O2 [99]), growth factors (G-CSF 
[100] and EGF [101]) and cytokines (LIF [102]). The activation of this signalling cascade 
affects several cellular processes such as proliferation, cell survival, motility and 
angiogenesis [259]. Initially, research on ERK5 focused mainly on cardiovascular cells 
and neuronal development. Generation of an ERK5 null mice revealed that this 
mutation leads to defects in angiogenesis and cardiac development, resulting in 
embryonic lethality [260]. More recently, however, the effects of this signalling 
cascade on myeloid cells have been addressed. Using a myeloid-specific ERK5 
deficient mouse model, it was shown that ERK5 activation impedes M1 polarisation 
under steady-state conditions [261].  
 
My work expanded this finding using both murine and human macrophages, and the 
widely-accepted polarising stimuli LPS + IFNg and IL-4. Using these models and the 
ERK5 inhibitor XMD17-109, I found that inhibition of ERK5 enhances (LPS + IFNg)-
induced M1 polarisation, and dampens IL-4-induced M2 phenotype. This was linked 
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to an effect on vomocytosis of C. neoformans, which is known to be affected by 
macrophage polarisation [83]. 
 
Our findings are in line with recent research from Dr. Tournier’s group, where they 
report that ERK5 deficiency enhances pro-inflammatory (anti-tumour) polarisation in 
tumour-associated macrophages (TAM) [262]. In this model, pro-inflammatory 
polarisation was dependent on STAT3 activation. The involvement of this signalling 
molecule on the effect of ERK5 inhibition on vomocytosis remains to be explored. 
 
 
 
7.2 Viral exposure enhances vomocytosis 
 
Cryptococcosis is particularly relevant among AIDS patients [14]. A study conducted 
in 2014 estimated that cryptoccocal meningitis was responsible for 15% of AIDS-
related deaths worldwide [14]. This highlights the importance of incorporating the 
context of a viral infection when studying C. neoformans infection. Thus, we set out to 
study vomocytosis of C. neoformans in macrophages co-infected with a viral agent. 
The main finding pertaining this research is that viral exposure enhances vomocytosis 
of C. neoformans. This result was obtained using an attenuated strain of HIV 
(HIVR9Denv + SIVvpx) as well as fully infectious GFP-tagged MeV. It was also 
recapitulated when macrophages were stimulated with polyIC, IFNa or IFNb, and 
abrogated when type-I interferon signalling was blocked.  
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The effect of type-I interferons on cryptococcosis has been looked at in the past, and 
different groups have arrived at opposing conclusions [114, 115, 174]. Using a murine 
model of cryptococcosis, Sato et al. showed that IFNAR KO animals had enhanced 
survival than wildtype animals. The effect was attributed to increased mucus 
production in the lung and improved fungal clearance in IFNAR KO animals, 
suggesting a detrimental role of type-I interferons on cryptococcosis [114].  
Almost in parallel and using a very similar murine cryptococcal infection model, 
Sionov et al. showed that treatment with polyICLC, a more stable version of polyIC, 
greatly enhanced survival of mice infected with C. neoformans. The protective effect 
was mediated by type-I interferon production and polarisation to a protective 
Th1/Th17 response [115]. In line with these findings, a beneficial role of type-I 
interferons on cryptococcosis had been reported earlier by Biondo et al. In this case, 
infection of IFNAR KO animals led to increased mortality, higher fungal burden and 
a non-protective Th2-skewed immune response [174].  
 
Our findings fit in with the results presented by Sionov et al. In their system, 
stimulation with polyICLC induces production of type-I interferons, which leads to 
decreased dissemination to the CNS and reduced mortality [115]. We show that type-
I interferons enhance vomocytosis of C. neoformans. Therefore, a possible mechanistic 
explanation for the effect of polyICLC observed is that elevated vomocytosis 
occurrence within the lungs (due to induction of type-I interferons) leads to fewer 
Cryptococcal cells within macrophages, reducing their ability to hijack these cells as a 
Trojan horse to disseminate to distal sites within the body such as the CNS. In 
agreement with this suggested mechanism, Sionov et al. mention that if the polyICLC 
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treatment is given 3 days post infection, when Cryptococcal cells have already reached 
the CNS, then they do not observe a protective effect [115]. 
 
Our research helps explain a previously observed phenomenon, and further 
highlights the importance of vomocytosis for disease progression. Given its covert 
escape nature, vomocytosis has always been thought to play a role in dissemination 
within the host. It was not until a decade after its first description, though, that the 
first evidence for this was put forward. Gilbert et al. showed that enhanced 
vomocytosis, through pharmacological inhibition of ERK5, leads to decreased 
dissemination in a zebrafish cryptococcosis model [84]. Nonetheless, it was noted that 
the location and timing of the vomocytosis event could render it beneficial or 
detrimental for the host. Sionov et al. remark that the protective effect of polyICLC is 
time-dependent further strengthens this notion.  
 
As it was mentioned in the introduction, there have been reports of vomocytosis-like 
events for some bacterial pathogens [85-88]. In these cases, assessment of whether the 
vomocytosis-like event was beneficial or detrimental to the host was also context-
dependent. In the case of UPEC, for example, release of intracellular bacteria was 
deemed beneficial for the host as it allowed for bacterial load to be eliminated with 
the flow of bodily fluids [87]. In the case of Serratia maracescens however, non-lytic 
exocytosis from epithelial cells was considered detrimental for the host as it aided 
bacterial dissemination [88]. 
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7.3 Bacterial exposure enhances vomocytosis 
 
Type-I interferons have historically been regarded as anti-viral cytokines [106, 263]. 
However, in more recent years, their effect into other non-viral infections has been 
explored [118]. Moreover, some non-viral pathogens have been seen to induce their 
production [129, 165, 264]. Thus, the possibility of other non-viral pathogens having 
an effect on vomocytosis of C. neoformans was explored. 
 
Pseudomonas aeruginosa is an opportunistic bacterial pathogen, present in soil and 
water. It causes disease in previously weakened individuals, being very relevant in 
cystic fibrosis patients [233]. It was chosen for the preliminary study of 
bacteria:Cryptococcus co-infection since both pathogens cause chest infections, and 
could therefore interact in pathophysiological conditions. It has also been reported 
that P. aeruginosa induces production of type-I interferons [235], which were shown to 
affect vomocytosis. Preliminary results show that P. aeruginosa is able to enhance 
vomocytosis of C. neoformans. It would be interesting to explore whether other 
bacterial pathogens have the same effect on vomocytosis. Stimulation with bacterial 
LPS had no impact on vomocytosis occurrence, suggesting that activation of this 
signalling pathway (LPS-TLR4) alone is not sufficient to elicit the effect. Further work 
testing different doses of LPS, other bacterial pathogens and addition of heat-killed 
bacteria is needed. 
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With the results presented so far, the emerging working model is that vomocytosis is 
triggered in response to stress, such as viral or bacterial infection. Cryptococcus-
containing macrophages, when exposed to a second infection, expel their phagosomal 
cargo potentially to devote resources and energy to dealing with the new threat. This 
would only apply to persisting live intracellular pathogens, since vomocytosis is not 
observed with heat-killed Cryptococcus. Cryptococcus-free macrophages would then be 
engaged in combating the ongoing second infection and secreting cytokines to recruit 
more immune cells to the site of infection. Recruited cells, such as neutrophils, could 
in turn phagocytose and kill the expelled Cryptococci. 
We showed that vomocytosis is modulated by the MAP kinase ERK5, which is known 
to be involved in the response to osmotic stress. It is therefore an interesting possibility 
that ERK5 be the integrating signalling molecule to coordinate vomocytosis at times 
of stress.  
 
 
 
7.4 Presence of Cryptococcus affects antigen presentation 
 
As it has been mentioned before, humans are typically exposed to C. neoformans at an 
early age [13]. Initial contact can lead to clearance by a competent immune system, or 
containment as granulomas in the lung [236, 238, 239]. We therefore set out to explore 
the impact of prolonged presence of C. neoformans within the lung environment on 
antigen presentation and antigen-induced T cell proliferation.  
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To this end, together with Dr. Guillaume Desanti, an in vitro bone marrow-derived 
dendritic cell (BMDC):T cell co-culture system was optimised. This system uses T cells 
recovered from transgenic OT-II mice, which are specific for the chicken ovalbumin 
peptide 323-339 (OVAp). Addition of commercially available OVAp, or of the 
complete chicken ovalbumin protein (OVA), allows to test for effects on antigen 
presentation and processing, respectively. 
This system was optimised for the use of C. neoformans mutant Dras1 [182, 183]. As 
explained elsewhere, this mutant remains viable but not actively proliferating when 
incubated at 37 °C [182, 183]. As a result, Dras1 is a good candidate to test the effects 
of prolonged exposure to Cryptococcus without overwhelming the culture system. 
 
The main finding from this ongoing project is that the presence of Cryptococcus inhibits 
antigen-induced proliferation of T cells. The effect is seen as a delay in 1-2 divisions 
within the experimental timeframe. Importantly, this inhibition is exclusively seen 
with OVA-induced proliferation and can be recapitulated by addition of purified 
capsule.  
 
Previous studies had commented on the inhibitory abilities of C. neoformans’ capsule 
on T cell proliferation. Collins and Bancroft showed that encapsulated strain of C. 
neoformans B3501 inhibits proliferation of T cells, and attributed the effect to the anti-
phagocytic effect of capsule on macrophages (macrophages were used as antigen 
presenting cells in this assay) [265]. Later on, Vecchiarelli et al. showed that the same 
strain did not induce maturation and activation of DC, which resulted in inhibited T 
cell proliferation when compared to an acapsular strain [266]. This effect was not due 
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to limited uptake, however, since the same result was shown after opsonising capsular 
Cryptococcus with anti-GXM antibody 18B7, which affords similar uptake to acapsular 
strain [266]. 
 
The results presented here expand these previous findings, adding that the capsule of 
C. neoformans interferes with processing of an unrelated antigen, OVA, which leads to 
diminished antigen presentation and T cell proliferation. 
 
The mechanism behind this effect is currently unknown, although preliminary work 
shows that the presence of Dras1 does not impede DC maturation. One tentative 
explanation could be that shed capsule components, either from extracellular 
Cryptococci or within Cryptococcus-containing phagosomes, interfere with antigen 
processing. Processing of exogenous proteins for presentation within an MHC-II 
complex involves degradation of the protein in acidified endosomes and 
incorporation of the resulting peptides to MHC-II molecules, the loaded complex is 
then trafficked to the cell surface [31]. Capsule components could be interfering with 
this process by protein adsorption to the sugar-rich capsule and masking of new 
potential antigens, or by buffering the phagosomal compartment to inhibit protein 
degradation. In support of this possible mechanism, it has been shown that the acid-
base properties of glucuronic acid residues in capsular polysaccharides are able to 
buffer phagosomal pH [74]. It would be interesting to test for the presence of 
intracellular capsule material within BMDC in this system, and the phagosomal pH 
under these experimental conditions. 
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7.5 Final remarks 
 
The work presented here was aimed to broaden our understanding of Cryptococcal 
infection making use of different techniques and in vitro systems. Throughout this 
Thesis I have tried to recreate physiologically relevant contexts in which to study this 
infection. Using time-lapse microscopy, I have looked at the interaction between 
Cryptococcus and human macrophages, focusing on the under-studied event of 
vomocytosis. I have explored the effects of including a second viral infection in this 
system, stemming from the high prevalence of cryptococcosis on HIV+/AIDS patients 
[14]. I have set up an in vitro dendritic cell: T cell co-culture system, which permits the 
study of antigen presentation and antigen-induced T cell proliferation. Using a mutant 
strain of C. neoformans (Dras1), I have studied the effects of extended exposure to a 
dormant infection on these processes, relating to the prolonged presence of C. 
neoformans in human lungs in vivo [238, 239]. I found that incorporating these context-
specific cues has important biological consequences; enhanced vomocytosis 
occurrence in viral co-infection and interference with antigen processing within 
antigen-presenting cells. Consequently, this work highlights the importance of 
incorporating environmental cues to previously established models and the effects 
these may have on cellular processes.  
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From 
peaches 
to patients: 
the many 
faces of 
cryptococci
Human diseases caused by 
fungal pathogens have long been 
neglected as a medical problem, 
but the dramatic increase in 
immunocompromised individuals 
over the last 50 years, resulting 
both from the HIV/AIDS pandemic 
and more widespread use of 
immunosuppressive therapies, 
has led to an annual toll of over 
2 million deaths due to fungal 
infections. Additionally, over 300 
million people are chronically 
infected by fungi, leading to 
problems ranging from skin 
irritation to blindness.
Paula I. Seoane, Rafael Schneider and Robin C. May
Coloured transmission electron micrograph of Cryptococcus neoformans, the cause of cryptococcosis,  
showing a single, circular encapsulated yeast. CNRI/Science Photo Library
Cryptococcus species
Amongst the life-threatening fungal 
pathogens, Cryptococcus neoformans 
and its close relative Cryptococcus gattii 
account for almost 1 million infections 
per year and around 650,000 deaths. 
Cryptococcal infections were recognised 
as a major threat only in the 1980s 
with the emergence of AIDS, but, in fact, 
the organism had been first isolated in 
1894 by an Italian researcher, Sanfelice, 
from fermented peach juice and, in the 
same year, from a patient with a chronic 
granuloma. 
 Both pathogenic Cryptococcus 
species are found in a diverse range of 
niches in the environment, particularly 
in decaying vegetation of several tree 
species. C. neoformans is also found in 
bird faeces, which partly explains the 
high incidence of this species in urban 
locations. 
Cryptococcosis
Cryptococcosis results from inhalation 
of fungal cells or spores from the 
environment, causing subsequent 
lung infection. The first step to disease 
development is the arrival of fungal 
cells deep in the alveoli of the lung. 
Consequently, desiccated yeast cells 
or spores are considered the most 
important infectious propagule due to 
their small size (~3 µm) in comparison 
to active yeast cells (4–10 µm), since 
only small cells can penetrate so far into 
the lung. In most individuals this initial 
pulmonary infection is rapidly contained, 
but in people lacking an appropriate 
immune response, the infection can 
spread to the blood and central nervous 
system, causing meningoencephalitis, 
which is rapidly fatal without treatment.
 The ability of these environmental 
fungi to cause human infections is 
underpinned by a number of classical 
virulence factors, most notably the 
production of a polysaccharide capsule 
(Fig. 1) which protects Cryptococcus 
from phagocytosis, and the production 
of melanin pigment, which protects 
the fungal cell from oxidative damage. 
Perhaps most remarkable, however, is 
the ability that cryptococci have to evade 
immune activation. 
How does Cryptococcus  
evade the immune system? 
Normally, exposure to fungal cells 
triggers a potent inflammatory response. 
However, Cryptococcus yeast cells are 
remarkably immunologically inert. 
Not only do they fail to elicit pro-
inflammatory cytokines from dendritic 
cells (as opposed to other fungi such as 
Candida albicans), they actively promote 
the production of anti-inflammatory 
cytokines such as IL-10 or IL-4. This 
cytokine profile enables Cryptococcus 
to repolarise the immune response, 
reducing the so-called Th1 response (a 
potent inflammatory and antimicrobial 
response, which is particularly effective 
in eradicating intracellular pathogens) 
and instead shifting towards a Th2 
profile, an inflammatory state that is 
targeted towards large pathogens such 
as parasitic worms and is ineffective  
at removing single-celled pathogens 
such as cryptococci. In parallel, a  
Fig. 1. Cryptococcus gattii cell stained with India ink, showing capsule (red), fungal cell wall (blue) and  
the budding yeast (yellow). Bar, 5 µm. Paula Seoane, Rafael Schneider and Robin C. May
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proportion of the infecting yeast  
cells expand dramatically in size to  
form giant or ‘titan’ cells. These cells  
are thought to arise from replication 
without concomitant mitosis, since  
they are polyploid and uninucleate,  
and block phagocytosis both of 
themselves and, interestingly, of 
normally-sized neighbouring  
cryptococci via a mechanism that  
is not yet characterised. 
Cryptococcus and phagocytes
If these strategies all fail and the 
invading fungus is engulfed by host 
phagocytes, cryptococci are able to 
engage an extra line of defence and 
persist as facultative intracellular 
pathogens (Fig. 2). Once inside the host 
cell, Cryptococcus cells have developed 
numerous mechanisms to both reduce 
the antimicrobial properties of the 
phagosome and to neutralise the low 
Fig. 3. Time-lapse images of J774 macrophages infected with GFP-tagged Cryptococcus neoformans 
exemplifying intracellular replication (a), lytic escape (b) and vomocytosis (c). The time post-infection is shown 
in each panel. Paula Seoane, Rafael Schneider and Robin C. May
Fig. 2. Cryptococcus neoformans cell (blue) being engulfed by a human macrophage (red and green).  
Paula Seoane, Rafael Schneider and Robin C. May
pH and reactive oxygen species that are 
abundant in this organelle. 
 Once established within the 
phagocyte, cryptococci are able to 
replicate rapidly but can also escape the 
macrophage via an intriguing non-lytic 
exocytosis, also known as vomocytosis 
(Fig. 3). Following vomocytosis, both 
the expelled cryptococci and the 
macrophage are undamaged. Thus this 
escape mechanism ensures minimal 
proinflammatory signaling, and is 
therefore thought to pose an advantage 
over lytic escape. 
How does Cryptococcus  
reach the brain tissue?
The most dangerous consequence 
of cryptococcal infection is 
meningoencephalitis, resulting from 
dissemination of the fungus to the 
central nervous system. To infect this 
immune privileged site, cryptococci 
must exit the lungs, enter peripheral 
blood circulation and bypass the blood–
brain barrier (BBB). It now appears 
that cryptococci accomplish this feat 
in three ways (Fig. 4). Firstly, yeast 
cells can make their way through tight 
junctions of the endothelial cells using 
proteases such as Mpr1, in a process 
called paracytosis. Secondly, yeast cells 
can infiltrate the BBB by transcytosis, 
a process that is mediated by the 
interaction between hyaluronic acid 
in the cryptococcal surface and CD44 
present in the luminal endothelium, 
resulting in direct uptake of the fungus 
by endothelial cells and migration 
through the cell’s cytoplasm to reach 
the brain tissue opposite. Finally, a 
third possibility involves cryptococci 
crossing the BBB whilst concealed 
within phagocytes, a so-called ‘Trojan 
Horse’ route. Evidence supporting this 
(a)
3:20 4:35 7:50 8:30
(b)
0:00 4:00 7:05 12:25
(c)
8:40 8:45 8:50 8:55
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“ “It now appears that the high pathogenicity of this lineage results from a novel “division of labour” virulence mechanism in which cryptococcal cells collaborate to drive extremely rapid intracellular proliferation and thus 
overwhelm the host.
mechanism comes from studies in mice 
where depletion of alveolar macrophages 
significantly reduced cryptococci burden 
in the brain tissue and direct infection 
with Cryptococcus results in lower 
dissemination to the brain than adoptive 
transfer of infected monocytes. 
Cryptococcus: one genus,  
several pathogens
One of the most remarkable findings 
of recent years has been the use of 
comparative genomic/phenotypic 
studies to reveal subtle differences in 
the biology of different cryptococcal 
lineages. Typically, infections with 
Cryptococcus gattii, although much rarer 
than Cryptococcus neoformans infections, 
cause more aggressive disease 
symptoms and respond more slowly 
to antifungal drugs. However, within 
each species certain lineages appear 
to be more pathogenic than others. For 
instance, the VNB lineage of Cryptococcus 
neoformans is associated with poorer 
patient outcomes than other strains. Most 
dramatic, however, is the involvement of 
the VGIIa lineage of Cryptococcus gattii 
in a large cryptococcosis outbreak that 
started in 1999 on Vancouver Island, 
Canada. During the following decade, 
236 human cases with 19 deaths 
were reported, almost none of which 
were in people with classical immune-
compromising conditions. Now known 
as the Pacific Northwest Outbreak, 
this disease cluster now represents 
the most serious outbreak of invasive 
fungal disease in the healthy population 
to date. It now appears that the high 
pathogenicity of this lineage results from 
a novel ‘division of labour’ virulence 
mechanism in which cryptococcal 
cells collaborate to drive extremely 
rapid intracellular proliferation and 
thus overwhelm the host, even in the 
presence of a fully functional immune 
response. 
Summary
Since its recognition as a major threat 
to human health in the 1980s, research 
on Cryptococcus has highlighted the 
extraordinary range of virulence factors 
used by this organism to drive disease. 
In particular, its ability to modulate 
host immunity and to enter the central 
nervous system by hiding inside 
macrophages has revealed unique 
aspects of host–pathogen biology. 
Intensive ongoing genetic, cell, biological 
and clinical investigations offer the 
prospect of us soon learning much more 
about this enigmatic human pathogen.
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Vomocytosis of live pathogens from macrophages is
regulated by the atypical MAP kinase ERK5
Andrew S. Gilbert,1 Paula I. Seoane,1 Poppy Sephton-Clark,1 Aleksandra Bojarczuk,2,3
Richard Hotham,2,3 Emanuele Giurisato,4,5 Adil R. Sarhan,1,6 Amy Hillen,7 Greetje Vande Velde,7
Nathanael S. Gray,8,9 Dario R. Alessi,6 Debbie L. Cunningham,1 Cathy Tournier,4
Simon A. Johnston,2,3 Robin C. May1*
Vomocytosis, or nonlytic extrusion, is a poorly understood process through which macrophages release live
pathogens that they have failed to kill back into the extracellular environment. Vomocytosis is conserved across
vertebrates and occurs with a diverse range of pathogens, but to date, the host signaling events that underpin
expulsion remain entirely unknown. We use a targeted inhibitor screen to identify the MAP kinase ERK5 as a
critical suppressor of vomocytosis. Pharmacological inhibition or genetic manipulation of ERK5 activity significantly
raises vomocytosis rates in human macrophages, whereas stimulation of the ERK5 signaling pathway inhibits
vomocytosis. Lastly, using a zebrafish model of cryptococcal disease, we show that reducing ERK5 activity in vivo
stimulates vomocytosis and results in reduced dissemination of infection. ERK5 therefore represents the first
host signaling regulator of vomocytosis to be identified and a potential target for the future development of
vomocytosis-modulating therapies.
INTRODUCTION
Phagocytes are an essential component of the innate immune system,
which function to identify, engulf, and destroy foreign particles. Al-
though the vast majority of microbes are readily killed by phagocytes
upon internalization, a number of important human pathogens have
evolved mechanisms to survive or replicate within this hostile host
environment. Phagocytes infected with these organisms have one of
two fates: either they successfully recognize and destroy the intracellular
pathogen or the pathogen lyses and kills the host cell.More than 10 years
ago, we and others discovered a third potential outcome, whereby host
macrophages expel the live pathogen residing within it in a process
known as vomocytosis or nonlytic extrusion (1, 2). Vomocytosis has
subsequently been observed with a diverse range of pathogens (3) and
in phagocytic cells from mammals (4), birds (5), fish (6), and amoebae
(7), suggesting that it is an evolutionarily conserved phenomenon.How-
ever, despite this marked conservation, the host molecules that regulate
vomocytosis have remained enigmatic.
RESULTS
To begin addressing the underlying molecular pathways that regulate
vomocytosis, we screened a library of inhibitors that target kinases
known to be expressed inmacrophages (table S1) (8). This initial screen
identified one compound [LRRK2-IN-1 (9)] that showed a small but
significant increase in vomocytosis rates without enhancing cell death.
LRRK2-IN-1 inhibits the leucine-rich repeat kinase LRRK2 but has ad-
ditionally been demonstrated to act against other kinases, including the
bromodomain protein BRD4 (10) and the extracellular receptor kinase
5 (ERK5) (11). Testing an independent second series of inhibitors
revealed a potent and reproducible enhancement of vomocytosis
with the ERK5 inhibitors XMD17-109 (12) or AX15836, but not with
a specific inhibitor of BRD4 [JQ1 (13)] or with an alternative inhibitor
of LRRK2 [HG1010201 (14)] (Fig. 1A and table S1). Notably, direct ex-
posure of cryptococci to ERK5 inhibitors in vitro did not alter fungal
morphology or growth rate (fig. S1), indicating that the impact of
ERK5 inhibition on vomocytosis acts at the level of the host macro-
phage and not of the pathogen itself. In addition, exposing cells to
LRRK2-IN-1 and XMD17-109 together did not enhance vomocytosis
levels beyond that of XMD17-109 alone, suggesting that it is the off-
target inhibition of ERK5 by LRRK2-IN-1 that accounts for its effect
on vomocytosis.
To confirm this role for ERK5 in enhancing vomocytosis, we first
exposed human macrophages, differentiated from peripheral blood
monocytes, to XMD17-109. It has previously been shown that primary
human macrophages show higher basal rates of vomocytosis than
phagocytic cell lines (2), but nevertheless, as with J774 cells (which
are originally derived from mouse), human macrophages showed a
significant increase in vomocytosis when ERK5 activity was inhibited
(Fig. 1B). Second, we tested the role of ERK5 in vomocytosis directly by
depleting ERK5 levels in macrophages using transient small interfering
RNA (siRNA)–based knockdown in J774 cells (Fig. 1C) or tamoxifen-
inducible ERK5 gene loss in murine bone marrow–derived macro-
phages (Fig. 1D). In both cases, we were unable to achieve full loss of
the ERK5 protein (fig. S2), but this partial reduction in ERK5 level
nevertheless resulted in a reproducible enhancement of vomocytosis.
Thus, either pharmacological inhibition or genetic removal of ERK5
enhances vomocytosis in vitro.
Vomocytosis has been reported to occur with a wide range of live
phagocytic targets but has never been observed with inert particles or
dead pathogens. In line with this observation, pharmacological inhibi-
tion of ERK5 similarly enhanced vomocytosis of a second fungal
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pathogen, Cryptococcus gattii, but despite extensive imaging we were
not able to observe any expulsion events for latex beads or heat-
inactivated cryptococci (Fig. 2A). Thus, ERK5 is acting as a suppressor
of the canonical vomocytosis pathway, rather than artificially inducing
expulsion of all phagocytic cargo.
The canonical ERK5 pathway involves ERK5 activation via the
upstreammitogen-activated protein (MAP) kinase MEK5 (15). Inhibi-
tion of MEK5 with the specific inhibitor BIX02189 (16) similarly raised
vomocytosis levels in macrophages (Fig. 2B), suggesting that vomocy-
tosis rates are normally suppressed by the MEK5-ERK5 signaling axis.
To test this possibility further, we exposed cells to insulin-like growth
factor 2 (IGF2),whichhaspreviously been shown to activateMEK5-ERK5
signaling up to eightfold (17) and to be implicated in phagocyte be-
havior (18). In line with this, IGF2 stimulation reduced cryptococcal
Fig. 1. Pharmacological or genetic inhibition of ERK5 enhances vomocytosis in vitro and ex vivo. (A) Vomocytosis is enhanced in J774.A1 cells by the LRRK2
inhibitor LRRK2-IN-1 (1 mM) but not by a second LRRK2 inhibitor, HG1010201 (1 mM). Vomocytosis is more strongly enhanced by specific inhibition of ERK5 (an off-target
of LRRK2-IN-1) by XMD17-109 (1 mM) but not by inhibition of a second off-target, BRD4, by the inhibitor JQ1 (1 mM). Dual application of LRRK2-IN-1 and XMD17-109 (1 mM of
each) showed significant enhancement of vomocytosis that was not significantly different to that of XMD17-109 alone. ns, not significant. (B) Application of 1 mM XMD17-109
to human PBMC-derived macrophages also significantly enhances vomocytosis rates in vitro. (C) Partial knockdown of ERK5 expression in J774.A1 by siRNA enhances
vomocytosis. (D) Tamoxifen-inducible reduction of ERK5 expression ex vivo in murine bone marrow–derived macrophages significantly raises vomocytosis rates. Statistical
significance was tested by c2 using a Bonferroni correction for multiplicity. All data represent pooled, averaged data from three to nine experimental repeats, with error bars
showing the SEM. Example movies used for scoring are shown in movies S1 and S2.
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expulsion rates from macrophages (Fig. 2B). Thus, pharmacological
or genetic inhibition of the ERK5 pathway enhances vomocytosis,
and indirect stimulation of the pathway via IGF2 suppresses it.
Macrophage behavior is strongly influenced by the local concen-
tration of cytokines, released both by themselves and by other cell
types. In particular, different cytokine environments can modulate
macrophage activation states (19), and we and others have previ-
ously shown that altered macrophage polarization states modify
vomocytosis rates (20). We therefore considered whether ERK5
might regulate vomocytosis by modifying macrophage polarization
and the local cytokine environment.
To determine the impact of ERK5 on macrophage polarization, we
assessed the expression of surface markers on J774 macrophages ex-
posed to XMD17-109. At rest, macrophages express both the pro-
inflammatory marker CD86 and the anti-inflammatory marker MGL
but are efficiently polarized to CD86hi (M1-like) cells when exposed to
exogenous interferon-g (IFN-g) and lipopolysaccharide (LPS) or con-
versely to MGLhi (M2-like) cells upon exposure to interleukin-4 (IL-4)
(Fig. 3A). Cells treated with XMD17-109 showed no change in the ex-
pression of CD86 markers (Fig. 3A, i) either at rest or stimulated with
IFN-g and LPS. In contrast, XMD17-109 treatment strongly reduced
the expression of MGL both in resting cells and in cells polarized by
exposure to IL-4 (Fig. 3A, ii). Thus, ERK5 inhibition in macrophages
leads to amodified inflammatoryprofile that prevents anti-inflammatory
polarization without modifying their response to inflammatory stimuli.
To determine the consequence of this modified inflammatory
profile, we performed enzyme-linked immunosorbent assay (ELISA)
analysis to quantify secreted cytokine levels in supernatants frommouse
Fig. 2. Modulation of the canonical ERK5 signaling pathway alters vomocytosis rate but does not induce expulsion of inert phagosomal cargo. (A) ERK5
inhibition enhances vomocytosis of both C. neoformans and C. gattii but does not induce vomocytosis of heat-killed cryptococci or inert 3-mm polycarbonate beads.
Numbers above each column represent the total number of individual fungal cells or beads scored. (B) Inhibition of MEK5 activity (an upstream regulator of ERK5) with
3 mM BIX02189 recapitulates the enhancement of vomocytosis seen with ERK5 inhibition in J774 macrophages, whereas stimulation of the ERK5 pathway via 1 mM IGF2
significantly reduces vomocytosis rates. Statistical significance was tested by c2 on raw data from three independent repeats. Error bars represent the SEM.
S C I ENCE ADVANCES | R E S EARCH ART I C L E
Gilbert et al. Sci. Adv. 2017;3 : e1700898 16 August 2017 3 of 8
D,i D,ii
P < 0.01 
100 
150 
200 
250 
300 
350 
400 
DMSO  XMD17-109 M
ea
n 
pa
rt
ic
le
 c
ou
nt
 p
er
 c
el
l 
DMSO control XMD17-109 
A,i A,ii
B,i B,ii
C,i C,ii
Fig. 3. ERK5 inhibition suppresses M2 macrophage polarization, alters secreted cytokine profiles, and modifies the actin cytoskeleton. (A) (i) Pharmacological
inhibition of ERK5 with XMD17-109 does not alter expression of the M1 macrophage marker CD86 in J774 macrophages at rest or under M1 (LPS and IFN-g) or M2 (IL-4)
stimulating conditions. (ii) However, IL-4–driven M2 polarization is strongly reduced in the presence of XMD17-109. Significance was tested using two-way analysis of
variance (ANOVA) on data from three independent replicates. Error bars show the SEM. (B) XMD17-109 inhibition of ERK5 activity in J774 macrophages increases
proinflammatory IL-12p40 secretion (i) while reducing the secretion of the M2 marker Ym1 (ii). Significance was tested using a ratio-paired t test. (C) XMD17-109
inhibition of ERK5 activity in human PBMC-derived macrophages increases proinflammatory TNFa secretion (i) while reducing the secretion of the anti-inflammatory
cytokine IL-10 (ii). Significance was tested using a ratio-paired t test. (D) J774 macrophages treated with XMD17-109 show a reduction in actin ruffles (revealed using
Alexa 488–phalloidin; i). (ii) Ruffle disruption by XMD17-109 results in increased numbers of smaller actin-rich fragments, quantified in binary images (n = 33 images
from n = 3 replicates, two-tailed t test; error bars are SEM). Images were captured using identical illumination, exposure, and postacquisition processing settings.
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macrophages (Fig. 3B) and human monocyte-derived macrophages
(Fig. 3C) treated with XMD17-109. In line with the reduction in IL-4
polarization induced by ERK5 inhibition, both cell types showed an
increased secretion of proinflammatory cytokines [IL-12p40 or tumor
necrosis factor–a (TNFa)] and a reduced secretion of M2-associated
proteins (Ym1 or IL-10) upon exposure to XMD17-109.
ERK5 has previously been implicated in cytoskeletal remodeling
(21, 22), and previouswork has shown thatmild inhibition of phagocyte
actin dynamics triggers enhanced vomocytosis (23). We therefore fixed
J774 cells exposed to C. neoformans in the presence or absence of
XMD17-109 and stained for filamentous actin. ERK5 inhibition did
not lead to any gross alteration of the actin cytoskeleton, in line with
our observation that XMD17-109 does not alter phagocytosis rates or
cell motility (both actin-driven processes). However, we noted a subtle
reduction in the number and size of actin-rich ruffles in treated cells,
suggestive of a slight destabilization of actin filamentation during
ERK5 inhibition (Fig. 3D). Thus, the impact of ERK5 inhibition
on vomocytosis likely results from a combination of reduced M2 in-
flammatory signaling and a diminished ability to constrain cryptococci
within filamentous actin “cages.”
Vomocytosis was first observedmore than a decade ago (1, 2), but an
enduring open question in the field has been whether it serves to in-
crease or reduce pathogenesis in infected organisms. Although in vivo
vomocytosis has been implied indirectly (4), it is only very recently that
extended imaging in the zebrafish model has provided direct evidence
for its occurrence within a living animal (6, 24).
We exploited this model to explore the impact of modifying vomo-
cytosis rates on cryptococcal disease progression.We infected zebrafish
larvae in the presence of XMD17-109 or a dimethyl sulfoxide (DMSO)
control and then used extended live-cell imaging of anesthetized fish to
quantify vomocytosis in vivo. As with our in vitro studies, ERK5 inhi-
bition led to significantly enhanced vomocytosis rates in vivo (Fig. 4A).
However, although the overall fungal burden at day 3 after infection did
not differ significantly between control and inhibitor-treated fish, ERK5
inhibition led to a significant decrease in disease dissemination from the
initial point of infection (Fig. 4B). In humans, cryptococcal dissemina-
tion from the lung (the initial point of entry) to other tissues (in partic-
ular, the central nervous system) is thought to depend, at least in part,
on “Trojan Horse” transportation within host phagocytes (25). Thus,
elevating vomocytosis rates presumably reduces dissemination by trig-
gering phagocytes to eject their fungal cargo before they migrate far
from the initial site of infection.
DISCUSSION
Together, these findings identify ERK5 as the first cellular signaling
component to regulate vomocytosis. There are a number of ERK5
inhibitors under clinical development (15), and further work is needed
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Fig. 4. ERK5 inhibition enhances vomocytosis and reduces dissemination in a zebrafish model of cryptococcosis. (A) Infected zebrafish treated with XMD17-109
show a significant (P = 0.001, Fisher’s exact test) increase in vomocytosis in vivo over 24 hours. Bars represent the median and 5th/95th percentile. (B) Overall fungal
burden at 3 days after infection is not significantly altered by ERK5 inhibition. Bars represent the median and 5th/95th percentile, with the boxed region representing
the interquartile range. (C) Individual infections can be individually scored as nondisseminated (restricted to the bloodstream; top), disseminated to muscle/tissue
blocks (middle), or disseminated to the central nervous system (bottom). CNS, central nervous system. (D) Infected fish treated with XMD17-109 show significantly
(P < 0.05, Fisher’s exact test) reduced dissemination from the site of infection. Bars represent the median and 5th/95th percentile.
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to understandwhether targeting vomocytosis has promising therapeutic
value. However, we note that the ERK5 locus is polymorphic in humans
and that specific polymorphisms have been linked to lung cancer risk in
smokers (26) and thus variation in ERK5 activity may contribute to the
significant individual variation in vomocytosis rate between healthy
donors and, consequently, to the risk of disseminated cryptococcosis.
MATERIALS AND METHODS
All reagents and media were purchased from Sigma-Aldrich, unless
specified otherwise.
Cryptococcus strains
Strains used wereC. neoformans var. grubii serotype Awild-type strains
H99 or KN99, green fluorescent protein (GFP)–expressing derivatives
KN99-GFP or H99-GFP, and C. gattii serotype B R265 or its GFP-
expressing derivative R265-GFP (27). These were grown overnight in
yeast peptone dextrose broth (2% glucose, 1% peptone, and 1% yeast
extract) at 25°C on an orbital rotator (20 rpm).
J774A.1 cell culture
J774A.1 murine macrophages were cultured at 37°C in 5% CO2 in
complete Dulbecco’s modified Eagle medium (DMEM) with 2 mM
L-glutamine, streptomycin (100 U/ml) and penicillin (0.1 mg/ml),
and 10% fetal bovine serum (FBS) and passaged when confluent by
scraping and resuspension in fresh medium.
Human primary macrophage isolation and culture
Allworkwithhuman tissuewasapprovedby theUniversityofBirmingham
Ethics Committee under reference ERN_10-0660. Twenty to fortyml of
blood was withdrawn from healthy volunteers by venipuncture and
diluted twice in cold phosphate-buffered saline (PBS) before layering
on top of 20 ml of Ficoll-Paque. Samples were centrifuged at 400g for
30 min at 20°C without braking in a swing bucket rotor. The white
disc of peripheral blood mononuclear cells (PBMCs) obtained was
washed twice in cold PBS (harvesting cells in between by centrifuga-
tion at 300g for 10 min), resuspended in PBS, counted, and then plated
onto multiwell dishes in RPMI 1640 with 10% FBS and granulocyte-
macrophage colony-stimulating factor (50 ng/ml).
Murine bone marrow–derived macrophage isolation
and culture
Mice carrying the erk5F allele and the CMV-CreER transgenes were
identified by polymerase chain reaction (PCR) on genomic DNA, as
previously described (28). The colony was maintained in a pathogen-
free facility at the University of Manchester, and all animal procedures
were performed under license in accordance with the UKHome Office
Animals (Scientific Procedures) Act 1986 and institutional guidelines.
Primary macrophages were obtained from bone marrow cells isolated
from femurs of genetically modified mice and cultured in DMEM
containing 10% FBS, 1% penicillin/streptomycin, and 20% L929 cell-
conditioned medium as a source of CSF-1 (colony-stimulating factor–1).
Where indicated, the cells weremock-treatedwithDMSOor incubated
with 4-hydroxytamoxifen (4-HT; 0.1 mM) at day 5 to induce Cre-
mediated recombination of the erk5F allele.
In vitro infection and imaging
Fungi were opsonized with pooled humanAB serum for 1 hour at 37°C
and 5%CO2 before infection.Macrophages were exposed to fungal cells
at a multiplicity of infection of 10:1 for 2 hours, with or without the
addition of inhibitors or DMSO controls. Extracellular fungi were
removed by washing with fresh medium, containing inhibitors or
DMSO control, and maintained under these conditions for 18 hours
of time-lapse imaging. Time-lapsemoviesweremade using aTi-ENikon
or Zeiss AxioObservermicroscope. Samples were incubated at 37°C and
5%CO2 in themicroscope imaging chamber. Images were taken every
5 min for 18 hours and compiled into single movie files for analysis
using NIS Elements or Zeiss Zen software, respectively. Movies were
blinded by a third party before manual scoring for vomocytosis and
macrophage integrity. Vomocytosis was scored visually using the
following preagreed guidelines:
(1)One vomocytosis event is the expulsionof internalized cryptococci
from an infected macrophage, regardless of the number of cryptococci
expelled if they do so simultaneously.
(2) Vomocytosis events are scored as independent phenomena if
they occur in different frames or from different macrophages.
(3) Vomocytosis events are discounted if the host macrophage sub-
sequently undergoes lysis or apoptosis within 30 min.
For fixed cell imaging, cells were plated onto glass coverslips and
then infected as above before fixing with 4% paraformaldehyde in
PBS (10 min) and then staining with Alexa 488–phalloidin (20 min).
Coverslips were mounted onto glass slides using ProLong Antifade
and imaged on a Zeiss Axio Observer.
ERK5 siRNA
Accell Mouse MAPK7 (ERK5)–SMARTpool siRNA was purchased
from Dharmacon GE Healthcare and used according to the manufac-
turer’s instructions. J774A.1 murine macrophages (5.0 × 103) were
seeded into a 96-well plate and incubated at 37°C and 5% CO2 in a
humidified incubator for 24 hours. SMARTpool siRNA, or a scrambled
siRNA control, was applied at 1 mMper well, incubated at 37°C and 5%
CO2 in a humidified incubator for 96hours, and then infected and time-
lapse–imaged as described above.
Secreted cytokine quantification
DuoSet ELISA Development kits from R&D Systems were used for all
cytokine quantification and used according to the manufacturer’s in-
structions. Secreted murine Ym1 was detected by sandwich ELISA
using anti-Ym1 antibody (Abcam). Media supernatants from infected
macrophages, treated with XMD17-109 or DMSO for 18 hours, were
serially diluted before ELISA analysis and cytokine concentrations
derived by reference to a standard curve.
Polarization assays
J774 macrophages were seeded at 0.2 × 106 cells per well in DMEM
containing 10% heat-inactivated FBS and then stimulated with IL-4
(20 ng/ml) (ImmunoTools) or LPS (20 ng/ml) (Sigma-Aldrich) +
1000 IU IFN-g (ImmunoTools), in the presence or absence of 1 mM
XMD17-109. After 24 hours, the cells were placed on ice and stained
for viability and macrophage activation markers (LIVE/DEAD Aqua
Thermo, CD11b-BV605 BD, MGL-PE BioLegend, and CD86-FITC
BD). Events were acquired using an Attune flow cytometer, and data
were analyzed using FlowJo 8.7.
Statistical analysis
Statistical analysis was performed using a combination of Microsoft
Excel, GraphPad Prism, MaxQuant (mass spectrometry tools), and
the statistical program R, together with the online software DAVID
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(Database for Annotation, Visualization and Integrated Discovery)
to detect significant enrichment of gene ontology clusters (29).
Zebrafish
Animal work was carried out per guidelines and legislation set out in
UK law in the Animals (Scientific Procedures) Act 1986, under Project
License PPL 40/3574. Ethical approval was granted by the University of
Sheffield Local Ethical Review Panel. We used the Nacre as our wild-
type strain.We used themacrophage Tg(mpeg1:mCherryCAAX)sh378
fluorescent transgenic zebrafish line (6). Zebrafish strains were main-
tained according to the standard protocols. Adult fish were maintained
on a 14:10-hour light/dark cycle at 28°C in UKHomeOffice–approved
facilities in the Bateson Centre aquaria at the University of Sheffield.
Zebrafish were infected as described previously (6) with 500 colony
forming units of Cryptococcus strain KN99-GFP. For time-lapse imag-
ing, zebrafish larvae were mounted in 0.8% low–melting point agarose
in E3 containing tricaine (0.168mg/ml). Imageswere capturedwithCFI
Plan Apochromat l [20×; numerical aperture (NA), 0.75 objective lens;
10 z-sections 2.5 mm apart], with Perfect Focus system, every 2 min for
12hours. For co-infection studies,weusedH99-GFP (27) andH99-dsRed
(30). For fungal burden and dissemination imaging, zebrafish were im-
aged in 96-well plates usingNikon Ti-E with a CFI Plan Achromat UW
(2×; NA, 0.06 objective lens), using Intensilight fluorescent illumination
with ET/sputtered series fluorescent filters 49002 (Chroma). Images
were captured with Neo sCMOS (Andor) and NIS Elements (Nikon).
Images were exported as tif files, and further analysis was performed in
ImageJ (31), as described previously (6).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/3/8/e1700898/DC1
table S1. Screened inhibitors of macrophage-expressed kinases.
fig. S1. Pharmacological inhibition of the MEK5/ERK5 signaling pathway does not alter
cryptococcal growth in vitro.
fig. S2. Quantification of ERK5 depletion in macrophages.
movie S1. Example time-lapse movie showing vomocytosis from J774 cells infected with H99-GFP
cryptococci and treated with DMSO (control).
movie S2. Example time-lapse movie showing vomocytosis from J774 cells infected with H99-GFP
cryptococci and treated with 1 mM XMD17-109.
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Characterizing the Mechanisms of Nonopsonic Uptake of
Cryptococci by Macrophages
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The pathogenic fungus Cryptococcus enters the human host via inhalation into the lung and is able to reside in a niche environment
that is serum- (opsonin) limiting. Little is known about the mechanism by which nonopsonic phagocytosis occurs via phagocytes in
such situations. Using a combination of soluble inhibitors of phagocytic receptors and macrophages derived from knockout mice
and human volunteers, we show that uptake of nonopsonized Cryptococcus neoformans and C. gattii via the mannose receptor is
dependent on macrophage activation by cytokines. However, although uptake of C. neoformans is via both dectin-1 and dectin-2,
C. gattii uptake occurs largely via dectin-1. Interestingly, dectin inhibitors also blocked phagocytosis of unopsonized Cryptococci
in wax moth (Galleria mellonella) larvae and partially protected the larvae from infection by both fungi, supporting a key role
for host phagocytes in augmenting early disease establishment. Finally, we demonstrated that internalization of nonopsonized
Cryptococci is not accompanied by the nuclear translocation of NF-kB or its concomitant production of proinflammatory
cytokines such as TNF-a. Thus, nonopsonized Cryptococci are recognized by mammalian phagocytes in a manner that
minimizes proinflammatory cytokine production and potentially facilitates fungal pathogenesis. The Journal of Immunology,
2018, 200: 3539–3546.
C ryptococcus neoformans and C. gattii are encapsulatedhuman fungal pathogens that cause cryptococcosisin immunocompromised and, more rarely, immuno-
competent individuals. Often found as free-living cells in soil
and avian excreta, Cryptococci are not intrinsic human path-
ogens. However, Cryptococci become human pathogens be-
cause several defense mechanisms possessed by these fungi
also act as virulence factors within a human or animal host (1),
including the ability, firstly, to survive and replicate within
free-living soil amoeba and, secondly, to evade clearance by
the host immune system by hiding and persisting within
macrophages (2, 3).
As Cryptococci enter hosts via inhalation into the lungs, they
are detected and phagocytosed by resident alveolar macrophages
(4). Phagocytosis is a multistep process that sequentially in-
volves receptor-mediated particle recognition, actin-driven up-
take, phagosome maturation, and particle clearance. It is critical
during the early innate immune response to ensure the removal
of microorganisms and apoptotic cells as well as subsequent
priming of the adaptive immune response through the produc-
tion and release of cytokines, such as TNF-a (5). Phagocytosis
of Cryptococci is typically inefficient unless they are opsonized
(coated) by Abs or complement proteins found in serum within the
circulatory system. Interestingly, there is a lack of serum opsonins
in the alveoli of the lungs, and so the initial uptake of Cryptococcus
upon colonization is most likely through a nonopsonized route (6).
Nonopsonic phagocytosis requires host cell phagocytic pattern
recognition receptors (PRRs) to directly recognize fungal cell
wall components (pathogen-associated molecular patterns
[PAMPs]) (7) such as b-glucans or mannan polysaccharides, but
the nature of this interaction for Cryptococci remains unknown. In
this article, we show that nonopsonized C. neoformans and
C. gattii enter macrophages in a spleen tyrosine kinase (Syk)–
dependent, mannose receptor–independent manner that involves
the receptors Dectin-1 and Dectin-2. This differential uptake of C.
neoformans and C. gattii corresponds to differential exposure of
PAMPs found on the fungal cell wall. Phagocytic kinetics of
macrophages and insect hemocytes in the absence or presence of
cellular receptor inhibitors were similar in response to fungal
targets. Finally, we demonstrate that entry of Cryptococcus does
not affect NF-kB nuclear translocation or subsequent TNF-a re-
lease, highlighting the remarkably noninflammatory capabilities
of this organism.
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Materials and Methods
Reagents
All reagents (e.g., heat-inactivated FBS, DMEM, L-glutamine, powdered yeast-
extract peptone dextrose, and PBS) were purchased from Sigma-Aldrich unless
stated otherwise. Mouse macrophage–CSF (130-094-129) and human GM-
CSF (130-093-862) were purchased from Miltenyi Biotec. Commercially
sourced inhibitors tested included the Syk–inhibiting plant metabolite,
Piceatannol (527948; Calbiochem); the b-1,3-glucan from brown algae
Laminaria digitata, Laminarin (L9634; Sigma-Aldrich); and mannan from
Saccharomyces cerevisiae (M7504; Sigma-Aldrich).
The Abs used in this study were rabbit anti-sheep RBCs, IgG fraction
(#55806; MP Biomedicals); rabbit anti-sheep RBCs, IgM fraction
(CL9000M; VH Bio/Cedarlane); rabbit anti–65 kDa subunit (p65) NF-kB
mAb (clone D14E12, #8242; New England Biolabs/Cell Signaling Tech-
nology); rat anti-aM (clone 5c6, MCA2289; Bio-Rad AbD Serotec); and
rabbit anti–Phospho-Syk (Tyr525/526 in humans, Tyr519/520 in mice,
clone C87C1, #2710; New England Biolabs/Cell Signaling Technology),
a kind gift from Y. Senis (University of Birmingham). Rhodamine-
Phalloidin and Alexa Fluor–conjugated secondary Abs were purchased
from Life Technologies and Calcofluor White from Sigma-Aldrich.
Glucan-6-phosphate and mouse anti-cryptococcal capsule Ab (clone
18B7) were kind gifts from D. Williams (East Tennessee State University)
and A. Casadevall (Albert Einstein College of Medicine), respectively.
Mice
Mice devoid of specific PRRs (in C57BL/6 background) were reported
previously (8, 9) and were housed under pathogen-free conditions in the
registered animal facility at the University of Aberdeen. Mice were allo-
cated to experimental groups on the basis of genotype and age-matching.
All animal procedures were performed according to the protocols provided
by the Animal Welfare and Ethical Review Body of the University of
Aberdeen and are regulated by the UK Home Office Animal (Scientific
Procedures) Act of 1986 and European Directive 2010/63/EU.
Yeast and bacterial cell growth conditions
C. neoformans strain H99, C. gattii strain R265, and Candida albicans
strain SC5314 were incubated in liquid yeast-extract peptone dextrose
medium for 24 h (unless stated otherwise) at 25˚C on a rotator at 20 rpm (or
37˚C, 200 rpm for C. albicans). Escherichia coli strain DH5a was incubated
in Luria-Bertani broth for 16 h at 37˚C in a shaking incubator at 200 rpm.
Yeast cells were centrifuged at 30003 g for 2.5 min (or 6000 3 g for 1 min
for E. coli), washed three times in PBS, and counted with a hemocytometer
prior to use.
Mammalian cell growth conditions
Cells from the murine macrophage–like cell line J774.A1 (American Type
Culture Collection number TIB-67) were cultured in DMEM supple-
mented with 2 mM L-glutamine and 10% heat-inactivated FBS at 37˚C, 5%
CO2 (10). As required, macrophages were scrapped in PBS, counted, and
seeded (50,000/well) onto 13 mm acid-washed glass coverslips, and in-
cubated for 24 h at 37˚C, 5% CO2 prior to experimental use.
Macrophages devoid of specific PRRs were derived from mouse bone
marrow. Bone marrows were flushed using a 21-gauge needle from the hind
leg bones of either receptor knockout (KO) or litter-matched wild type (WT)
mice. Monocytes were differentiated into macrophages with 20 ng/ml M-
CSF (Miltenyi Biotec) for 7 d.
Pooled PBMCs were isolated from whole blood from healthy volunteers
using density gradient centrifugation with Ficoll-Paque (GE Healthcare).
The mononuclear layer was collected and washed with PBS to remove
platelets. Monocytes were purified by adherence to plastic in RPMI 1640
media supplemented with 5% heat-inactivated FBS, 2 mM glutamine,
100 mg/ml streptomycin, and 100 U/ml penicillin at 37˚C, 5% CO2 for 1 h.
Nonadherent cells were removed with PBS and adherent cells differenti-
ated into macrophages with 20 ng/ml recombinant human GM-CSF
(Miltenyi Biotec) for 7 d. This study was covered by the University of
Birmingham’s Science, Technology, Engineering, and Mathematics Ethi-
cal Review Committee.
Phagocytic challenge
Macrophages were serum starved for 2–16 h with serum-free medium
at 37˚C, 5% CO2. Where needed, inhibitors were added directly and
left for a further 30 min. Next, media were removed prior to fresh
serum-free medium being added containing either 1 mg/ml 18B7 Ab
(against cryptococcal capsule) or unopsonized targets at a multiplicity
of infection of either 10:1 or 20:1 for 20–180 min at 37˚C, 5% CO2.
Cells were washed three times with PBS to remove unbound yeast/
bacteria cells and fixed in 4% paraformaldehyde for 10 min at room
temperature (RT).
Galleria mellonella maintenance
Larvae of the greater wax moth, Galleria mellonella, were sourced from
Livefoods Direct (U.K.) and stored in wood shavings in the dark at 13˚C.
This study was covered by the University of Stirling’s Animal Welfare and
Ethical Review Body. Healthy larvae weighing between 0.2 and 0.4 g were
used in all experiments. Larvae were inoculated with different concen-
trations of inhibitors via intrahemocele injection 1 h prior to infection with
1 million C. neoformans H99 per larva as described previously (11).
Controls consisted of larvae that received a 20 ml PBS inoculum. Three to
five larvae were used per treatment, with all treatments being performed on
at least three independent occasions.
For phagocytosis, larvae were bled and hemolymph treated as previously
described (12). Briefly, pooled hemolymph was mixed with 0.5 ml PBS
and added onto a 13 mm coverslip in a 24-well plate. Hemocytes were
centrifuged onto the coverslips for 10 min at 5003 g at RT before washing
three times with PBS to remove noninternalized yeasts. Cells were then
fixed with 4% paraformaldehyde before permeabilization and immunos-
tained as described below. All determinations were performed on at least
three independent occasions.
Immunofluorescence and scoring
Fixed cells on coverslips were permeabilized with 0.1% Triton X-100 for
5 min (if necessary to identify internalized yeasts), washed with PBS, and
blocked with 0.5% BSA in PBS for 30 min. Appropriate primary Abs
(1:200 dilution) were added to cells, left for 30 min at RT, washed with
PBS, and counterstained with the appropriate fluorophore–conjugated
secondary Ab, along with Rhodamine-Phalloidin and Calcofluor White.
Coverslips were then washed in PBS and distilled water before mounted
in ProLong Gold Antifade Reagent (Life Technologies) and analyzed by
microscopy.
For counting of phagocytosed yeast/bacteria, fixed but unpermeabilized
cells on coverslips were stained with Calcofluor White to highlight the
external yeasts. Coverslips were analyzed with a Nikon Eclipse Ti mi-
croscope under a 633 oil immersion objective. Between 5 and 10 fields of
view of each coverslip were counted for number of macrophages and as-
sociation of microbial cells. At least 100 macrophages were observed for
each coverslip.
The enrichment in phosphorylated Syk at sites of yeast binding and the
translocation of p65 into the nucleus during NF-kB activation were
studied and scored by the Nikon A1R confocal microscope using 203 to
633 objectives. For the former, a minimum of 25 infected cells per
condition were analyzed for a discrete local enrichment in marker signal
(Syk) at bound particles. For the latter, between three and five fields of
view for each sample/coverslip were counted for the number of macro-
phages with p65 marker signal located within the nucleus and expressed
as a percentage of the total number of macrophages (%NF-kB nuclear
translocation).
In vitro cytokine production
J774.A1 and primary human macrophages were cultured in 96-well
microtiter plates (Greiner) at 10,000 cells/well in a final volume of 200 ml.
Cells were stimulated with either control medium, LPS, or a range of
unopsonized pathogenic yeasts. After 6 h of incubation at 37˚C, plates
were centrifuged (500 3 g for 10 min), and the supernatant was collected
and stored at280˚C until cytokine assays were performed. Levels of TNF-
a were determined by commercial ELISA kits, used according to the in-
structions of the manufacturer (R&D Systems).
Statistical analyses
Analysis carried out on the results described in this paper was by a gen-
eralized linear model using a Poisson error distribution in R (R Devel-
opment Core Team). This was tested for significance using a post hoc Tukey
honest significant difference (HSD) test.
Results
Uptake of nonopsonized Cryptococci via mannose receptor is
activation dependent
As previously observed, the levels of nonopsonic uptake of
Cryptococci is very low (e.g., 0.4% of C. neoformans serotype
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D was taken up by unstimulated mouse peritoneal macro-
phages; or 7–21% of C. gattii R265 was taken up by human
dendritic cells (DCs); (13, 14)) and our results are in agree-
ment with those findings – 8.89 or 5.83% of primary human
macrophages contained one or more C. neoformans H99 or C.
gattii R265, respectively (based on the carrier controls in
Figs. 1C, 2B), after 2 h of incubation. The mannose receptor is
broadly expressed on macrophages and important for the
nonopsonic uptake of fungal pathogens such as C. albicans
and Pneumocystis carinii (15, 16). The uptake of C. neofor-
mans H99 or C. gattii R265 by J774.A1 macrophages
pretreated with soluble mannan (a competitive inhibitor of
mannose receptor binding) was unaltered relative to control
(untreated) cells (Fig. 1A). Similarly, M-CSF differentiated
bone marrow macrophages (BMMs) from mannose receptor
KO mice (MR KO) showed no reduction in uptake of either
C. neoformans or C. gattii relative to WT control cells
(Fig. 1B). Interestingly, however, GM-CSF–differentiated
primary human macrophages showed a strong inhibition of up-
take under the same conditions (Fig. 1C), suggesting that the
mannose receptor may play a greater role in cryptococcal uptake
into human cells than those of mice.
Phagocytosis of unopsonized Cryptococci is Syk-dependent
The other major class of nonopsonic phagocytic receptors for
fungi are the dectins (17). Both dectin-1 and dectin-2 require
Syk activity for their function, via ITAMs contained within
dectin-1 itself or via membrane association with ITAM–
containing Fc receptor g-chain in the case of dectin-2
(18). Inhibiting Syk activity in J774.A1 cells by using picea-
tannol (19) resulted in a marked reduction in their ability to
phagocytose either C. neoformans H99 or C. gattii R265 (Fig. 2A,
p , 0.05). The same observation was also seen in GM-CSF–dif-
ferentiated primary human macrophages from pooled monocytes
isolated from human volunteers (Fig. 2B). In line with this,
staining with an anti–Phospho-Syk Ab showed intense ac-
cumulation of active Syk at phagocytic cups forming around
nonopsonized Cryptococci (Fig. 3). This Ab was raised
against the tyrosine phosphorylated residues at positions 525
and 526, located in the activation loop of the Syk kinase
domain and essential for Syk function (20). Therefore, we
propose that the localization of this Ab to the sites of non-
opsonic uptake of Cryptococci and the activity of picea-
tannol in blocking uptake suggests that Syk activity is
required for internalization.
Phagocytosis of unopsonized Cryptococci is partially
dependent on Dectin-1
To test for a role for the dectin family of receptors during
phagocytic uptake of nonopsonized Cryptococci, we first ex-
posed J774.A1 macrophages (Fig. 4A) or differentiated pri-
mary human macrophages (Fig. 4B) to the dectin-1 inhibitor
glucan-6-phosphate before challenging with either unopson-
ized C. gattii R265 or C. neoformans H99. This inhibitor
FIGURE 1. Mannose receptor is important but dis-
pensable during uptake of Cryptococcus particles.
Mouse macrophage cell line J774.A1 (A) or differenti-
ated BMMs (B) (WT or MR KO) or differentiated pri-
mary human macrophages (C) were challenged with
either C. neoformans H99 (Cn, black bars) or C. gattii
R265 (Cg, white bars) for 60 min, processed for im-
munofluorescence, and scored for phagocytosis as
described in Materials and Methods. Where indi-
cated, J774.A1 and primary human macrophages were
pretreated with 100 mg/ml mannan (MAN) for 30 min
before the addition of Cryptococcus particles. Phago-
cytosis indices were related to the values obtained from
the negative controls. Number in bars indicate the total
number of phagocytes counted. Results are expressed as
the mean 6 SD of at least three independent experi-
ments.
FIGURE 2. Uptake of Cryptococcus particles is
Syk-dependent. Mouse macrophage cell line J774.
A1 (A) or differentiated primary human macro-
phages (B) were challenged with unopsonized
C. neoformans H99 (Cn, black bars) or C. gattii
R265 (Cg, white bars) for 60 min, processed for
immunofluorescence, and scored for phagocytosis
as described in Materials and Methods. Phagocy-
tosis indices were related to the values obtained
from the negative controls. Number in bars indicate
the total number of phagocytes counted. Results are
expressed as the mean 6 SD of at least three in-
dependent experiments.
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partially blocked the uptake of both species of Cryptococcus,
suggesting dectin-1 contributes toward Cryptococci uptake but is
not the sole recognition receptor involved in this process
(Fig. 4A, 4B). In line with this, M-CSF–differentiated BMMs
from dectin-1 and dectin-2 KO mice both showed substantially
impaired uptake of C. neoformans H99 – surprisingly, this was
not the case for C. gattii R265 (Fig. 4C). This suggests either the
presence of another Syk-dependent nonopsonic receptor or that
both dectins are redundant with each other for C. gattii, but not
C. neoformans uptake.
Nonopsonic uptake in the Galleria model
The greater wax moth, G. mellonella, is widely used as a model
organism in the study of host–pathogen interactions with a variety
of human pathogens (21). As with other insects, G. mellonella
does not possess an adaptive immune system like mammals but
possesses a complex innate immune system that includes phago-
cytic cells, termed hemocytes (22, 23). We therefore tested
whether nonopsonic uptake of Cryptococci in G. mellonella
showed similar receptor dependency as in mammalian cells by
pretreating larvae for 1 h with soluble mannan, glucan-6-phosphate,
FIGURE 3. Activated Syk is essential for
the uptake of Cryptococcus particles. Mouse
macrophage cell line J774.A1 was chal-
lenged with either (IgG-opsonized or
unopsonized, U/O) C. neoformans H99 or C.
gattii R265 for 15 min (B), processed for
immunofluorescence, and analyzed by con-
focal microscopy of localized phospho-Syk
(B and C) as described in Materials and
Methods. (A) Schematic diagram J774.A1
macrophage with intracellular actin cyto-
skeleton (red) and yeast particles (blue). To
confirm phospho-Syk localization, the bot-
tom of the cells was observed first [(A), grey
dashed line and (B), bottom panels], before
moving to the middle of the cells [(A), purple
dashed line, (B), top panels]. Pixel intensities
for 20 cells per sample were determined [(C),
right] and normalized to the intensity at the
center of the cell [(C), left]. (A and C) The
green triangles denote phospho-Syk. The
black line denotes the outline of a cell as
imagined from the side (i.e., its z-axis). Re-
sults are expressed as the mean 6 SD of at
least three independent experiments. Scale
bar, 20 mm.
FIGURE 4. Dectins are required for
uptake of Cryptococcus particles. Mouse
macrophage cell line J774.A1 (A), differ-
entiated primary human macrophages (B),
or differentiated BMMs (C) (WT, Dectin-1
KO, or Dectin-2 KO) were challenged
with either C. neoformans H99 (Cn, black
bars) or C. gattii R265 (Cg, white bars) for
60 min, processed for immunofluores-
cence, and scored for phagocytosis as de-
scribed in Materials and Methods. Where
indicated, J774.A1 were pretreated with
100 mg/ml glucan-6-phosphate (G6P) for
30 min before the addition of Cryptococ-
cus particles. Phagocytosis indices were
related to the values obtained from the
negative controls. Number in bars indicate
the total number of phagocytes counted.
Results are expressed as the mean 6 SD
of at least three independent experiments.
*p , 0.05. ns, not significant (p $ 0.05).
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or laminarin. The full genome sequence of Galleria is currently
available but not fully annotated (24). However, several b-1,3-
glucan–binding protein analogs and C-type lectins have been
characterized in this species, as well as other Lepidopterans,
namely Manduca sexta (25, 26), Bombyx mori (27), and Plodia
interpunctella (28). Recognition of fungal PAMPs (e.g., curdlan
and mannan) by membrane-bound receptors modulate cellular
(hemocyte)-directed immunity in insects (encapsulation, nodula-
tion, and phagocytosis) (29). Although soluble mannan did not
significantly reduce association of Cryptococci with Galleria
hemocytes in data presented in this paper, both glucan-6-
phosphate and laminarin led to a marked reduction in uptake
(Fig. 5, p , 0.001 for both when compared to the PBS controls).
Interestingly, administering glucan-6-phosphate or laminarin for
24 h appeared to partially protect the insect larvae from infection by
both unopsonized species of Cryptococcus (Fig. 6), suggesting that
disease establishment in this model organism requires the fungus
to grow intracellularly, something that has previously been pro-
posed for human hosts (30).
Cryptococcal uptake by macrophages does not lead to
increased proinflammatory cytokine secretion
Unlike many pathogens, internalization of opsonized Cryptococci
into phagocytes is not accompanied by the production of proin-
flammatory cytokines such as TNF and IL-1a or IL-1b (31, 32). To
test whether this is also true of nonopsonic uptake, we measured
the secretion of TNF-a and nuclear translocation of p65 (a major
regulator of cytokine transcription) from J774.A1 macrophages upon
challenge with unopsonized or serum-opsonized C. neoformans H99
or C. gattii R265. Although LPS-stimulated macrophages showed
strong nuclear translocation of p65, neither IgG-opsonized nor
unopsonized C. neoformans H99 or C. gattii R265 stimulated NF-kB
activation (Fig. 7A). However, NF-kB activation could be restored in
cryptococcal exposed macrophages by the subsequent addition of
LPS (Fig. 7B).
Furthermore, to test whether internalization of unopsonized
Cryptococci into J774.A1 mouse macrophages or primary human
macrophages elicits the production of proinflammatory cytokines
such as TNF, we measured the secretion of TNF-a from J774.A1
macrophages or primary human macrophages upon challenge with
unopsonized C. neoformans H99 or C. gattii R265, with C. albi-
cans and LPS as controls. With J774.A1 mouse macrophage and
primary human macrophages, C. albicans- or LPS-stimulated
macrophages showed stronger TNF-a production compared to
varying doses of C. neoformans H99 or C. gattii R265 (Fig. 8;
p = 0.04 for C. albicans versus media control, p . 0.05 for C.
albicans versus C. neoformans/C. gattii). Overall, this suggests
that Cryptococci do not actively block inflammatory signaling in
host cells and do not induce a strong inflammatory stimulus fol-
lowing nonopsonic uptake.
Discussion
In this study, we examined the phagocytic uptake of unopsonized
cryptococcal yeast particles by macrophages. This process relies on
the use of phagocytic receptors, which can be categorized either as
opsonic or nonopsonic. Opsonic phagocytic receptors include the
Fc receptor and complement receptor families, which recognize
Ab- or complement-opsonized (coated) particles, respectively.
Nonopsonic phagocytic receptors are PRRs, such as the C-type
lectin family of receptors, which recognize distinct PAMPs on
the fungal surface (33).
Although phagocytosis of Cryptococcus within the circulatory
system would occur predominantly through an opsonized (coated)
uptake route because of the presence of Abs and/or complement
proteins found in serum, this is not always the case. For example,
the first encounter of the human body with Cryptococcus is
through the lungs when desiccated yeast cells or spores are
breathed in. These cryptococcal particles encounter their initial
immunological challenge through resident alveolar macrophages
and DCs in a serum-deficient or low-serum environment (34–36).
Interestingly, it was reported recently that between 25 and 40%
of mouse lung-resident macrophages are able to phagocytose
C. neoformans particles through a scavenger receptor pathway
(37). Therefore, this confirms that initial uptake of Cryptococcus
FIGURE 5. Administration of polysaccharides blocks uptake of Cryp-
tococcus particles to hemocytes in the G. mellonella larvae model. Larvae
were inoculated with 60 mg of blocking sugars 1 h prior to infection for 2 h
with 106 C. neoformans H99 (black bars) or C. gattii R265 (white bars).
Uptake of yeast of hemocytes was determined under light microscopy.
Results are expressed as the mean 6 SD of at least three inde-
pendent experiments. *p , 0.05 (related to PBS control). ns, not
significant (p $ 0.05).
FIGURE 6. Glucan administration protects G. mellonella larvae from
infection by C. neoformans or C. gattii. Larvae were inoculated with 60 mg
of blocking sugars 24 h prior to infection for a further 24 h with 106
C. neoformans H99 (black bars) or C. gattii R265 (white bars). Fungal load
was determined by serially diluting homogenized larvae and plating ali-
quots onto erythromycin containing agar plates. Yeast cell density were
related to the values obtained from the negative (PBS) controls and
expressed as cfu3 105/larva. Results are expressed as the mean6 SD of at
least three independent experiments. *p , 0.05 (related to PBS control).
ns, not significant (p $ 0.05).
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by macrophages is most likely through a nonopsonized route, and
there is a need to understand the mechanisms that underpin this
process (6). We confirmed that, compared with the bacterium
E. coli or fungus C. albicans, Cryptococci cells are not readily
taken up by mammalian macrophages, most likely because of
the presence of the capsule, which renders Cryptococci anti-
phagocytic (38, 39). By using a combination of a soluble mannose
inhibitor and MR KO tissue, we demonstrated that mannose re-
ceptor was not necessary for the uptake of either species of
Cryptococcus, in line with recent data from the zebrafish model
(40), although this is not the case in primary human macrophages.
We note that others have shown MR KO mice to be more sus-
ceptible to C. neoformans (41) and demonstrated a role for this
receptor, along with FcgRII (CD32) in driving cryptococcal up-
take into DCs (42). Thus, mannose receptor dependency appar-
ently varies across different cell types and tissue contexts.
Next, we pursued a different set of nonopsonic PRRs, dectin-1
and dectin-2, which are C-type lectin receptors that are highly
expressed in macrophages and are key b-glucan receptors (43, 44).
Recognition of soluble or surface expressed b-glucans on yeasts
is sufficient to initiate and mediate phagocytosis and proin-
flammatory cytokine responses (45). Both of these receptors re-
quire Syk activity (18, 46, 47), and, indeed, our data clearly
demonstrate the activation of Syk at phagocytic cups containing
unopsonized Cryptococci, as well as a strong dependency on Syk
for particle uptake. Interestingly, pharmacological inhibition of
dectins inhibited uptake of both C. neoformans and C. gattii in
J774.A1 mouse and human macrophages, but BMMs from dectin-
1– and dectin-2–KO mice showed defects only in the uptake of
C. neoformans and not C. gattii, an effect that has been observed
before (48). The most parsimonious explanation is therefore that
the two dectin receptors are redundant for the uptake of C. gattii,
but not C. neoformans, perhaps reflecting differing surface com-
ponents between the two species, as reported recently (49). Such
surface variation between species, strains, and potentially devel-
opmental stages of Cryptococci may explain many of the previous
inconsistencies in the literature regarding dectin dependency
(or otherwise) (50, 51).
Alongside mouse macrophages, we adopted wax worm
larvae (G. mellonella) as an alternative model for understanding
cryptococcal virulence and host immune responses (52–54) in
which cryptococcal phagocytosis has previously been reported
(55). Our data demonstrate striking similarities in patterns of
uptake between this invertebrate host and murine phagocytes. In
addition, we showed that inhibiting phagocytosis in this alterna-
tive host reduces disease burden, highlighting the importance of
host phagocytes as a niche for cryptococcal replication.
We acknowledge that although there are currently no direct
dectin receptor homologs identified in G. mellonella, many C-type
lectins have been characterized in other insect models, for ex-
ample; the tobacco hornworm, Manduca sexta (immulectin-2 fa-
cilitates phagocytosis of bacteria (56)); webworm, Hyphantria
cunea (lectin (57, 58)); silkworm, Bombyx mori (BmLBP and
BmMBP (59, 60)); and the cockroach, Blaberus discoidalis
(a b-glucan–specific lectin (61)). These invertebrate C-type lectins
FIGURE 7. Uptake of Cryptococcus did not affect
NF-kB nuclear translocation. J774.A1 macrophages
were challenged with a variety of opsonized or
unopsonized pathogenic fungi, SRBCs, or soluble ago-
nists (LPS or PMA), processed for immunofluores-
cences, analyzed by microscopy (A), and scored for p65
nuclear translocation (B), as described in Materials and
Methods. (A) Representative images of PMA- (top) or
LPS- (bottom) stimulated J774.A1 macrophages and
stained to highlight either actin or p65. Actin was
stained using rhodamine-phalloidin; p65 was stained
using the anti–65 kDa subunit (p65) NFkB mAb with an
anti-rabbit Alexa Fluor–488. Scale bar, 20 mm.
FIGURE 8. Uptake of Cryptococcus did not affect proinflammatory
cytokine response. J774.A1 macrophages (black bars) or differentiated
primary human macrophages (white bars) were challenged with a variety
of unopsonized pathogenic fungi (C. neoformans, Cn; C. gattii. Cg;
Candida albicans, Ca) or LPS, and subsequent supernatants were analyzed
by ELISA, as described in Materials and Methods. Results are expressed
as the mean 6 SD of at least three independent experiments. *p , 0.05.
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show up to 35% similarity with mammalian C-type lectins and can
bind to several PAMPs, including LPS, lipoteichoic acid, and
b-glucan and are inducible when the host is exposed to microbial
challenge or ligands and the mechanisms for uptake of pathogenic
microbes by G. mellonella hemocytes are similar to that of human
neutrophils (62).
Two key reports have shown that there are at least three scav-
enger receptors involved in the recognition of different serotypes of
Cryptococcus neoformans, namely the homologous genes from
the nematode Caenorhabditis elegans, CED-1 and C03F11.3, as
well as the mouse MARCO scavenger receptors (37, 63). Inter-
estingly, knocking out MARCO gene from mice did not abolish
uptake of C. neoformans by lung-resident mononuclear phago-
cytes (37), suggesting a role or roles for the extent and distribution
of multiple receptors and ligands on the surface of both host cell
and yeast.
Finally, we demonstrate that entry of Cryptococcus does not
affect NF-kB nuclear translocation and its subsequent TNF-a
release in the Dectin-1/Syk/NF-kB signaling axis—both in J774.
A1 mouse macrophages and in primary human macrophages.
Although it is known that Dectin-1 coupling to Syk leads to
downstream activation of NF-kB, which coordinates the tran-
scription of innate response genes, including expression of
proinflammatory cytokines such as TNF-a (64–66), this appears
not to be the case for cryptococcal uptake.
In conclusion, we propose that unopsonized Cryptococci are
recognized and engulfed via mannose receptor- or dectin-based
recognition in vitro depending on the activation state of the host
cells. The absence of an associated proinflammatory cascade allows
the yeast to exploit this intracellular niche for rapid disease es-
tablishment.
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14 Abstract
15 Cryptococcus neoformans is an opportunistic human pathogen, which causes serious disease 
16 in immunocompromised hosts. Infection with this pathogen is particularly relevant in HIV+ 
17 patients, where it leads to around 200,000 deaths per annum. A key feature of cryptococcal 
18 pathogenesis is the ability of the fungus to survive and replicate within the phagosome of 
19 macrophages, as well as its ability to escape via a novel non-lytic mechanism known as 
20 vomocytosis. We have been exploring whether viral infection affects the interaction between 
21 C. neoformans and macrophages. Here we show that viral infection enhances cryptococcal 
22 vomocytosis without altering phagocytosis or intracellular proliferation of the fungus. This 
23 effect occurs with distinct, unrelated human viral pathogens and is recapitulated when 
24 macrophages are stimulated with the anti-viral cytokine interferon alpha (IFNα). Importantly, 
25 the effect is abrogated when type-I interferon signalling is blocked, thus underscoring the 
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26 importance of type-I interferons in this phenomenon. Our results highlight the importance of 
27 incorporating specific context cues while studying host-pathogen interactions. By doing so, we 
28 found that acute viral infection may trigger the release of latent cryptococci from intracellular 
29 compartments, with significant consequences for disease progression.
30
31 Non-Technical Author Summary
32 Infectious diseases are typically studied in the laboratory in isolation, but in real life people 
33 often encounter multiple infections simultaneously. Here we investigate how the innate 
34 immune response to the fatal fungus Cryptococcus neoformans is influenced by viral 
35 coinfection. Whilst virally-infected macrophages retain a normal capacity to engulf and kill 
36 Cryptococci, they demonstrate a dramatically enhanced propensity to expel them via the 
37 process known as non-lytic expulsion or vomocytosis. Activation of vomocytosis is 
38 independent of the type of virus encountered, since both HIV and measles (two entirely 
39 unrelated viral pathogens) trigger the same effect. Instead it is driven by interferon-α, a generic 
40 ‘antiviral’ response, which signals back to the infected macrophage, triggering expulsion of the 
41 fungus. We propose that this hitherto unobserved phenomenon represents a ‘reprioritisation’ 
42 pathway for innate immune cells, by which they can alter the frequency with which they expel 
43 one pathogen (Cryptococcus) depending on the level of threat from a secondary viral infection.
44
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45 Introduction 
46
47 Since their discovery in 1957 by Isaacs and Lindenmann (1), the antiviral effects of type I 
48 interferons have been well documented (2-4). More recently, their roles in non-viral infections 
49 have been investigated (5, 6). Different bacterial stimuli have been shown to elicit type I 
50 interferon production, and in turn these so called “antiviral cytokines” play a role in the 
51 outcome of bacterial infections (7-9).  This stems in part from the complex and sometimes 
52 contradictory effects that type I interferons have on host cells, for instance in enhancing 
53 inflammatory responses in some infectious settings (6) to preventing hyperinflammation in 
54 others (10, 11), and even affecting the priming of immune responses at lymph nodes (12).
55
56 To date, little is known about the interplay between type I interferons and fungal infections, 
57 despite the fact that many life-threatening fungal infections occur in the context of chronic viral 
58 infection. This is particularly true of Cryptococcus neoformans, a globally distributed 
59 opportunistic pathogen that is responsible for nearly 200,000 deaths per year in human 
60 immunodeficiency virus (HIV) infected people, where it causes cryptococcal meningitis (13). 
61 Extensive work over many years has demonstrated that a key feature of cryptococcal 
62 pathogenesis is the ability of the fungus to survive, proliferate within, and then escape from, 
63 host macrophages (14-17). Macrophages are among the first immune cells to encounter the 
64 fungus within the human host (18) , and thus are very important in the fight against this 
65 pathogen. These cells are able to phagocytose and contain the threat, as happens in 
66 immunocompetent hosts, but can also by hijacked by Cryptococcal cells and used as a “Trojan 
67 horse” to disseminate to distal sites within the body, particularly to the central nervous system 
68 (19). Engulfed Cryptococcal cells can escape from host macrophages through lytic or non-lytic 
69 mechanisms, the latter being known as vomocytosis or non-lytic extrusion (20, 21). Most 
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70 studies to date have focused on the interaction of Cryptococcus with healthy host cells, and 
71 consequently how this intracellular lifestyle may be impacted by viral coinfection remains 
72 unknown.
73
74 Here we show that viral infections enhance vomocytosis of Cryptococci from infected 
75 macrophages, without affecting phagocytosis or intracellular proliferation rate of the fungus. 
76 This effect is lost when signalling through the type I interferon receptor is blocked, and can be 
77 recapitulated by addition of exogenous IFNα. Thus, antiviral responses by the host have a 
78 hitherto unexpected impact on the release of intracellular pathogens by vomocytosis.
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79 Materials and Methods
80 All reagents were purchased from SIGMA unless otherwise stated.
81
82 Cryptococcus Strains
83 Cryptococcal strains were grown in Yeast Peptone Dextrose (YPD) broth (2% glucose, 1% 
84 peptone and 1% yeast extract) at 25°C on a rotator (20 rpm). Yeast from overnight cultures 
85 were centrifuged at 6500 rpm for 2 minutes and resuspended in PBS at the required 
86 concentration. All experiments were carried out using C. neoformans var. grubii serotype A 
87 strain Kn99α. Wildtype, GFP- (22) or mCherry-expressing (23) derivatives of  Kn99α were 
88 used, as stated for each figure.
89
90 Virus strains
91 HIV-1 virus stocks were generated by transfection of human embryonic kidney 293T cells 
92 (European Collection of Authenticated Cell Cultures) as previously described (24, 25).  The 
93 R9HIVΔenv virus was derived from clade B HIV-1 strain (NL43) with 500bp deletion in env, 
94 pseudotyped with vesiculostomatitis virus G envelope. SIV3mac single round virus like 
95 particles (VLPs) containing vpx (SIV3vpx) were generated by transfection into 293T cells with 
96 pSIV3+ and pMDG plasmids (26, 27). At 48, 72h and 96h viral containing supernatant was 
97 harvested, centrifuged at 800 x g for 10 min and filtered through 0.45 um filter then centrifuged 
98 on a 20% sucrose cushion at 20,000 x g for 2h at 4°C. Purified virus was then re-suspended in 
99 RPMI media and frozen at -80°C. To quantify single round HIV infection, a vial was thawed 
100 for each harvest and serial dilutions used to infect CCR5/CD4 and CXCR4/CD4 transfected 
101 NP-2 cells. At 72h post infection wells were fixed in ice cold acetone-methanol and infected 
102 cells were identified by staining for p24 protein using a 1:1 mixture of the anti-p24 monoclonal 
103 antibodies EVA365 and EVA366 (NIBSC, Center for AIDS Reagents, UK). Infected cells 
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104 were detected by light microscopy to provide a virus titre (focus-forming U/mL). The SIV3vpx 
105 particles were quantified after thawing using a reverse transcriptase (RT) assay colorimetric kit 
106 (Roche) following the manufacturer’s instructions to provide a RT ng/mL titre.
107
108 Recombinant MeV strain IC323 expressing green fluorescent protein (MeV-GFP) was 
109 generated as previously reported by Hashimoto et al. (28) MeV-GFP represents a virulent field 
110 isolate from Japan (Ichinose-B (IC-B) strain) and was isolated from a patient with acute 
111 measles in 1984 (29). For the generation of virus stocks, Vero (ATCC CCL-81) cells 
112 overexpressing human SLAMF1 receptor (vero-hSLAM cells) were grown in T75 tissue 
113 culture flasks to approximately 80% confluency in DMEM supplemented with 0.4 mg/mL 
114 G418. Flasks were infected with MeV-GFP at an MOI of 0.01:1 in 5 mL media for 1 hour at 
115 37°C. After 1h a further 10 mL of DMEM supplemented with 10% FBS was added and 
116 infection allowed to continue for 48 h. At harvest the flasks were frozen to -80°C. After 
117 thawing, the collected supernatants were centrifuged at 2500 rpm for 10 min at 4°C to pellet 
118 cell debris. Aliquoted virus in supernatant was then frozen to -80°C. MeV-GFP viruses were 
119 then titred using the TCID-50 method. Vero-hSLAM cells were seeded into flat-bottomed 96 
120 well plates and infected with serial dilutions of thawed MeV-GFP in triplicate. After 72 h, 
121 wells were scored for positive or negative infection under UV illumination on a Nikon TE-
122 2000 microscope. 
123
124 Ethics Statement
125 All work with human tissue was approved by the University of Birmingham Ethics Committee 
126 under reference ERN_10-0660. Samples were collected specifically for this work and were not 
127 stored beyond the duration of the experiments described herein.  All donors provided written 
128 consent prior to donation. 
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129
130 Human macrophage isolation and culture
131 20-40 mL of blood were drawn from healthy donors by venepuncture. 6 mL of whole blood 
132 were carefully layered on top of a double layer of Percoll (densities of 1.079 and 1.098 g/mL). 
133 Samples were centrifuged in a swing bucket rotor at 150g for 8 minutes, followed by 10 
134 minutes at 1200g, with acceleration and break set to zero. The resulting white disc of peripheral 
135 blood mononuclear cells (PBMC) was transferred to a clean vial and incubated with red blood 
136 cell lysis buffer at a ratio of 1:3 for 3 minutes, with gentle mixing throughout to prevent clot 
137 formation. Cells were then washed with ice cold PBS twice, with centrifugation at 400g for 6 
138 minutes in between each wash, and counted with a haemocytometer. 1x106 PBMC were seeded 
139 onto 48-well plates in RPMI-1640 media containing 1% penicillin/streptomycin, 5% heat-
140 inactivated AB human serum and 20 ng/mL M-CSF (Invitrogen). Cells were washed with PBS 
141 and resuspended in fresh media on days 3 and 6 of differentiation. Macrophages were ready to 
142 use on day 7. A yield of 1x105 macrophages per well was estimated.
143
144 Cryptococcus infection
145 Fungi were opsonised with 10% human AB serum or 18B7 antibody (a kind gift from Arturo 
146 Casadevall) for 1 hour and then added to macrophages at a multiplicity of infection of 10:1. 
147 Infection was carried out in serum free-media, at 37°C with 5% CO2. After 2 hours, cells were 
148 washed 3 times with PBS to remove any extracellular fungi and fresh serum free-media was 
149 added. 
150
151 Drug treatments
152 Exogenous compounds were added to macrophages at two stages; when infecting with 
153 Cryptococcus and again when replenishing with fresh media after removing extracellular fungi. 
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154 Compounds tested include interferon alpha (IFNα) at concentrations ranging from 5 to 100 
155 pg/mL (Bio-Techne), polyinosinic-polycytidilic acid (polyIC) at 3 and 30 ng/mL (Invivogen), 
156 type-I interferon receptor inhibitor (IFNARinh) at 2.5 µg/mL (pbl assay science). 
157
158 Co-infection assay
159 Human monocyte-derived macrophages were infected with either attenuated human 
160 immunodeficiency virus (HIV) or MeV-GFP as follows:
161 For attenuated HIV co-infections, 24h before cryptococcal infection, human monocyte-derived 
162 macrophages were infected either with R9HIVΔenv at a MOI of 10:1, SIV3vpx at 3 ng/mL or 
163 both in serum free RPMI. At 24 h post infection duplicate wells were fixed in ice cold acetone-
164 methanol and infected cells were identified by staining for p24 protein as described above. 
165 Experimental wells were infected with antibody opsonised-Cryptococcus Kn99α-GFP for 2 
166 hours, washed to remove extracellular fungal cells, and replenished with fresh serum free-
167 media.
168
169 Alternatively, macrophages were infected with MeV-GFP at an MOI of 5:1 in serum free-
170 media and kept at 37°C with 5% CO2. After 24 hours, cells were washed with PBS and fresh 
171 media, supplemented with 5% heat-inactivated human AB serum, was added. After 3 days, 
172 cells were co-infected with serum opsonised-Cryptococcus Kn99α-mCherry for 2 hours, 
173 washed to remove extracellular fungal cells, and replenished with fresh serum free-media.
174
175 Live imaging
176 Infected samples were kept at 37°C with 5% CO2 in the imaging chamber of a Ti-E Nikon 
177 Epifluorescence microscope. Images were taken every 5 minutes over an 18-hour period and 
178 compiled into a single movie file using NIS Elements software. Movies were blinded by a third 
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179 party before manual scoring for phagocytosis of Cryptococcus, virus infection rates, 
180 vomocytosis events, intracellular proliferation rates and macrophage integrity.  
181
182 Growth curve assay
183 A 10-fold diluted cryptococcal overnight culture was inoculated into YPD broth in a 48-well 
184 plate (final dilution in well: 1000-fold), in the presence or absence of type-I interferons. The 
185 plate was sealed with a breathable membrane and incubated at 37°C within a fully automated 
186 plate reader (FLUOStar, BMG Omega). Optical density readings at 600 nm were taken every 
187 30 minutes over a 24 hour-period, with orbital shaking in between readings.
188
189 Data analysis
190 Statistical analysis was performed using GraphPad Prism 6. Categorical data of phagocytosis 
191 or vomocytosis occurrence in the different conditions was assessed using Chi2 test and Fisher’s 
192 exact test. If data was normally distributed as assessed by Shapiro-Wilk test, then it was 
193 compared using Student’s t test. Figures show percentage of cryptococcus-infected 
194 macrophages experiencing at least one vomocytosis event within each experiment. For 
195 intracellular proliferation rates, data was analysed using Mann-Whitney test. Growth curves 
196 were fitted to sigmoidal curves and the parameters were compared using Kruskal-Wallis test. 
197 All data shown corresponds to at least three independent experiments.
198 Raw data (collated manual counts for multiple timelapse movies) are provided as supplemental 
199 material for each figure.  Original timelapse movies, upon which manual scoring was 
200 performed, are freely available upon request from the authors. 
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201 Results
202
203 Given the relevance of cryptococcosis to HIV+ patients (13), we set out to test whether HIV 
204 infection had an effect on vomocytosis of C. neoformans. Human monocyte-derived 
205 macrophages were infected with HIV-1 capable of a single-round of infection and subsequently 
206 with C. neoformans and then used for time-lapse imaging over 18 hours. Subsequent scoring 
207 showed that virally infected cells had a significantly higher occurrence of cryptococcal 
208 vomocytosis (Figure 1A), whilst fungal uptake and intracellular proliferation were unaltered 
209 (Figure 1C, 1E).
210
211 The experimental HIV system we used here includes co-transduction with SIV3vpx VLPs in 
212 order to counteract the antiviral effect of SAMHD1 and ensure maximal HIV infection of the 
213 macrophages (26, 30) (Figure S1A). Interestingly, we noted that the addition of SIV3vpx or 
214 R9HIV∆env alone also increased vomocytosis (Figure S1B).  Since neither condition results 
215 in widespread viral infection of host cells, this suggested that the enhancement of vomocytosis 
216 occurs at the level of viral detection, rather than being a consequence of active HIV infection. 
217
218 To explore this further, we tested whether vomocytosis was altered in macrophages infected 
219 with an unrelated macrophage-tropic virus (31); measles (MeV, Figure 1B). The measles strain 
220 used represents a virulent field isolate from Japan. Once again, infection with the virus resulted 
221 in significantly enhanced vomocytosis of Cryptococcus. Neither HIV nor measles infection 
222 affected uptake of Cryptococcus nor the intracellular proliferation rate (IPR) of the fungus 
223 (Figure 1C-F), suggesting that the viral effect acts specifically at the level of vomocytosis, 
224 rather than fungal pathogenicity per se, and that it is independent of the type of virus.
225
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226 To test whether active viral infection was required for enhanced vomocytosis, we mimicked 
227 the effect of viral exposure by stimulating macrophages with polyinosinic-polycytidilic acid 
228 (polyIC). PolyIC is a double-stranded RNA synthetic analogue, which is known to trigger 
229 antiviral responses by binding to TLR3 (32). Human monocyte-derived macrophages were 
230 stimulated with polyIC and infected with C. neoformans simultaneously. Infected cells were 
231 imaged over 18 hours and scored for vomocytosis (Figure 2A).  As with HIV or MeV infection, 
232 polyIC stimulation enhanced vomocytosis of Cryptococcus.  Thus, it is likely that the antiviral 
233 reaction of the host macrophage, rather than an aspect of viral pathogenesis, is the trigger for 
234 enhanced vomocytosis from infected host cells.  
235
236 The hallmark of the cellular anti-viral response is the induction of type-I interferons. Among 
237 these, the best studied are IFNα and IFNβ. During HIV infection specifically, the induction of 
238 IFNα is the most relevant (33). We therefore tested whether the impact of viral infection on 
239 vomocytosis could be recapitulated by exposure to interferon-α (IFNα). Stimulation of human 
240 monocyte-derived macrophages with 10 pg/mL IFNα (a level that closely matches that seen in 
241 HIV-infected patients (33)) resulted in significantly enhanced vomocytosis of Cryptococcus 
242 (Figure 2B) without altering cryptococcal growth, uptake or IPR (Figure S2). Interestingly, we 
243 noticed that higher doses of IFNα suppressed this effect, suggesting that the impact of 
244 interferons on vomocytosis can be rapidly saturated. 
245
246 To confirm that type-I interferons were behind the increase in vomocytosis observed, we 
247 performed the viral infection experiments in the presence of a type-I interferon receptor 
248 (IFNAR) inhibitor (Figure 3). The addition of IFNAR inhibitor blocked the enhancement of 
249 vomocytosis otherwise elicited by viral infection in both HIV- and Measles-infection settings, 
250 confirming that type-I interferon signalling is necessary for this effect. Interestingly, this effect 
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/512293doi: bioRxiv preprint first posted online Jan. 4, 2019; 
12
251 was particularly prominent on virally infected cells rather than neighbouring cells which were 
252 not infected (Non-MeV; Figure 3B), suggesting that the impact of IFNα signalling on 
253 vomocytosis is highly localised and specific to the autocrine responses occurring within 
254 infected cells, rather than endocrine responses mediated through cytokines.
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255 Discussion
256
257 In this study we set out to explore the consequences, if any, of viral infection on Cryptococcal 
258 infection, focusing on the non-lytic escape mechanism known as vomocytosis. Infection with 
259 either HIV or measles virus led to an enhancement in vomocytosis of C. neoformans, without 
260 affecting uptake or intracellular proliferation of the fungus (Figure 1), an effect that could be 
261 recapitulated by stimulation with IFNα and abrogated when signalling from type-I interferon 
262 receptor was blocked (Figures 2 and 3). Thus, viral coinfection stimulates expulsion of 
263 intracellular fungi via Type I interferon signalling.  
264
265 The effect was seen using two distinct viral pathogens which differ, among other parameters, 
266 in the magnitude of anti-viral response they elicit in human macrophages. Relative to other 
267 viral infections, HIV is very good at avoiding the induction of type-I interferons (24, 25). 
268 Nonetheless, the low levels of type-I interferons induced by HIV, potentially enhanced by the 
269 co-infection with Cryptococcus, are sufficient to have a significant effect on vomocytosis. 
270 Infection with measles virus has been reported to induce limited production of type-I 
271 interferons in macaque models, albeit with potent induction of interferon-stimulated genes (34, 
272 35). To date, there is no direct correlation between measles infection and cryptococcosis. 
273 However, given that both pathogens have a distinct respiratory phase it is possible that they 
274 interact within this shared niche, potentially through low doses of antiviral signalling. 
275
276 Why might antiviral signalling induce vomocytosis?  One possibility is that vomocytosis serves 
277 to “reset” phagocytes that have been unable to kill their prey, thus allowing them to serve a 
278 useful purpose in phagocytosing other pathogens rather than remaining “unavailable”.  In that 
279 context, a potent inflammatory signal such as IFNα may serve to accelerate this process during 
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280 localised infection, returning macrophages to functionality faster than would otherwise occur.  
281 The consequences of vomocytosis on disease progression, however, are likely to be highly 
282 context dependent; in some settings, this may enable a more robust immune response, but in 
283 others it may serve to inadvertently disseminate the fungus to distal sites.  
284
285 This is supported by previous reports showing variable outcomes of interferon signalling on 
286 cryptococcal infection in mice.  Sato et al. (36) showed that IFNARKO mice have lower fungal 
287 burden than WT mice and consequently argue that type-I interferon signalling is detrimental 
288 for the host during cryptococcal infection. Supporting this notion but using the sister species 
289 C. gatti, Oliveira et al (37) show that infection with influenza virus worsens the prognosis of 
290 subsequent fungal infection. On the other hand, Sionov et al (38) showed that stimulation with 
291 IFNα or with the double-stranded RNA analogue pICLC protected the host from infection by 
292 either C. neoformans or C. gatti infection.  This effect was time-dependent, with the protective 
293 effect of pICLC treatment only occurring if administered during the first 72 hpi before the 
294 fungus reaches the brain.  A tempting model, therefore, is that stimulating vomocytosis via 
295 antiviral signalling early in infection (when the fungus remains in the lung) helps prevent 
296 dissemination, whilst triggering vomocytosis later on may actually enhance fungal spread and 
297 accelerate disease progression.  
298
299 Taken together, our findings therefore suggest that the antiviral response, and IFNα in 
300 particular, induce the expulsion of intracellular cryptococci and that this effect could be 
301 advantageous or detrimental to the host, depending on the localization of the infected 
302 phagocyte and timing of the event.
303
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422 Figure Captions
423 Fig 1. Viral infection enhances vomocytosis of C. neoformans
424 Human monocyte-derived macrophages were infected with HIV (left) or measles virus (right) 
425 and subsequently infected with C. neoformans. Time-lapse microscopy videos were manually 
426 scored for vomocytosis (top), uptake (middle) and intracellular proliferation rate of C. 
427 neoformans (bottom). A-B Graphs show percentage of cryptococcus-infected macrophages 
428 which have experienced at least one vomocytosis event. C-D Percentage of crytptococus-
429 infected macrophages. E-F Intracellular proliferation rate of C. neoformans over 18 hours. In 
430 all cases, data corresponds to at least 3 independent experiments. Categorical vomocytosis and 
431 phagocytosis data was analysed by Chi2 test followed by Fisher's exact test. * p < 0.05; **** p 
432 < 0.0001. IPR data was analysed using Mann-Whitney test.
433
434 Fig 2. Antiviral response increases vomocytosis
435 Human monocyte-derived macrophages were stimulated with different doses of polyIC (A) or 
436 IFNα (B), and infected with C. neoformans. Graphs show Mean + SD of percentage of 
437 cryptococcus-infected macrophages which have experienced at least one vomocytosis event. 
438 Chi2 test followed by Fisher's exact test performed on raw vomocytosis counts. Data 
439 corresponds to at least three independent experiments.
440
441 Fig 3. Type-I interferon signalling is necessary to enhance vomocytosis
442 Human monocyte-derived macrophages were infected with HIV (A) or GFP-expressing 
443 measles virus (MeV-GFP, B) and subsequently with mCherry-expressing C. neoformans 
444 (Kn99α-mCherry), in the presence or absence of an IFNAR blocking antibody. GFP negative 
445 cells, which did not have an active Measles infection, were termed “Non-MeV”. Graph shows 
446 Mean + SD of percentage of Cryptococcus-infected macrophages which have experienced at 
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447 least one vomocytosis event. Fisher's exact test performed on raw vomocytosis counts. Data 
448 corresponds to two and three biological repeats, respectively.
449
450 Supporting information
451 Fig S1
452 A. Human monocyte-derived macrophages were infected with VLPs as indicated. After 24 
453 hours, viral infection was assessed by p24 staining (blue).
454 B. Cells were infected with VLPs as indicated, and subsequently infected with C. neoformans. 
455 Time-lapse microscopy videos were manually scored for vomocytosis. Graph shows 
456 percentage of cryptococcus-infected macrophages which have experienced at least one 
457 vomocytosis event. Chi2 test followed by Fisher's exact test performed on raw vomocytosis 
458 counts from 5 independent experiments.
459
460 Fig S2
461 A. Cryptoccocal cells were grown in the presence or absence of IFNα over 24 hours. Growth 
462 was assessed by optical densitiy readings at 600 nm.
463 B-C. Human monocyte-derived macrophages were infected with C. neoformans in the 
464 presence of different doses of recombinant IFNα.  Time-lapse microscopy videos were 
465 manually scored for phagocytosis and intracellular proliferation rate of the fungus (B and C, 
466 respectively). 
467 Data corresponds to 3 independent experiments.
468
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